Injectable Multi-Drug Formulation for the Postoperative Management of Ocular Surgery by Mohammadi, Maziar
  
Injectable Multi-drug Formulation for the 
Postoperative Management of Ocular Surgery 
 
by  
Maziar Mohammadi 
 
 
 
A dissertation submitted in partial fulfillment  
of the requirements for the degree of 
 Doctor of Philosophy  
(Mechanical Engineering)  
in the University of Michigan 
2017 
 
 
 
 
 
Doctoral Committee: 
 
Professor Ronald G. Larson, Chair  
Associate Professor Jordan J.  Green 
Assistant Professor Xiaogan Liang 
Professor Michael J. Solomon 
  
 
 
 
Maziar Mohammadi 
maziar@umich.edu 
ORCID id: http://orcid.org/0000-0001-8515-7717 
 
 
© 2017 Maziar Mohammadi 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
 
 
 
 
 
 
Dedication 
 
To my wife and my parents for their unconditional love and unfailing support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii 
 
 
Acknowledgements 
I am very grateful to my advisor, Professor Ronald Larson, for his valuable guidance throughout 
my PhD research. The fact that he believed in me and allowed me to pursue a topic of research 
with such complexity has encouraged me to take risks to achieve high rewards and will have a 
significant impact in my professional life. It would not have been possible to successfully 
complete my PhD without his endless support and mentorship. In addition to guiding me in my 
academic endeavors, Professor Larson has taught me a great deal about humility and kindness. He 
supported me in completing part of my PhD at Johns Hopkins University School of Medicine, 
which had an immense impact on both my personal and professional life. It has been a true 
blessing to have him on my side and for that I am very grateful.  
I would like to express my sincere thanks to Dr. Jordan Green, Associate Professor at Johns 
Hopkins University School of Medicine, for allowing me to join his group during the third year of 
my PhD. Although I was a new member, he made me feel right at home. The lessons I learned 
from him and his group with regards to drug delivery have been instrumental in achieving my 
academic goals and will be truly useful in my career.  
I would like to thank Dr. Cagri Besirli, Assistant Professor in the Kellogg Eye Center at the 
University of Michigan, for his responsiveness and encouragements. His valuable advice and 
intellectual guidance right from the inception of my PhD project through its completion have 
been extremely useful.  
Next, I would like to thank Professor Michael Solomon and Dr. Xiaogan Liang for spending their 
valuable time to assist as my PhD committee members. Their valuable advice and ideas have had 
a significant influence in the progress of my PhD.  
 iv 
All of the steps accomplished in the chapters of this dissertation have been made possible by the 
invaluable input from my colleagues. I am thankful to Eric D. Larson and Jun Liu for developing 
the Brownian Dynamics model, and Daniel Beltran-Villegas for his immense technical guidance. 
I appreciate Ali Salehi for his great advice regarding the LbL project and Ryan Branch and Lucas 
Cygan for their help with the LbL experiments. I am thankful to Professor Nick Kotov for 
allowing me to use his lab’s QCM device as well as LbL robot and Douglas Montjoy from his lab 
for the many fruitful discussions regarding LbL films. I am thankful to Dr. Ron Shmueli, David 
Wilson, Jayoung Kim, and Jesse Zheng for their patience and willingness to teach me many 
valuable lessons regarding drug delivery. I am very grateful to Sandhya Ramachandran for help 
with the experiments. Kisha Patel is especially thanked for her assistance with performing the 
experiments and her consistent dedication to research. I am very grateful to Professor Alexander 
Popel and Dr. Niranjan Pandey for their advice regarding drug formulations.  I would also like to 
thank Nisha Hollingsworth and Ying Liu for their help with the multidrug formulation project. I 
am very thankful to my collaborators in the projects regarding HIF inhibition: Dr. Akrit Sodhi 
and Dr. Monika Deshpande (ocular drug delivery), as well as Professor Gregg Semenza and Dr. 
Debangshu Samanta (cancer project).   
In addition, I would like to thank all of the members of Larson group, Elnaz Hajizadeh, Hossein 
Rezvantalab, Ryan Marson, Taraknath Mandal, Weizhong Zou, Wenjun Huang, Ali Salehi, Kyle 
Huston, Soroush Moghadam, Abdulrazaq Adams, Ryan Hall, Nisha Hollingsworth, Yufei Wei, 
and Ying Liu, for the amazing time that I had with them during my stay in Ann Arbor. I am 
thankful to the members of Green lab at Johns Hopkins University School of Medicine, Dr. 
Camila Zamboni, Dr. Johan Karlsson, Dr. Stephany Tzeng, Kisha Patel, Sandhya Ramachandran, 
David Wilson, Jayoung Kim, Randall Meyer, Yuan Rui, Kelly Rhodes, Hannah Vaughan, Elana 
Ben-Akiva, Denis Routkevitch, James Shamul, Kamran Siddiq, Mark Supernant, and Pranshu 
Bhardwaj for being so welcoming and for their willingness to help me with my project.  
 v 
I would like to end my acknowledgments by thanking those who have been with me from the 
very beginning: my beloved family. I am very grateful to my parents for instilling in me honesty, 
the desire to grow, and the ambition to achieve my goals. I am eternally in your debt, “Maman” 
and “Baba.” If it was not for your sacrifice, dedication, support and prayers, I would not be where 
I am today. In addition, I am very thankful to the love of my life who entered my world at a time 
when I least expected it, my wife Parisa. During my moments of weakness and doubt, it was her 
unconditional love and support that made me confident and kept me going. Thank you very much 
for your understanding and for the many weekends that you spent in the lab working by my side. 
Next, I would like to thank my kind father-in-law and mother-in-law for their affection, support, 
and encouragement. Last but not least, especial thanks to my brother and sister for their continued 
support and affection.  
I would like to thank Howard Hughes Medical Institute for the International Student Research 
Fellowship. The research conducted in this project was supported by the Air Force Office of 
Scientific Research under MURI project #W911NF-10-1-0518, Research Discovery Fund by Paul 
R. Lichter, M.D., National Science Foundation, under grant DMR 1403335, and National 
Institutes of Health under grant No EY026148. 
 
 vi 
 
 
Table of Contents 
 
Dedication ........................................................................................................................................................ ii 
Acknowledgements ........................................................................................................................................ iii 
List of Tables ....................................................................................................................................................x 
List of Figures ................................................................................................................................................. xi 
List of Appendices ..........................................................................................................................................xv 
Abstract ......................................................................................................................................................... xvi 
Chapter 1: Introduction .................................................................................................................................1 
     1.1. Background ...........................................................................................................................................1 
          1.1.1. Eye drops ......................................................................................................................................2 
          1.1.2. Topical gels ..................................................................................................................................3 
          1.1.3. Contact lenses ...............................................................................................................................3 
          1.1.4. Nanocarriers .................................................................................................................................4 
          1.1.5. Proteins .........................................................................................................................................4 
          1.1.6. Implants ........................................................................................................................................5 
          1.1.7. Multidrug delivery systems ..........................................................................................................5 
     1.2. Dissertation overview ...........................................................................................................................6 
     1.3. References ............................................................................................................................................8 
Chapter 2: Brownian Dynamics Simulations of Coagulation of Dilute Uniform and Anisotropic 
Particles under Shear Flow Spanning Low to High Peclet Numbers ......................................................11 
     2.1. Introduction ........................................................................................................................................11      
     2.2. Simulation methodology ....................................................................................................................16 
          2.2.1.Incorporation of shear flow in Brownian dynamics method .......................................................16 
          2.2.2. Simulation details .......................................................................................................................20 
          2.2.3.Error analysis ...............................................................................................................................23 
     2.3. Results and discussion ........................................................................................................................24 
          2.3.1. No-flow case ...............................................................................................................................24 
               2.3.1.1. Effect of hydrodynamic interactions on binding kinetics ...................................................24 
               2.3.1.2. Induced-dipole attraction ....................................................................................................26 
          2.3.2. Shear flow ...................................................................................................................................28 
               2.3.2.1. Implementation of rectangular simulation boxes ...............................................................28 
               2.3.2.2 Particle trajectories with HI .................................................................................................38 
               2.3.2.3. Binding kinetics in the absence of hydrodynamic interactions ..........................................40 
 vii 
               2.3.2.4. Normalized collision time in the presence of HI ................................................................43 
               2.3.2.5. Influence of inter-particle forces on coagulation kinetics ..................................................44 
                    2.3.2.5.1. Induced dipole attraction ............................................................................................44 
                    2.3.2.5.2. Electrostatic repulsion and depletion attraction .........................................................48 
     2.4. Binding kinetics for particles with surface anisotropy .......................................................................50 
     2.5. Conclusions ........................................................................................................................................52 
     2.6. Acknowledgements ............................................................................................................................52 
     2.7. References ..........................................................................................................................................52 
Chapter 3: Growth Kinetics in Layer-by-Layer Assemblies of Organic Nanoparticles and 
Polyelectrolyte. ..............................................................................................................................................55 
     3.1. Introduction ........................................................................................................................................55 
     3.2. Experimental section ..........................................................................................................................59 
          3.2.1. Materials .....................................................................................................................................59 
          3.2.2. Quartz crystal microbalance measurements ...............................................................................60 
          3.2.3. Growing thick multilayer films ..................................................................................................62 
          3.2.4. Atomic force microscopy studies ...............................................................................................63 
          3.2.5. Scanning electron microscopy studies ........................................................................................64 
          3.2.6. Error analysis ..............................................................................................................................64 
     3.3. Results and discussion ........................................................................................................................65 
          3.3.1. PEI/PS- system ...........................................................................................................................65 
               3.3.1.1. Effect of nanoparticle concentration ..................................................................................66 
               3.3.1.2. Effect of solution pH ..........................................................................................................67 
               3.3.1.3. Effect of molecular weight .................................................................................................71 
          3.3.2. PAA/PS+ system ........................................................................................................................73 
               3.3.2.1. Effect of molecular weight .................................................................................................74 
               3.3.2.2. Effect of salinity .................................................................................................................79 
          3.3.3. Film characterization ..................................................................................................................83 
               3.3.3.1. Atomic force microscopy study ..........................................................................................83 
               3.3.3.2. Scanning electron microscopy study ..................................................................................87 
                    3.3.3.2.1. Effect of molecular weight .........................................................................................87 
                    3.3.3.2.2. Thick film growth .......................................................................................................88 
     3.4. Conclusions ........................................................................................................................................89 
     3.5. Changing direction for drug delivery application ..............................................................................90 
     3.6. Acknowledgments ..............................................................................................................................91 
     3.7. References ..........................................................................................................................................92 
Chapter 4: Injectable Multi-drug Formulation for Postoperative Treatment Following Ocular 
Surgery ..........................................................................................................................................................95 
     4.1. Introduction ........................................................................................................................................95 
 viii 
     4.2. Description of the experiment ..........................................................................................................102 
          4.2.1. Materials ...................................................................................................................................102 
          4.2.2. Synthesis of microparticles .......................................................................................................103 
               4.2.2.1. Deprotonation of levobunolol hydrochloride ...................................................................103 
               4.2.2.2. Levobunolol loaded microparticles ..................................................................................103 
               4.2.2.3. Levobunolol hydrochloride-loaded microparticles ..........................................................103 
               4.2.2.4. Dexamethasone-loaded microparticles .............................................................................104 
          4.2.3. Preparation of the hydrogel ......................................................................................................104 
          4.2.4. Hydrogel characterization ........................................................................................................105 
          4.2.5. Drug release studies ..................................................................................................................106 
          4.2.6. Drug loading and release characterization ...............................................................................107 
          4.2.7. Scanning electron microscopy ..................................................................................................108 
          4.2.8. Error analysis ............................................................................................................................109 
     4.3. Results ..............................................................................................................................................109 
          4.3.1. Particle characterization ...........................................................................................................109 
          4.3.2. Hydrogel characterization ........................................................................................................111 
          4.3.3. Effect of deprotonation on levobunolol loading and release ....................................................114 
          4.3.4. Effect of hydrogel on sustaining drug release ..........................................................................116 
          4.3.5. Effect of hydrogel type on drug release profile ........................................................................119 
          4.3.6. Use of polymer type to fine-tune the drug release profile ........................................................122 
          4.3.7. Varying the microparticle or moxifloxacin mass to tune the daily drug release ......................123 
          4.3.8. Multi-drug delivery hydrogel ...................................................................................................125 
     4.4. Conclusions ......................................................................................................................................127 
     4.5. Acknowledgements ..........................................................................................................................128 
     4.6. References ........................................................................................................................................128 
Chapter 5: Blocking Expression of Hypoxia Inducible Factors with Sustained Release Strategies ...133 
     5.1. Introduction ......................................................................................................................................133 
     5.2. Description of the experiment: .........................................................................................................135 
          5.2.1. Materials ...................................................................................................................................135 
          5.2.2. Doxorubicin loaded nanoparticles ............................................................................................135 
               5.2.2.1. Deprotonation of doxorubicin hydrochloride ...................................................................135 
               5.2.2.2. Synthesis of doxorubicin loaded NPs ...............................................................................135 
               5.2.2.3. Synthesis of dye loaded NPs ............................................................................................136 
          5.2.3. Acr loaded NPs .........................................................................................................................137 
               5.2.3.1. Nanoprecipitation .............................................................................................................137 
               5.2.3.2. Double emulsion method ..................................................................................................137 
               5.2.3.3. Single emulsion method ...................................................................................................138 
 ix 
               5.2.3.4. Single emulsion nanoprecipitation method ......................................................................138 
          5.2.4. Drug release characterization ...................................................................................................139 
          5.2.5. Blood half-life and biodistribution determination ....................................................................139 
          5.2.6. HIF assessment in cancer model in vivo ...................................................................................140 
          5.2.7. In vitro cell studies on ocular cells ...........................................................................................140 
          5.2.8. In vivo studies for VEGF expression levels in the eye .............................................................140 
          5.2.9. Error analysis ............................................................................................................................141 
     5.3. Results ..............................................................................................................................................141 
          5.3.1. Nanoparticle characterization ...................................................................................................141 
               5.3.1.1. Doxorubicin/dye loaded NPs ............................................................................................141 
               5.3.1.2. Acriflavine loaded nanoparticles: .....................................................................................143 
          5.3.2. Drug release characterization ...................................................................................................146 
          5.3.3. HIF inhibition in the cancer model ...........................................................................................147 
               5.3.3.1. Nanoparticles half-life in the blood stream and biodistribution .......................................147 
               5.3.3.2. HIF inhibition in vivo in a cancer model ..........................................................................150 
          5.3.4. Ocular drug delivery .................................................................................................................151 
               5.3.4.1. HIF inhibition in vitro ......................................................................................................152 
               5.3.4.2. Angiogenesis inhibition in vivo ........................................................................................153 
     5.4. Conclusions ......................................................................................................................................156 
     5.5. Acknowledgements ..........................................................................................................................156 
     5.6. References ........................................................................................................................................157 
Chapter 6: Conclusions and Future Directions .......................................................................................159 
     6.1. Binding kinetics of particles under flow ..........................................................................................159 
     6.2. Layer-by-layer assembly of polyelectrolytes and nanopartilces ......................................................160 
     6.3. Multidrug carrier for the postoperative management of ocular surgery ...........................................161 
     6.4. Inhibiting HIF expression for drug delivery for cancer or ocular diseases ......................................162 
     6.5. References ........................................................................................................................................164 
Appendices ..................................................................................................................................................165 
 
 x 
 
 
List of Tables 
Table 2.1. Particles relative velocities scaled with !γa  as a function of non-dimensionalized gap (ε) 
compared with analytical values given by Pozrikidis.24 .................................................................................40 
Table 3.1. Optimum LbL buildup for different PE/NP composites studied as a function of NP size and MW 
of PE. ..............................................................................................................................................................77 
Table 5.1: Characteristics of dox, Dox plus dye and dye loaded NPs. .........................................................142 
Table 5.2: Z-average, PDI and Acr loading for NPs synthesized with different schemes. ..........................145 
 
 
 xi 
 
 
List of Figures 
Fig. 1.1. Anatomy of the eye.4 ..........................................................................................................................2 
Fig. 2.1. Normalized collision times as a function of inverse cubic box length ( x y zL L L= = ), in the 
absence of flow and no interaction potential.  The limiting values at infinite box size are given by Eq. (2.1) 
for the absence of HI and Eqs. (2.19)-(2.20) with HI, where in the case of HI the particles are assumed to 
collide when the gap between them reaches 50 nm. Since the sphere radius is 1 µm, the numerical value of 
xL  in µm can also be taken to be box dimension made dimensionless with the particle radius. ..................26 
Fig. 2.2 Comparison of extrapolated binding time from simulations with theoretical predictions of Eqs. 
(2.19)-(2.21) for the presence of induced-dipole attraction, and HI. .............................................................27 
Fig. 2.3. Particle concentration field, normalized to unity on average, for the central xy  plane, depicting 
the shadow effect, for 295Pe = , without HI, and binning resolution=1 µm.  Here a is the particle radius. 30 
Fig. 2.4. (a) A rectangular box used to overcome the shadow effect, which in (b) it is approximated by a 
cylindrical domain for estimating the collision time, as described in the text. ..............................................31 
Fig. 2.5. Normalized concentration field for a long rectangular box for 295Pe = , without HI, and binning 
resolution=1 µm. ............................................................................................................................................31 
Fig. 2.6. Comparison of simulated normalized collision times for 138Pe =  in cubic and rectangular boxes, 
and their approach to the Smoluchowski orthokinetic limit. Inset shows the dependence of the slope of lines 
in the main figure for rectangular boxes vs. ℓn(Ly / 2a) . .............................................................................33 
Fig. 2.7. The “upturn” in binding time as the box becomes very long for different box widths, at a small 
shear rate ( 0.15Pe = ). Empirical fits for simulation boxes with widths of 40 and 100 µm shown in the 
figure are 1 5ˆ 0.768 2 6.7029 10.62V x xLt L
−−= ++ ×  and 1 5ˆ 0.797 3.717 1.463 10V x xt L L
− −= + + × , 
respectively. Particles have a radius of 1 µm. ................................................................................................34 
Fig. 2.8. Normalized concentration contours for the central xy  plane in a rectangular box with aspect ratio 
of 100, 0Pe = , without HI, and binning resolution=1 µm. .........................................................................36 
Fig. 2.9. Normalized concentration contours in the central yz  plane, with 295Pe = , without HI, and 
binning dimension of 0.2 µm in y  and z  directions. ...................................................................................38 
Fig. 2.10. Simulated particle trajectories. (a) Coordinates ( .x y ) of the second particle position in shear 
flow in a frame in which the origin moves with the test particle, compared with the trajectory from Zhu and 
Ingber.23 Test particle is shown with a closed circle, and second particle by an open circle. (b) The 
logarithmic variation of ε, gap normalized by the sphere radius a, vs. second particle longitudinal position 
compared with results of Pozrikidis.24 The particles are all placed in the xy  plane, with z  = 0. ................39 
Fig. 2.11. Dependence of normalized collision time on Pe  in the absence of HI. (a) Comparison with 
Smoluchowski limit,12 with low-Pe  formula of van de Ven25 and with simulation results of Xu et al.11. (b) 
Fits for entire and partial ranges of Pe . .......................................................................................................41 
Fig. 2.12. Dependence of normalized collision time on Pe  with HI. The line shows the low- Pe  
perturbation result from Russel et al.14 ...........................................................................................................44 
 xii 
Fig. 2.13. Comparison of simulation results with those reported by Feke and Schowalter13 for fl  of 1000. 
For box width 20 µm and 40 µm, a fixed box length range (from 100 to 700 µm) was used, while for the 
other box widths, the box length range was varied to avoid the shear-induced shadow effects. Overlaps 
between simulation results, while box width is varied from 15 to 20 µm, and 20 to 40 µm is shown. .........45 
Fig. 2.14. Simulation results over the entire range of Pe  with induced-dipole attraction at two different 
fl  values, along with asymptotic results from Feke and Schowalter.13 ........................................................47 
Fig. 2.15. Dependence of normalized collision time on Pe  for an explicit potential given in Eqs. (30-32), 
and in the absence of a potential but with a cut off distance. .........................................................................49 
Fig. 2.16. (a) Janus spheres relative orientations. Only state (i) leads to a binding event. (b) Binding time 
versus Pe  for uniform and Janus spheres with 50% of each sphere’s surface attractive, and an inner cut 
off for binding set to 50 nm. Simulation data are fit by the functional forms given in the legend. ...............51 
Fig. 3.1. The effect of NP concentration and size on the growth kinetics of a PEI/PS- thin film. PS- NPs are 
deposited during the even-numbered steps. PEI with a MW of 750 kg/mol is used. In the legend, the 
numbers in the parentheses indicate the pH value of the solutions. For each case, the diameter of the 
employed NPs is given in nm in the figure legend. “CP” stands for concentration of particles. In this and all 
figures, the polymer monomer concentration used in the solutions is 0.23 M. ..............................................66 
Fig. 3.2. The effect of pH on LbL growth of a PEI/PS- composite. PEI with a MW of 70 kg/mol and 41 nm-
sized PS- particles are employed. The concentration of PS- NPs is 0.1 wt%. ...............................................68 
Fig. 3.3. The role of MW of PEI on growth of PEI/PS- LbL film, for PS- NP size of 26 nm. ......................71 
Fig. 3.4. The same as Fig. 3.3, except for a particle size of 41 nm. ...............................................................72 
Fig. 3.5. The same as Fig. 3.3, for particle size of 100 nm. ...........................................................................73 
Fig. 3.6. Effect of MW of PAA on PAA/PS+ LbL buildup with 23 nm-sized PS+ particles. For this and 
subsequent figures, the pH values for each deposition solution (PAA or PS+) is indicated in parenthesis in 
the figure legend. Note the small value of error bars for PAA with MW of 2 kg/mol. .................................74 
Fig. 3.7.  The same as Fig. 3.6, for 44 nm-sized PS+ particles. Data for PAA with a MW of 30 kg/mol have 
error bars, but these are too small to be visible. .............................................................................................75 
Fig. 3.8. The same as Fig. 3.6, for 100 nm-sized PS+ particles. ....................................................................76 
Fig. 3.9. The effect of KCl concentration on growth kinetics of PAA/PS+ multilayers, for PAA with a MW 
of 5 kg/mol, and 44 nm-sized PS+ particles. Concentration of NPs was 0.1 wt%. The concentrations of salt 
(CS) in the PAA and PS+ solutions are shown in the legend. The ionic strength was 37, 93, and 147 mM 
for PAA solutions with salt concentrations of 0, 50, and 100 mM, respectively. For PS+ suspensions 
however, pH adjustment did not change the ionic strength of the suspensions. Thus, the ionic strength 
values were the same as salt concentration reported. .....................................................................................80 
Fig. 3.10. The same as Fig. 3.9 except for PAA with a MW of 240 kg/mol. The concentration of PS+ NPs 
was set to 0.1 wt%. The ionic strength for PS+ suspensions with salt content of 0, 50, and 100 mM was 0, 
50, and 100 mM, respectively. Also, the ionic strength for PE solutions with salt concentrations of 0, 50, 
and 100 mM was 34, 92, 149 mM, respectively. ...........................................................................................81 
Fig. 3.11. AFM images of PEI/PS- composites with 41 nm-sized PS- particles and different MWs of PEI 
for different numbers of layers. All the images were obtained once PS- NPs are deposited for 1st, 3rd, 6th, 
and 8th bilayers. The pH values for the NP and PEI deposition steps were 7, and 9.9, respectively. No salt 
ions were added for the growth of these films except for the ions introduced to the system to adjust the pH. 
The scale bars for the main images are also shown. The insets show the corresponding images rendered 
using a fixed 700 nm scale bar to allow comparison of film height uniformity on an absolute scale. ..........84 
Fig. 3.12. Ratio of roughness to thickness, extracted from AFM images, for the PEI/PS- multilayers 
depicted in Fig. 3.11. The inset shows the variation of absolute roughness. For some data points, the error 
bar is too small to be visible. ..........................................................................................................................86 
 xiii 
Fig. 3.13. Surface morphology of LbL films composed of 8 double layers of PEI and PS-, with the same 
materials and the same conditions as for Fig. 3.11, with PEI MWs of 25 kg/mol (a), 70 kg/mol (b), and 750 
kg/mol (c). The main figures have a magnification of 400 while the insets have a magnification of 80,000. 
The scale bars represent a length of 100 µm in the main figures, while those of insets indicate a length of 
500 nm. ...........................................................................................................................................................87 
Fig. 3.14. Characteristics of LbL film composed of 59 double layers of PEI and PS- NPs, with PEI MW of 
70 kg/mol. PEI and PS- solutions were deposited at pH values of 9.9 and 7, respectively. No salt was used 
in either of the film ingredients except for the addition of HCl or KOH for pH adjustment. (a) Surface of 
the film with a magnification of 400 in the main figure and 80,000 in the inset. The scale bars show a 
length of 100 µm for the main figure and 500 nm for the inset. (b) Cross sectional view of the film with a 
magnification of 8,000. The arrow indicates the interface between the substrate and the film. ....................88 
Fig. 3.15. a) Preliminary design of a colloidal LBL drug carrier.  Letters of A, C, and P represent 
antibiotics, corticosteroid and IOP regulating agents, respectively that were planned to be loaded in the 
drug carrier.  b) Schematic depiction of layered release of drug content, c) Desired cumulative drug release 
profile for each layer of drug delivery implant over time required by clinicians. ..........................................90 
Fig. 4.1. a) Our drug delivery platform enables delivery of at least three drug molecules. A broad-spectrum 
antibiotic (A) is added directly to the hydrogel network, while a potent corticosteroid (C) and ocular 
hypotensive agent (H) are encapsulated within the MPs and thereafter loaded into the hydrogel. b) The 
thermosensitive hydrogels are engineered to be liquids at room temperature, c) While they form a hydrogel 
network at body temperature. d) This eases the implantation via intraocular injections with a very small-
guage needle and thus provides minimal invasiveness. ...............................................................................101 
Fig. 4.2. SEM micrographs on a) levobunolol HCl-loaded MPs with 75/25 (lactic/glycolic acid ratio) 
PLGA, deprotonated levobunolol-loaded MPs with b) 60/40, c) 75/25 and d) 85/15 PLGA and e) 
dexamethasone-loaded MPs with 50/50 PLGA. All of the images were taken at a magnification of 1000, 
and scale bar shows a distance of 10 µm. .....................................................................................................110 
Fig. 4.3. Phase diagram for different triblock copolymers used in this research, a) PLGA-PEG-PLGA, b) 
PLA-PEG-PLA, c) PLCL-PEG-PLCL. ........................................................................................................112 
Fig. 4.4. Rheological results for different triblock copolymers; a) Storage modulus, b) Loss modulus. 
Results were obtained at 1Hz oscillation frequency.  The PLGA-PEG-PLGA triblock copolymer was a 3/1 
blend of AK91 and AK12. The PLA-PEG-PLA was AK100 only. The PLCL-PEG-PLCL was a 6/1 blend 
of AK108 and AK109. .................................................................................................................................113 
Fig. 4.5. Variations of a) storage and b) loss moduli with oscillation frequency at different temperatures for 
PLCL-PEG-PLCL polymer solutions. ..........................................................................................................114 
Fig. 4.6. (a) Comparison of release of levobunolol with levobunolol HCl from MPs. (b) Release of 
dexamethasone from samples containing different levobunolol type. For these samples no hydrogel was 
present and drug release from MPs alone was compared. In this and all of the subsequent figures, error bars 
represent standard deviations between duplicate measurements and data points represent average values of 
duplicate measurements. ...............................................................................................................................116 
Fig. 4.7. Comparison of drug released from MP-loaded in PLCL-PEG-PLCL hydrogels with that from MPs 
alone, a) levobunolol, b) dexamethasone. ....................................................................................................117 
Fig. 4.8. Drug release kinetics for different types of hydrogels, a) Moxifloxacin, b) Levobunolol and c) 
Dexamethasone. Data points are the average between duplicate measurements and error bars represent 
standard deviation. ........................................................................................................................................120 
Fig. 4.9. Effect of polymer encapsulating levobunolol on regulation of release duration from the drug 
delivery system. ............................................................................................................................................122 
Fig. 4.10. Comparison of a) moxifloxacin, b) levobunolol and c) dexamethasone release profile when the 
loaded drug content is decreased by a factor of 2. .......................................................................................125 
Fig. 4.11. A multi-drug delivery hydrogel capable of releasing three different drug molecules at different 
release rates. .................................................................................................................................................126 
 xiv 
Fig. 5.1. Dox/dye loaded NPs size distribution, a) Dox loaded NPs, b) dye plus Dox loaded NPs, c) dye 
loaded NPs. ...................................................................................................................................................142 
Fig. 5.2. Z-average for Acr loaded NPs synthesized with a) nanoprecipitation (Acr.HCl), b) 
nanoprecipitation, c) double emulsion, d) single emulsion, e) single emulsion nanoprecipitation. Plots b-e 
are for NPs loaded with Acr. ........................................................................................................................144 
Fig. 5.3. Percent released Dox from Dox loaded NPs compared with Dox plus dye loaded NPs. ..............146 
Fig. 5.4. Release kinetics of Acr from NPs, in vitro. ...................................................................................147 
Fig. 5.5. Blood half-life for the dye loaded NPs compared to the Dox plus dye loaded NPs in mice bearing 
breast tumor. .................................................................................................................................................148 
Fig. 5.6. Biodistribution of the NPs in different organs. ..............................................................................150 
Fig. 5.7. In vivo efficacy of NPs on inhibiting HIF in cancer model. Imaging of animals and analysis of the 
results were done by Dr. Debangshu Samanta and David Wilson. ..............................................................151 
Fig. 5.8. HIF expression levels for free a) Acr and b) Dox compared with c) those drugs loaded in NPs, in 
vitro. At each condition, black band is indicative of HIF presence.  Experiments were performed by Dr. 
Sodhi’s group. ...............................................................................................................................................152 
Fig. 5.9. Effect of free drug compared with drug loaded NPs on VEGF levels after 1 day post-treatment, in 
vivo. Determination of VEGF level was done by Dr. Sodhi’s group. ..........................................................153 
Fig. 5.10. Effect of NPs on reduction of VEGF compared with free drug after 3 days post NP injection. a) 
Acr, b) Dox. In this and subsequent figure, control represents the animals that received PBS injection. 
BNPL and BNPH refer to animals that received blank NPs at a low and high concentrations, respectively. 
AFL and AFH represent animals that received free Acr at a dose of 2.5 and 7.5 mg/Kg, respectively, while 
DFL and DFH refer to animals that received free dox at dosages of 6 and 18 mg/Kg, respectively. ANPL, 
ANPH, DNPL and DNPH represent animals that received the same dosages of Acr or Dox mentioned 
before but in the NP form. VEGF level was determined by Dr. Sodhi’s group. ..........................................154 
Fig. 5.11. VEGF levels in retina 7 days after treating the mice with free drug or drug loaded NPs. a) Acr, b) 
dox. VEGF level was assessed by Dr. Sodhi’s group. .................................................................................155 
Fig. B.1. Influence of pH drift on the PEI/PS- film buildup, PEI (odd numbered steps) and PS- (even 
numbered steps) are deposited at pH values of 9.9 and 7, respectively. No salt was added to either of the 
ingredient of the LbL film except for the ions introduced to the solutions by pH adjustment. ...................167 
Fig. B.2. The effect of deposition time on LbL growth of PEI/PS- composite. ...........................................168 
Fig. B.3. An optical micrograph of the surface features of the LbL films. PEI with a MW of 70 kg/mol and 
PS- particle size of 41 nm were used, with six double layers deposited. .....................................................169 
Fig. B.4. Charge compensation factor for PEI/PS- composites grown with different pH values (pH of each 
deposition solution is shown in the parentheses in the legend). PEI with a MW of 70 kg/mol and 41 nm-
sized PS- particles are used for this experiment. ..........................................................................................171 
Fig. B.5. The effect of PS+ concentration on LbL film buildup of PAA/PS+ composite. PAA with MW of 
240 kg/mol and 100 nm-sized PS+ particles were employed. CP refers to the concentration of particles. .172 
Fig. B.6. Surface characteristics of LbL films composed of 8 bilayers of PEI with MW of 70 kg/mol and 41 
nm sized PS- particles deposited at different pH values. No salt was added for the deposition of either of 
film ingredients. a) Film growth at pH amplified condition. PEI and PS- are deposited at pH values of 9.9 
and 7, respectively. b) PEI and PS- are both deposited at pH value of 7. For the plots in the inset, maximum 
value of color bar is fixed to 700 nm. ...........................................................................................................173 
 
 
 
 xv 
 
 
List of Appendices 
Appendix A: Supplementary Information for Chapter 2 .......................................................................165 
     A.1. Brownian Dynamics method ...........................................................................................................165 
     A.2. References .......................................................................................................................................166 
Appendix B: Supplementary Information for Chapter 3 .......................................................................167      
     B.1. Effect of pH drift ..............................................................................................................................167 
     B.2. Effect of deposition time ..................................................................................................................168 
     B.3. Film surface .....................................................................................................................................169 
     B.4. Charge compensation factor ............................................................................................................170 
     B.5. Effect of nanoparticle concentration on the growth of PAA/PS+ composite ..................................171 
     B.6. Effect of deposition pH on surface morphology of the LbL films ..................................................172 
     B.7. References ........................................................................................................................................173 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xvi 
 
 
 
 
Abstract 
In this dissertation, the interaction between particles or particles and polymers were examined. In 
addition, outcomes of such studies were used to develop drug delivery formulations.  
Initially, by carrying out Brownian dynamics (BD) simulations binding kinetics between two 
spheres in the dilute limit under shear flow for the entire Pe values (measure of flow strength) 
was studied. Effects of Pe, hydrodynamic interactions, inter-particle potential and surface 
anisotropy were studied. Results were in agreement with previous literature that had limited range 
of applicability including zero and infinite shear rate Smoluchowski limits, as well as high Pe 
perturbation results of Feke and Schowalter [J. Fluid Mech. 133, 17-35 (1983)].  
Next, developing a drug delivery system for the postoperative management of ocular surgery was 
considered. In routine care after cataract surgery, patients are required to receive antibiotics for a 
week and steroids for at least a month. Later during postoperative treatment period, ocular 
pressure increases and could be managed by administration of ocular hypotensives, which adds to 
postoperative treatment burden. Currently, the required drug molecules in the postoperative 
treatment are delivered mainly by eye drops, which have significant shortcomings, such as poor 
patient compliance, low drug bioavailability and allergic reactions. Hence, different routes were 
pursued to make a formulation that reduces reliance on the patients to use eye drops.  
Initially, layer-by-layer (LbL) assembly of nanoparticles (NPs) and polyelectrolytes was 
considered as a viable strategy. The goal was to layer different sheets of LbL films with different 
drug loaded NPs in order to fine-tune the drug release profile. The effect of different parameters 
on the growth of LbL films was studied and the optimal conditions to grow thick LbL films with 
inexpensive blank NPs were attained. Unfortunately, by switching from blank polystyrene NPs to 
 xvii 
biodegradable poly(D,L-lactide-co-glycolide) (PLGA) NPs, the growth of LbL films was 
interrupted.   
Therefore, we were faced with the challenge of modifying our research to find a more robust 
solution for postoperative management following cataract surgery. In a subsequent attempt, the 
multidrug release system was developed utilizing thermoresponsive polymer solutions. The 
invented drug release system is composed of microparticles incorporated into a bulk hydrogel that 
was engineered to be in liquid form at room temperature for simple delivery into the eye and form 
a hydrogel network at physiological body temperatures to act as a depot release platform. The 
delivery platform was designed to mimic current topical application of postoperative ocular 
formulations, releasing the antibiotic for up to a week, and the corticosteroid and the ocular 
hypotensive agents for at least a month. Different means to finely tune drug release was 
demonstrated. To ensure the most linear drug release, more hydrophobic blocks such as PLCL 
should be used in the triblock copolymer. Increasing the hydrophobicity of the polymer 
encapsulating the drug molecules, it was possible to prolong the release duration of drugs 
substantially.  
Finally, preliminary results on overcoming the poor bioavailability of free drug molecules to be 
used for the treatment of ocular diseases and cancer were examined. Two anti-hypoxia inducible 
factors (anti-HIFs) were successfully loaded in PLGA NPs with small particle size and 
considerable drug loading. Next, drug release from NPs was evaluated, in vitro. Finally, the effect 
of NPs on inhibiting HIF expression and blocking angiogenesis were examined in vivo. Results 
demonstrate significant improvements using NPs compared to free drug. 
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                                                                       Chapter 1 
                                                                     Introduction 
1.1. Background 
Eyes are important body organs. Without them one can’t see the beauty of the world surround us. 
Based on recent reports, approximately 285 million people suffer from severe vision impairment 
throughout the world, and approximately 7 million people join this community annually.1,2 As a 
result, significant effort has been focused on developing technologies for improving the delivery 
of the drug molecules to the eyes, improving treatment outcomes and enhancing vision recovery 
rate. Anatomy of an eye is shown in Fig. 1.1. Eye is a particularly attractive organ for drug 
delivery application. It is more accessible compared to internal body organs. This eases the direct 
injection of the drug delivery system to the eye avoiding the toxicity caused by drug molecules 
delivered through systemic drug delivery. Even though for drug delivery to other parts of the 
body, there are restrictions on the size of the drug delivery vehicle (e.g. <200 nm particles for 
intravenous drug delivery), tolerance of the eye for implants is much higher, since as shown in 
Fig. 1 vitreous cavity has a large volume (~4 ml in a human eye) and can accept large implants as 
long as they don’t interfere with the vision. In fact, implants as large as few mm long (e.g. 
Iluvien® which is 3.5 mm long) have been approved by FDA for the intravitreal injection to the 
eye.2,3 In addition, with local delivery of the implant to the target site, the required dosage of the 
drug for the optimum effectiveness is relatively low compared to other route of administrations. 
In this regard, several technologies have been developed to deliver drug molecules to the eye, and 
they are summarized in the following sections.  
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Fig. 1.1. Anatomy of the eye.4  
 
1.1.1. Eye drops 
Eye drops are the most commonly used drug delivery schemes for the treatment of eye diseases. 
They are inexpensive and less invasive compared to intraocular injections. However, they have 
several shortcomings, which has limited their treatment efficiency. Majority of the patients with 
ocular disorders are elderly, so they might have difficulty using eye drops. In addition, due to 
rapid clearance of small drug molecules by the body, eye drops have to be administered between 
4 to 8 times daily, which is not only a burden for the patients, but also might reduce treatment 
outcomes if the drug is not administered at the right time. Due to presence of several ocular 
barriers as well as drug clearance by the tear flow and blinking, below 5% of administered dose 
makes it to the target site in the eye.2,5,6 As a result, eye drops are dosed several times higher than 
the dosage required for the treatment. Drug overdose as well as some of the excipients that are 
used in eye drops could lead to burning sensation, eye surface irritation, and allergic reactions.7,8 
All in all, there is huge patient noncompliance when it comes to using eye drops.1,9,10  
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1.1.2. Topical gels 
In situ forming gels are introduced to avoid rapid clearance of drug administered through eye 
drops. They are typically a viscose liquid and after instillation form a gel, due to change in pH, 
temperature, and ionic strength of the solution. These gels have a higher residence time on the 
surface of the eye and they are more likely to have a higher bioavailability (the required drug 
concentration in the eye) compared with eye drops. In addition, topical gels could sustain the 
release of drug molecules on the surface of the eye, thereby reduce the need for frequent 
administration.4 Some in situ forming gels are currently available in the market for the treatment 
of bacterial conjunctivitis, inflammation and glaucoma.4 However, these gels with the drug 
molecules loaded in have to be transparent to avoid interference with the vision. In addition, even 
though using these gels reduces the administration frequency, there will still be reliance on 
patients to instill these gels on a daily basis.4  
 
1.1.3. Contact lenses 
Contact lenses are alternative means of sustaining the drug release duration on the surface of the 
eye, and reducing the reliance on the patient to administer the drug molecules via eye drops or 
gels. The fact that contact lenses could serve the dual purpose of improved vision as well as 
delivering the required medications to the eye for chronic diseases makes them a more attractive 
option. In addition, unlike other implants, contact lenses don’t require intraocular injection and 
thus, they are a less invasive treatment option. Contact lenses could cause patient discomfort over 
time. In addition, wearing them for a long time may increase the risk of bacterial growth and 
infection.11 Further improvement in drug release technologies used in contact lenses (e.g. 
nanoparticles (NPs), micelles, liposomes, layer-by-layer films, etc.) are required to prolong the 
drug release duration, avoid sudden burst release of the drug from contact lenses during use or 
storage, and enhance their shelf life.12-14 In addition, such sustained release technologies should 
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not dramatically alter mechanical properties of the contact lenses and their ability to permeate 
oxygen and ions. Incorporation of the drug molecules could also reduce the transparency of the 
contact lenses and interfere with the vision.12 Contact lenses have been subject of extensive 
research on treatment of glaucoma or inflammation.12 However, due to the mentioned limitations, 
they have not made their way to the market yet.  
 
1.1.4. Nanocarriers 
There have been numerous studies on the use of nanocarriers in different forms including 
polymeric NPs, micelles, dendrimers, liposomes for drug delivery to the eye.15 Due to their small 
size targeted nanocarriers could bind and localize to the target site and reduce the side effect of 
drug molecules by local drug delivery.16 Nanocarriers have either been administered as a topical 
formulation17 as well as direct injection into the vitreous cavity.18 A potential concern with 
nanocarriers is appearance of snow-globe effect and their interference with the vision due to their 
small size and resulting Brownian motion. In addition, nanocarriers degrade too fast to be able to 
sustain the release of the drug molecules for an extended period of time. Furthermore, due to their 
small size, drug loading in nanocarriers could be limited. Lastly, aggregation of nanocarriers in 
the container closure (which will impact the ultimate product’s shelf-life) or after administration 
in the eye (which reduces their localization in the target site) should be addressed.16  
 
1.1.5. Proteins 
Proteins are an efficient means to treat the diseases of the back of the eye including age related 
macular degeneration, diabetic retinopathy and macular edema. Due to their large size (>100 
kDa), they can’t cross the ocular barriers if administered in the form of topical formulations and 
thus they are delivered to the eye with direct intraocular injections.1,19 Proteins have fewer side 
effects compared to small molecule drug delivery, as they are made up of amino acid sequences 
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that are found naturally in the body. They are several proteins approved by FDA including 
Aflibercept also known as Eylea® and Ranibizumab also known as Lucentis® for the treatment 
of diseases of the back of the eye. One of the limitations of the proteins is their short intravitreal 
half-life and fast clearance from the eye. This requires subsequent injection of proteins to ensure 
their optimal efficiency. Frequent injections are not only an inconvenience for the patients but 
also lead to several complications including retinal detachment, infection and cataract formation. 
To prolong their effect, proteins have been encapsulated in the sustained release mechanisms.19  
 
1.1.6. Implants 
There are several FDA approved implants, including Retisert®, Vitrasert®, Ozurdex®, and 
Iluvien® for the sustained delivery of small molecules to the eye.2 The ability of these implants to 
prolong the release of encapsulated drug molecules for several months is remarkable. Retisert and 
vitrasert are non-biodegradable and they require a surgical procedure for implantation and a 
follow up surgery for removal once the drug molecule is completely released. Ozurdex is a 
biodegradable implant and can be administered via intravitreal injection. A common side effect 
for all of the mentioned implants is elevation of ocular pressure.2,20-25 To suppress elevated 
ocular pressure, patients need to use anti-glaucoma drugs.  
 
1.1.7. Multidrug delivery systems 
Despite the significant effort on development of sustained release technologies for the treatment 
of ocular diseases, there has not been much focus on delivering multiple drug molecules to the 
eye. Some of the mentioned technologies are designed to release a single drug molecule. 
Modifying those technologies to enable multidrug delivery would make them more complex and 
reduces their reliability. For the eye drops and topical gels, having multiple drugs in the same 
solution could risk unfavorable drug-drug interactions and reduces the treatment efficiency.  
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ODTx, which stands for “on demand therapeutics,” is a multi-chamber stimuli responsive ocular 
implant. It can hold multiple drug molecules in its chambers and by laser activation and resulting 
increase in its membrane pore size, it can initiate the release of drug molecules. The implant is 
currently being evaluated in preclinical studies.2,26   
To address the challenges in the treatment of proliferative vitreoretinopathy, Zhou et al designed 
a multidrug implant.27 The implant was a cylinder made out of PLGA and was capable of 
releasing a corticosteroid, an antimetabolite, and a thrombolytic drug to the eye. Using a 20-
gauge needle, the implant could be delivered to the eye via intravitreal injection. They 
demonstrated sustained drug release profile and the ability to finely tune it for several weeks.27  
 
1.2. Dissertation overview  
One of the objectives of this dissertation is to study the interaction between particles with each 
other or particles and polymers. The overall goal is to use these findings to develop formulations 
for drug delivery applications. Initially, some fundamental understanding about binding kinetics 
of particles and assembling those in different layers between polyelectrolytes are obtained.  
In Chapter 2, Brownian dynamics (BD) simulations are performed to study the binding kinetics of 
two particles in the dilute limit under shear flow. The goals were: 
- To calculate the binding kinetics between two particles considering hydrodynamic 
interactions, and various interparticle forces to capture the previous data reported in the 
literature, which had limited applicability and also go beyond that and provide binding 
kinetic results for the entire flow strength. 
- To study the binding time of anisotropic particles for various flow strength 
Next, effect of interactions between particles and polymers to grown layer-by-layer (LbL) films is 
addressed in Chapter 3. The goal of chapter 3 is as follows: 
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- To study the effect of polyelectrolyte molecular weight, ionic strength of the media as 
well as particle size and charge on the growth of LbL films.  
- To demonstrate the ability to grow LbL films with thickness of at least few microns. 
As the next step, the outcomes of these studies were used to develop formulations for drug 
delivery applications. Initially, drug delivery for postoperative management of ocular surgery 
(and cataract surgery in particular) is considered. In routine care after cataract surgery, patients 
are required to receive antibiotics (for a week) to prevent infection and steroids (for at least a 
month) to suppress any inflammatory response. Following a few days after surgery, elevation of 
ocular pressure could occur, due to inflammation or steroid response. To control ocular pressure, 
ocular hypotensives need to be delivered (for at least a month). For the postoperative 
management following ocular surgery, the current treatment paradigm is using eye drops and 
relying on the patients (who are usually elderly) to properly administer the drug molecules at the 
right time. Limitations of the eye drops were highlighted in the previous section. Hence, to 
overcome such limitations, the technology is optimized in vitro to make sure all three drug 
molecules required for postoperative management of cataract surgery can be released at required 
concentrations and proper timing.  
To develop the multidrug carrier, the initial goal was to use LbL assembly of drug loaded NPs 
and polyelectrolytes. The plan was to use inexpensive polystyrene particles for the initial studies 
(demonstrated in Chapter 3) and once the optimum parameters to grow thick LBL films were 
determined, particles would be replaced with more valuable drug loaded biocompatible particles. 
Our preliminary results indicated that growth of LbL films is challenging with large NPs. In 
addition, Jianshan Liao, a member of Larson Group observed that biodegradable particles further 
slow down growth of such films.28 Finally, over the course of this part of the project, the low 
reliability of LbL films to fine-tune the release of multiple drugs became more obvious due to 
their uneven surface morphology. These findings triggered the use of a different idea to enable 
multidrug delivery platform.  
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In a subsequent attempt, thermoresponsive hydrogels were employed to address the need for such 
drug delivery system (Chapter 4). The thermoresponsive hydrogels are liquid at room 
temperature, which enables injectability. Upon exposure to body temperature, they form a depot 
for sustaining the release of drug molecules. This chapter addresses the following points: 
- To load drug molecules with different hydrophobicity and dosage as well as release 
duration requirements in thermoresposnive hydrogels.  
- To show the flexibility of the drug delivery system in finely tuning the drug release 
dosage, profile and duration for different drug molecules encapsulated, in vitro. 
The technology that is developed during this PhD project and highlighted in Chapter 4 could be 
widely applied for different ocular indications by changing the drug molecule encapsulated in the 
MPs or in the hydrogel network. 
Chapter 5 presents preliminary results on using anti-hypoxia inducible factors (anti-HIF) loaded 
NPs to treat cancer and eye diseases. The overall goal of this chapter is as follows:  
- To synthesize NPs loaded with anti-HIF agents with small enough particles size (<200 
nm) and high drug loading (>10 µg/mg of NPs). 
- To evaluate pharmacokinetics of NPs in vivo.  
- To prolong the effect of anti-HIF agents on inhibition of HIF expression or angiogenesis. 
Finally, chapter 6 briefly highlights the obtained results and provides recommendations for future 
directions.   
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Chapter 2 
Brownian Dynamics Simulations of Coagulation of Dilute Uniform and Anisotropic 
Particles under Shear Flow Spanning Low to High Peclet Numbers 
 
This chapter is reproduced from [M Mohammadi, ED Larson, J Liu, RG Larson, Brownian 
dynamics simulations of coagulation of dilute uniform and anisotropic particles under shear flow 
spanning low to high Peclet numbers, 2015, The Journal of Chemical Physics 142 (2), 024108.], 
with the permission of AIP Publishing. 
 
2.1. Introduction 
Coagulation of colloids has considerable practical application, including but not limited to 
removing undesired reactants or bi-products from industrial solutions,1 inducing surface 
modification,2,3 and creating ordered colloidal structures.4-6 On the other hand, for some cases, it 
is desirable to prevent flocculation to maintain a homogenous suspension applicable to 
pharmaceutics,1 inkjet printing, coatings,7 and heat transfer fluids8-10 to name a few. Thus, fully 
understanding the binding kinetics of colloids is essential to expedite or delay flocculation.  
For a dilute suspension, the first stage in coagulation is the formation of binary pairs. Brownian 
diffusion and flow convection are the major mechanisms affecting coagulation. The terms 
“perikinetic” and “orthokinetic” apply to coagulation in the limits where Brownian diffusion and 
flow convection, respectively, dominate the rate of coagulation.11 These two limits correspond to 
zero and infinite Peclet number, respectively, where the Peclet number is defined as the ratio of 
shear rate to particle diffusion rate.  
 12 
A century ago, Smoluchowski determined the collision rates of dilute spheres in both the 
perikinetic and orthokinetic limits, where hydrodynamic interactions (HI) between the spheres are 
neglected. This collision rate equals the flocculation rate if particle attractions are infinitely strong 
and infinitely short-ranged, so that particle motions are unaffected by inter-particle forces until 
contact, and then the particles bind irreversibly. The average Smoluchowski flocculation time 
( Bt )  multiplied by the particle number concentration (n ) gives a rescaled flocculation time Vt , 
which is given by Eqs. (2.1) and (2.2), respectively for the perikinetic and orthokinetic limits.12,13 
Later, by introducing the concept of a “stability ratio” W , defined by Eq. (2.3), the effects of 
both HI and finite-range attractive potentials were taken into consideration.13 
tV−B
Smoluchowski = tBn =
1
JB
Smoluchowski
=
3µ
8kBT
  
(2.1) 
tV−S
Smoluchowski = tSn =
1
JS
Smoluchowski
=
3
32 !γa3
 
(2.2) 
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V
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V
t JW
t J
= =  
(2.3) 
In the above, Vt  denotes binding time per unit volume (i.e., binding time multiplied by particle 
concentration as noted above), µ  is the fluid viscosity, J  is the coagulation rate per unit 
concentration, a  is the particle radius, Bk  is the Boltzmann constant, T  is the temperature, W  is 
the stability ratio, and !γ
 
is the shear rate. Moreover, the subscripts B  and S  denote Brownian 
and shear dominated flocculation, respectively. Calculations of the stability ratio and therefore 
binding time have been reported in the presence of HI and finite-ranged potentials, in both the 
perikinetic and orthokinetic limits.13,14 
Determining the binding time outside of the perikinetic and orthokinetic limits, where both 
Brownian diffusion and fluid convection are important, is challenging.13 Swift and Friedlander 
suggested linear independence of Brownian motion and shearing flow, so that their effects on the 
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rate of binding could be simply added together.15 They backed this idea with their experimental 
results for polystyrene particles. However, later, more detailed, studies proved that the presumed 
linear independence of Brownian motion and flow is not valid.11,13,16 
Thirty years ago, Feke and Schowalter therefore carried out a perturbation expansion of the 
convection-diffusion equation for spherical particles to determine the effects of weak Brownian 
motion on orthokinetic coagulation.13 They considered the effects of finite-ranged inter-particle 
forces (electrostatic repulsion and induced-dipole attraction), as well as HI. (With HI present, the 
finite-range attractive forces must become singular at particle contact to drive particle contact in 
the presence of singular lubrication resistances.) Their analysis yielded both the binding rate in 
the orthokinetic (infinite Pe ) limit, plus a correction term of order 1/ Pe . They set a uniform 
particle concentration boundary condition in the upstream region. Thus, their method only applies 
to a strongly convection-dominated regime. They studied both shear and uniaxial extensional 
flows and emphasized the nonlinear relationship between Brownian diffusion and flow type and 
strength. They concluded that, depending on the flow number, which is the dimensionless ratio of 
the strength of the flow to the strength of the attractive potential, weak Brownian motion can lead 
to a positive or negative deviation from the orthokinetic coagulation rate.  
Lattuada and Morbidelli recently (in 2011) carried out a numerical simulation using a finite 
difference method to study the effect of repulsive inter-particle forces on steady-state coagulation 
of binary pairs in an axisymmetric extensional flow, over the entire range of Pe  values, with 
HI.1 Their effort is one of the most advanced numerical studies of flow-induced coagulation to 
date. However, they noted that the governing convection-diffusion equation is very stiff, and 
implementation of both the short-ranged inter-particle interactions, and the far field boundary 
conditions, necessitated limiting their analysis to flows with cylindrical symmetry to reach 
converged results. Thus, simulating shear flows, for which the particle concentration field is 
three-dimensional, was still not possible using their method, even with modern computer power.  
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Another scheme employed for predicting the flocculation rate of colloids is Brownian dynamics 
(BD) simulations, in which a Langevin stochastic differential equation is numerically integrated 
in order to determine the positions of particles and their collision rates at discrete time intervals. 
Xu et al. recently performed BD simulations in the absence of HI to determine the rate of 
formation of particle pairs at intermediate shear rates between the perikinetic and orthokinetic 
limits.11 They avoided problems of specifying boundary conditions for determining the steady-
state rate of coagulation by solving an initial value problem of a shear flow suddenly imposed on 
a suspension of 20,000 spheres initially randomly distributed in a periodic cubic box. They 
calculated the initial rate of formation of particle pairs over a long enough time to get a 
reasonable average but short enough to avoid loss of many particles.  Their method, while valid in 
principle, is wasteful in that a vast majority of particles does not collide and so does not 
contribute to the average collision time. The use of a huge number of spheres allows good 
averages to nevertheless be obtained, but also makes extension of the method to allow inclusion 
of HI impossibly expensive.  
Within the past year, Kelkar et al. employed two theoretical models and BD simulations to 
investigate binding kinetics of dense colloidal suspensions in the absence of flow.7 They also 
neglected HI, but accounted for short-time effects on binding in the dense-concentration limit, 
where particle-particle correlations affect the time-dependent binding rate. As an initial state, they 
assumed an equilibrated particle spatial distribution in the absence of coagulation, and then 
suddenly switched on the binding of colliding particles. In fact, attaining such an initial condition 
for particles capable of coagulation would appear to be a challenging task experimentally.  
This brief summary of both now-classic work, and very recent theory and simulations, shows that 
the basic problem of coagulation rates of sheared colloidal suspensions has not been solved, even 
in the dilute-particle limit and with spherical particles, except for negligibly slow or very fast 
flows.  In addition, novel colloids with non-uniform surface composition or dimpled surfaces 
have been introduced recently as building blocks for producing complex structures like helices, 
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and chains.4-6 A particular example of particles with spherical shape but anisotropic interaction, is 
that of “Janus” particles, with an axisymmetric surface “cap” or face with attractive interactions 
that differ from that of the rest of the particle surface. For Janus spheres, in addition to separation 
distance, relative orientation of particles also affects binding kinetics. Determination of 
aggregation rates for Janus spheres by solving a convection-diffusion equation (e.g., such as that 
solved by Lattuada and Morbidelli1) would be even challenging than solving it for uniform 
spheres in shearing flow, because of the two extra degrees of freedom required to keeping track 
of the orientational degrees of freedom of the two colliding particles.  
Recently, Larson Group implemented a BD simulation method to study binding kinetics of 
colloids, including Janus colloids, in the dilute limit, in the absence of flow, in the presence or 
absence of a potential, and with full HI.6 A key innovation in this method was the use of BD 
calculations with only two spheres, since in the dilute limit only the interactions of pairs of 
spheres can influence the binding rate, even with HI.  Here, this method is extended to investigate 
the effects of shearing flow of arbitrary strength on coagulation. The goal of this research is to 
provide a robust simulation method, able to predict recognition kinetics of colloids over the 
whole Pe  range, in the dilute limit. (The developed method is extendable to the non-dilute limit 
by breaking HI into near-field lubrication and far-field multibody interactions with the method of 
Stokesian dynamics,17 although this extension is not undertaken here.) To cope with the far-field 
boundary conditions at infinity, a set of periodic rectangular simulation boxes with different 
aspect ratios and different sizes are used and results are extrapolated towards infinite box size. In 
this way, a “shear-induced shadow effect” is overcome whereby parts of the box suffer a 
statistical depletion of particles that becomes non-physical in a finite periodic box, when either 
the fore and aft shadows, or the side shadows interact. Simulation results are compared and 
validated with several existing reports in different coagulation regimes, including the 
Smoluchowki no-HI limits,12 and the results from Feke and Schowalter13 in the high-shear limit 
with HI and attractive interactions. Also, different potential types are employed to consider a 
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range of inter-particle forces from pure attraction to a combination of attraction and repulsion. 
The ability to simulate particles with surface anisotropy opens promising routes for better 
understanding shear-enhanced self-assembly of complex structures formed from novel 
anisotropic colloids.  
 
2.2. Simulation methodology 
The code for Brownian dynamics simulations was developed by Eric Larson and Jun Liu under 
direction of Professor Ronlad Larson. The contribution of author of this dissertation in this regard 
was finding the proper boundary conditions and simulation box size to ensure the convergence of 
the results.  
 
2.2.1. Incorporation of shear flow in Brownian dynamics method 
Previously,6 a 12 12×  resistance matrix was established to account for the translational and 
rotational motions between two spheres induced by HI using formulae given by Jeffrey and 
Onishi.18 The basics of the implemented BD method are described in Appendix A. Essentially, to 
include the effects of shear flow, another term has to be included in the Langevin stochastic 
equation (See Appendix A), which describes shear-induced HI effects. This term entails double-
dot products of third-rank g  or h  tensors into the second-rank rate of strain (E ) tensor. Eq. (2.4) 
can be written following Jeffrey’s work:19  
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The elements a,b( !b)  and c  are second-rank tensors which relate the forces and torques on each 
sphere to their translational and rotational velocities. The tilde sign on b  matrices is the transpose 
operator.20 Also, g  and h  are third-rank tensors describing the coupling between the flow field 
and the resulting translational and rotational motion, respectively.19,20 In addition, E  is the rate of 
strain tensor for a shear flow, U  is the translational velocity, Ω  is the rotational velocity, µ  is 
the fluid viscosity, and F  and T  are the external force and torque exerted on each sphere, 
respectively. Finally, x  is the position vector.19,20  
In Eq. (2.4), subscripts 1 and 2 for variables or matrices refer to spheres 1 and 2, respectively. For 
instance, 12a  is the proportionality constant multiplying the force exerted on sphere 2 ( 2F ) to 
give the translational velocity of sphere 1 ( 1U ). Finally, variables without a subscript describe 
the flow.19,20 
Shear flow at any point is described by a superposition of a solid-body rotation and an extensional 
flow via Eq. (2.5): 
Sv x E x=Ω× + ⋅  (2.5) 
where x  is the position vector, and Ω  and E  are the vorticity vector and rate of strain tensor, 
respectively. 
In Eq. (2.4), mobility tensors , ( )a b b
:
 and c  are obtained by inverting the 12 12×  resistance 
matrix established previously.6 To describe the shear-induced HI effects on the translation and 
rotation of spheres, the general form of the third-rank tensors mentioned in Eq. (2.4), i.e. 11g , 
12g , 21g , 22g , 11h , 12h , 21h , and 22h  for far and near-field cases, must be obtained using Eq. 
(2.6).19,20  
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(2.6) 
The dimensionless resistance functions 
( )
ijk
G αβ  and ( )
ijk
H αβ  can be obtained using Eqs. (2.7) and 
(2.8), respectively.19  
( ) ' ' ' ' ' ' ' '1( ) ( 2 )
3ijk
G G
i j ij k i jk j ik i j kG X d d d Y d d d d d
αβ
αβ αβδ δ δ= − + + −  
(2.7) 
( ) ' ' ' '( )
ijk
H
i jkm m j ikm mH Y d d d d
αβ
αβ ε ε= +  
(2.8) 
where 'd  is a unit vector connecting the centers of the spheres, δ  is Kronecker delta, and ε  is 
the third-rank Levi-Civita tensor. Also, α  and β  are used to refer to spheres 1 or 2, while 
subscripts i , j , and k , (and dummy variable m ) are employed to distinguish matrix and vector 
elements defined by the three spatial dimensions, where G , and H  are third-rank tensors. 
Moreover, X
 
and Y represent the hydrodynamic functions for flows axisymmetric and 
transverse to spheres’ centerlines, respectively, as discussed in Jeffrey.19 Similar to figures shown 
in the previous publication by Larson Group,6 the G , and H  functions were plotted against gap 
between the spheres and it was concluded that the cross-over formulae given by Jefferey and 
Onishi18 and Jeffrey19 appropriately bridge the near- and far-field limits.   
In Eqs. (2.7) and (2.8), when ' '1 21, 0,d d= =  and 
'
3 0d = , the centers of the two spheres are on 
the x -axis, and the expressions for the third-rank tensors ( )
ijk
G αβ  and ( )
ijk
H αβ
 
become relatively 
simple. To determine the effect of shear flow for an arbitrary orientation between the two spheres 
without needing to express ( )
ijk
G αβ  and ( )
ijk
H αβ
 
for all particle configurations, a special frame is 
defined in which the x  axis is oriented along the axis connecting the centers of the two spheres. 
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The tensor E  describing the shear flow is rotated into the special frame using a matrix Q  which 
is defined as:  
( , ) ( ) ( )x zQ R Rθ φ φ θ=  (2.9) 
Where R  is the standard rotation matrix, and θ  and φ  correspond to the polar and azimuthal 
angles with respect to the x -axis, respectively. The rate of strain in the original frame is given by 
Eq. (2.10), and in the special frame will be of the form mentioned in Eq. (2.11): 
E = γ
i
2
0 1 0
1 0 0
0 0 0
⎡
⎣
⎢
⎢
⎢
⎤
⎦
⎥
⎥
⎥
 
(2.10) 
' ( , ) ( , )TE Q EQθ φ θ φ=  (2.11) 
After rotating the E  tensor into the special frame, using Eq. (2.4) the translational and rotational 
sphere velocities are calculated. Then, these velocities for each sphere are rotated back into the 
original frame using Eqs. (2.12) and (2.13), below.  
1 2
'
1 2 ( , ) ororU Q Uθ φ=  
(2.12) 
1 2
'
1 2 ( , ) oror Q θ φΩ = Ω  
(2.13) 
While these rotations of frame involve extra computations, they use only second rank tensors, and 
save us the complication of expressing the third rank tensors ( )
ijk
G αβ  and ( )
ijk
H αβ  in an arbitrary 
frame, in which each tensor would contain 27 non-zero components.  
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2.2.2. Simulation details 
To save computation time while preserving accuracy, a variable timestep is used that avoids 
sphere overlap, by requiring that the maximum decrease in the gap h  between particles during a 
timestep is less than or equal to some fraction λ  (usually 1/20) of the gap.  
The general equation to determine timestep size for equal sized spheres is shown in Eq. (2.14). 
Neglecting HI, an upper limit for the decrease in gap between particles is obtained by adding the 
maximum possible decrease in gap due to the Brownian motion (first term on the left side) and 
shear flow (second term on the left side).  
2 3
6kBTΔt
3π (2a)µ
+ !γ ycosψ Δt = λh  
(2.14) 
Where Bk  is Boltzmann constant, T  is temperature, tΔ  is timestep size, µ  is fluid viscosity, a  
is the sphere radius, !γ  is shear rate, y  is the separation between the particle pairs in the shear 
gradient direction, and hλ  is the maximum distance that the particle is moved in a single 
timestep. The factor of 2 3  in the first term on the left-hand side is to account for the fact that 
both spheres can diffuse in three orthogonal directions. The second term is a projection of the 
shear flow velocity onto the vector connecting the centers of the two spheres and ψ is the angle 
between this vector and the velocity vector of the shear flow at the location of sphere 2. Solving 
Eq. (2.14) yields the appropriate timestep size. Obviously, as particles get closer, the timestep 
size becomes smaller, but much time is saved by taking large steps when particles are far apart, 
while retaining accuracy.   
To prevent the integration from taking too long when the spheres get very close, a cutoff shift 
distance is introduced (1 nm in this research). This means that when hλ  is less than 1 nm, 1 nm 
is substituted for hλ  in Eq. (2.14) before solving for tΔ . Also, if the coefficient !γ ycosψ  is 
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less than 10-8 m/s, the equation is made easier to solve by removing this term and then solving the 
modified equation for tΔ . 
To determine binding times, two particles are placed randomly within the simulation box and the 
equations are integrated until a “collision” occurs, and the time to collision is recorded. Since 
hydrodynamic lubrication forces become singular when the particles come into contact, two 
methods are used to deal with this. For purely attractive potentials due to van der Waals 
interactions, the attractive force is singular at contact and this overcomes the singularity in the 
hydrodynamic force. As a second approach, for a combined attractive and repulsive potential with 
a secondary minimum, or in the absence of a singular attraction, a cut off distance is imposed 
close to the minimum in the potential (50 nm, unless stated otherwise) at which separation 
distance the particles are assumed to have aggregated, and the simulation is stopped at that point. 
Of course, when the potential is not singular, particle pairs will eventually separate due to 
hydrodynamic or Brownian forces, but for a reasonably deep minimum in potential at a distance 
away from the particle surface, binding can be long-lived enough to be considered “permanent,” 
and hence cutting off the simulations at a pre-determined separation distance can be a reasonable 
approximation in some cases. Of course, in the absence of HI, particles simply collide, and the 
time of collision is taken from the point at which overlap first occurs.  
For Janus particles with surface anisotropy, binding requires not only proximity, but also that the 
attractive sides face each other. Thus, simulating coagulation of Janus particles requires 
determination of relative orientation of spheres after each timestep, as well as particle positions.  
At the end of each integration timestep, the origin of the coordinate system is translated to the 
center of one of the two spheres, the “test sphere” or sphere 1 at the center of the periodic 
simulation box. This eases the calculations, since it keeps the position of the test particle at zero, 
while the position of the second particle is updated accordingly. This method also assures that in 
the periodic domain, the closest particle to the test particle is always the second particle within 
the simulation box, and not any of its periodic images. Since in the dilute regime, the dynamics 
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are dominated by particle pairs only, this method also guarantees that the strongest two-body 
interaction with the test sphere is the one calculated. (Hydrodynamic interactions of the test 
sphere with periodic images of either sphere are not calculated, which is appropriate in the dilute-
suspension limit.) If the second sphere passes through a wall of the box even after the test particle 
has been re-centered, then the test particle is re-introduced on the opposite face of the box. 
For the case of periodic boundary condition in a shear flow, once a particle leaves the box in the 
velocity gradient direction and returns in the other side, it experiences a sudden shift in its 
longitudinal velocity.  For the two-particle simulations, a dramatic effect of the periodic boundary 
condition for the velocity field is not expected, and so the simplest method is used, which allows 
a jump in velocity when crossing the boundary in the y  direction. This was checked by also 
using the Lees-Edwards boundary condition21 where once the particle leaves the simulation box 
in the velocity gradient direction, it will be placed on the other side with a different longitudinal 
position to account for the mentioned jump in velocity. Deviations of less than 5% were observed 
in the absence of HI between these two types of boundary conditions, showing that either 
boundary condition is able to impose an appropriate uniform concentration in the far field. For 
simulations of dense suspensions, it would be necessary, however, to use the Lees-Edwards 
boundary conditions.  
The two particles were initially placed randomly inside the simulation box and then the equations 
were integrated until collision; a single “run” consists of a repetition of this around 2000 times, to 
obtain good averages of collision times and particle sampling of the simulation domain for a 
given shear rate. Simulations were performed using a computer cluster22 and desktop computers. 
The duration of a run (as defined above) typically ranged from a few minutes (in the absence of 
HI) to several days (with HI) on a single processor. Due to the novel scheme implemented for the 
simulation boxes, which will be discussed later in the Results and Discussion Section, these run 
times represent a huge savings of computational time. Simulations were performed using a 
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constant temperature of 300K . The viscosity of water at this temperature, namely 
30.865 10 .sPaµ −= ×  was chosen, and the particle radius was chosen to be one micron for 
both particles ( 1a b mµ= = ).  
 
2.2.3. Error analysis 
The standard error of the normalized binding times was calculated using Eq.  
(2.15): 
2
1
1 ˆ ˆ( )
( 1)
TN
r V i V
iT T
e t t
N N −=
= −
− ∑  
 
(2.15) 
Where Vˆt  is the binding time normalized by the zero-shear rate Smoluchowski limit in the 
absence of HI (Eq. (2.1)), TN  is the number of binding events (around 2000 in this study), and 
Vˆt  is average normalized binding time for the TN  binding events. 
In the Results and Discussion section, it will be shown that to determine the normalized binding 
time for the infinite dilution, results are linearly extrapolated against inverse box length. Taking 
this linear extrapolation of the form 11 2Vˆ xt m m L
−= + , the total error ( Te ) of normalized binding 
time for infinite dilution is calculated using Eqs. (2.16)-(2.18): 
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where Be  represents the standard error resulting from Brownian noise in the simulations amongst 
BN  data points, and ie is the standard error for uncertainty in the intercept of fitting a linear line 
to data points using least square method. Also, BN  is number of different box sizes used to do an 
extrapolation towards infinite dilution. 
As mentioned before, each run resulting in a binding event between two particles was repeated 
around 2000 times. After roughly 1000 collisions, the value of average binding time did not 
change dramatically, implying that 2000 repetitions were adequate enough to reduce the random 
noise. The error in the intercept of linear fit ( ie ) contributes more to the total error than does 
Brownian noise ( Be ). Error analysis shows that the total error in the binding time in the infinite 
dilution is generally between 1-5 %. For some cases (e.g. high shear rates), however, the error 
value can be as large as 8 %. 
 
2.3. Results and discussion 
2.3.1. No-flow case 
In the absence of flow, only Brownian diffusion and the inter-particle potential affect particle 
motion.  
2.3.1.1. Effect of hydrodynamic interactions on binding kinetics 
The collision time for two equal-sized spheres in the infinite dilution limit and in the absence of 
flow, with HI, is calculated using the Smoluchowski solution:6  
3
8V B
Wt
k T
µ
=   
(2.19) 
( ) ( ) ( )
11 11 11
2
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( ) ( ) 12
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Here, µ  is fluid viscosity, a  and b are the particle radii, Bk  is Boltzmann’s constant, T  is 
temperature, W  is the “stability ratio,” PU  is the interaction potential between the two particles, 
and d  is center to center distance. Moreover, ( )G s  is a hydrodynamic coefficient that represents 
the effects of HI in retarding the relative velocity of the two spheres. In the equation for the 
inverse of ( )G s , the superscripts α  and β  on each matrix A  identify the sphere (sphere 1 or 
sphere 2), and the numeric subscript “11” designates the first diagonal element of each 3 3×  A  
matrix, which is the component governing resistance to changes in gap; i.e., squeezing motion, as 
discussed in previous paper published by Larson Group.6  
As mentioned above, to avoid the singularity in the hydrodynamic functions that occurs at 
particle contact, a cut off distance can be introduced into the integral in Eq. (2.20) and into BD 
simulations. When the inter-particle distance becomes smaller than the cut off distance, a 
collision is deemed to occur. Taking 50 nm as the cut off distance, W  is found to be 2.09 from 
the integration of Eq. (2.20), in the absence of an explicit interaction potential (i.e., 0PU = ). 
(The use of the cut off can be considered to represent the effect of a deep square well potential 
whose outer boundary lies at the cut off distance, so that there is no effect of the potential until it 
suddenly becomes very strong when the particle gap falls below the cut off.) Later in this project, 
a Hamaker attractive potential will be used, which becomes singular at contact and overcomes the 
repulsive singularity of the resistance matrix.  
Figure 2.1 depicts the effect of inverse cubic box length xL  on normalized collision times for the 
case of no flow. For this case, cubic boxes with dimensions ranging from 100 to 700 µm are used 
and results are linearly extrapolated against 1/ xL  to reach the infinite dilution limit.  
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Fig. 2.1. Normalized collision times as a function of inverse cubic box length ( x y zL L L= = ), in the 
absence of flow and no interaction potential.  The limiting values at infinite box size are given by Eq. (2.1) 
for the absence of HI and Eqs. (2.19)-(2.20) with HI, where in the case of HI the particles are assumed to 
collide when the gap between them reaches 50 nm. Since the sphere radius is 1 µm, the numerical value of 
xL  in µm can also be taken to be box dimension made dimensionless with the particle radius.  
 
The collision times, extrapolated to infinite dilution agree well with literature values both with 
and without HI (i.e., the Smoluchowski limits given by Eqs. (2.1) and (2.19)-(2.20)). The results 
show that HI slows down the binding of the particles, because of the strong lubrication resistance 
as the particles approach each other. The results in Fig. 2.1 also agree with the recent simulation 
results of Liu and Larson,6 and are in fact based on the same method. 
 
2.3.1.2. Induced-dipole attraction 
The following expression can be used for the attractive Hamaker potential HamakerU  between 
equal-sized spheres, which is a singular function at particle contact.13 
2 2 2 2
ker 2 2 2 2
2 2 4ln
6 4Hama
A a a d aU
d a d d
⎡ ⎤−
= − + +⎢ ⎥−⎣ ⎦
 
(2.21) 
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Here d  is the inter-particle distance, a is the particle radius, and A  is the Hamaker constant, 
reflecting the strength of van der Waals interactions.13  
The outer cut off distance, which is the gap distance above which effect of attraction of one 
particle on the other is taken to be negligible within the code, is set to 600 nm. The inner cut off 
distance is the gap below which particles are assumed to have collided. In the absence of flow, 
the collision time was found to be insensitive to the inner cut off distance, for cut off distances 
between 1 to 15 nm, which is a good indication of convergence of numerical method.  
Figure 2.2 depicts the variation of the normalized binding time with inverse cubic box length in 
the presence of a Hamaker attractive potential, in the absence of flow, with HI. Using Eqs. (2.19)-
(2.20), the predicted stability ratios are found to be 2.46, 1.9, and 1.38 for A / kBT = 0.1, 1, and 
10, respectively.  
 
 
Fig. 2.2 Comparison of extrapolated binding time from simulations with theoretical predictions of Eqs. 
(2.19)-(2.21) for the presence of induced-dipole attraction, and HI. 
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Figure 2.2 shows good agreement of the extrapolated values of the simulated normalized binding 
time with theoretical predictions, and that binding time is reduced by 40% as A / kBT  increases 
100-fold from 0.1 to 10. 
 
2.3.2. Shear flow 
2.3.2.1. Implementation of rectangular simulation boxes 
The strength of the shearing flow relative to particle diffusion is set by the Peclet number, given 
by:  
Pe = 3πµa
3 !γ
kBT
 
(2.22) 
Figure 2.3 shows the normalized concentration profile of the second particle in the central xy 
plane (where z = 0) at a high Pe , where, as mentioned earlier, the coordinates are centered on 
the first particle’s center. The concentration profile was obtained by binning particle positions in 
cubic cells of dimension equal to one particle radius. This profile is for a cubic box in 
which 100x y zL L L mµ= = = . As can be seen, there is a low-particle-concentration “shadow” of 
roughly cylindrical shape, oriented in the flow direction. When the particle enters this region, 
collision with the test sphere occurs very quickly, when flow is fast (i.e., high Pe ). But outside 
this region the particle spends much of its time repeatedly shooting across the periodic box. It is 
physically realistic for a depletion “shadow” to exist downstream of the test particle at high Pe . 
However, the shadow upstream of the particle (where “upstream” is at negative x  for 0y >  
where the flow is in the positive direction, and is at positive x  for 0y < , where the flow is in the 
negative direction) is an artifact of the periodic boundary conditions. No simple way could be 
found to introduce fresh particles into the upstream side of the box that would be robust to 
changes in Pe , and would not suffer artifacts arising from the variation of velocity across the 
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upstream surface of the box, and the presence of corners and sides of the box through which 
particles can diffuse. Periodic boundary conditions on all sides of the box seem to be the safest 
way to attain a far-field concentration of unity, when the box becomes asymptotically large.  
However, to approach the large-box limit at high Pe  where the downstream depletion shadow 
becomes highly elongated, the box must become very long in the x  direction, and cubic boxes 
become so voluminous that collisions become unreasonably rare. Under fast shear, the collision 
time is controlled by the time required for the second particle to diffuse into the cylindrical 
shadow region. This suggests the use of rectangular boxes (Fig. 2.4, a) with box length much 
larger than its width and height, so that the particle can diffuse into the shadow region faster, to 
both establish a uniform concentration far upstream of the test sphere and to accelerate collisions. 
Figure 2.5 reveals that the shadow is indeed obviated in a long rectangular box.  While the 
concentration field in Fig. 2.5 is noisy because of the stochastic nature of the simulations, and 
binning approximation, it will be shown that an accurate estimate of the collision time is 
nevertheless obtained.  
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Fig. 2.3. Particle concentration field, normalized to unity on average, for the central xy  plane, depicting 
the shadow effect, for 295Pe = , without HI, and binning resolution=1 µm.  Here a is the particle radius.  
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Fig. 2.4. (a) A rectangular box used to overcome the shadow effect, which in (b) it is approximated by a 
cylindrical domain for estimating the collision time, as described in the text. 
 
 
Fig. 2.5. Normalized concentration field for a long rectangular box for 295Pe = , without HI, and binning 
resolution=1 µm. 
 
As shown in Fig. 2.4b, to roughly estimate the collision time for a rectangular box in which the 
rate-limiting step for collision is lateral diffusion into the shadow region, the rectangular box is 
replaced with a cylindrical domain, and the diffusion equation in cylindrical coordinates is solved 
assuming negligible variation in concentration along the angular and longitudinal directions (Eq. 
(2.23)). The effect of convection is accounted for by assuming that a particle will quickly collide 
with the test sphere once it has diffused into the inner “shadow” cylinder with radius equal to that 
of the test sphere. With boundary conditions of uniform concentration in the far field ( / 2yR L= ), 
and zero concentration at the edge of the shadow ( R a= ), the collision flux and binding time are 
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calculated using Eqs. (2.24) and (2.25) below. While Eq. (2.25) provides a rough estimate, its 
accuracy should improve as the box width increases.  
 
10 ,nr
r r r
∂ ∂⎛ ⎞= ⎜ ⎟∂ ∂⎝ ⎠
 
 
(2.23) 
Collision flux = #collisions
time×area
= D ∂n
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)
 
 
(2.24) 
tV =
ℓn(
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2a
)
2πD
1
Lx
 
 
(2.25) 
In the above formulae, n  is the concentration of the second particle, D
 
is the diffusion 
coefficient, and the “area” used to compute the collision flux is that of the cylindrical shadow 
region (= 2 xaLπ ). Equation (2.25) indicates that for rectangular boxes that are too short to allow 
collisions to occur before the particle has crossed by length of the box, the dimensionless 
collision time per unit volume is inversely proportional to the box length, as is confirmed in the 
simulation results in Fig. 2.6. Furthermore, Eq. (2.25) shows that slopes of lines of normalized 
collision time vs. 1xL
−
 should be proportional to ( / 2 )yn L al , which is in fact also demonstrated 
to hold, in the inset to Fig. 2.6.   
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Fig. 2.6. Comparison of simulated normalized collision times for 138Pe =  in cubic and rectangular boxes, 
and their approach to the Smoluchowski orthokinetic limit. Inset shows the dependence of the slope of lines 
in the main figure for rectangular boxes vs. ℓn(Ly / 2a) . 
 
Figure 2.6 shows that for cubic boxes, the plot of normalized binding time versus inverse box 
length is nonlinear, making extrapolation to infinite box size difficult.  For rectangular boxes, 
however, the plots are linear, and the extrapolated values for all box widths converge to expected 
infinite-shear-rate Smoluchowski limit. (Data for box widths of 60 and 80 µm follow the same 
trend but are omitted for clarity.) So it appears that using rectangular boxes can counteract the 
adverse effect of the longitudinal shadow. (Later it will be shown that when the Pe  becomes 
extremely large (> 300), the ratio of box length to its width or height has to be increased even 
further to obviate the shadow.) 
Since for rectangular boxes, predictions for different box widths approach the same infinite-
shear-rate Smoluchowski limit as the box is elongated, to save computational time a relatively 
narrow 20 µm width is used for simulations of binding kinetics in all flows with strength of about 
15 300Pe< < .  
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For smaller shear rates ( 15Pe < ), however, as the box length is increased, an upturn appears in 
the plot of collision time vs. 1xL
− . This upturn occurs at ever-smaller box lengths as the shear rate 
decreases. As the box width is increased, however, the upturn is postponed to larger box lengths, 
as shown in Fig. 2.7. Thus, to minimize the effects of the upturn, for lower shear rates, 
simulations are carried out for larger box width (i.e. 40 µm). Also, with the exception of 
extremely fast flow with van der Waals inter-particle attraction, which will be discussed shortly, 
simulation results for very long boxes ( Lx > 700µm ) are ignored to allow a fit of a straight line to 
the simulation data to obtain the extrapolated value of the collision time.  
 
Fig. 2.7. The “upturn” in binding time as the box becomes very long for different box widths, at a small 
shear rate ( 0.15Pe = ). Empirical fits for simulation boxes with widths of 40 and 100 µm shown in the 
figure are 1 5ˆ 0.768 2 6.7029 10.62V x xLt L
−−= ++ ×  and 1 5ˆ 0.797 3.717 1.463 10V x xt L L
− −= + + × , 
respectively. Particles have a radius of 1 µm. 
 
As can be seen in Fig. 2.6 for all box widths, and in Fig. 2.7 for box widths greater than 20 µm, 
for xL  below a critical value (i.e., large enough 
1
xL
− ), lines of normalized collision time for 
rectangular boxes are linear, and can be fit by 11 2Vˆ xt m m L
−= + . Also for very large xL  (small 
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1
xL
− ), where the normalized collision time dramatically increases, the upturn can be fit to the 
formula 13ˆ /V xt m L
−= . So the expression 1 11 2 3ˆ /V x xt m m L m L
− −= + +  is able to fit the simulation 
results with the constant 1m  giving the extrapolated value of the collision time at infinite dilution 
without the effect of the upturn. Examples of this fit are shown for the simulation results in Fig. 
2.7 for box widths of 40 and 100 µm. This fit seems to work for most of simulation cases. In the 
rest of this chapter however, a linear extrapolation scheme is pursued, in which data for high xL  
where the upturn occurs is omitted. Similar results are obtained, however, if the upturn is also 
fitted using the above empirical formula, except for extremely high shear rates discussed below. 
To explore the cause of the upturn for very long boxes and low shear rates, Fig. 2.8 shows the 
normalized concentration contours in the central xy  plane for a very long rectangular box, in the 
absence of flow. The box dimensions ( 1000xL mµ= , 10y zL L mµ= = ) are chosen such that 
the resulting collision time will be in the upturn region.  
Fig. 2.8 clearly shows that when the aspect ratio becomes very large, a depletion slab appears 
around the test sphere, extending across the entire box in the y  direction, and the z  direction as 
well (not shown). This depletion slab is a consequence of the periodic boundary conditions. The 
second particle, when it is a great distance along the x  axis away from the test particle, and flow 
is absent or slow, takes a much longer time to diffuse to the plane containing the test particle and 
its periodic images in the yz  plane, than it does to diffuse within that plane to the nearest 
periodic image. Hence the second particle sees the array of periodic images of the test particle as 
a single absorbing slab. The diffusion time thus becomes very long, since the test particles 
towards which the second particle must diffuse are much farther away, on average, than would be 
the case for randomly distributed particles, or for a particle in a cubic box and its periodic images. 
In other words, as the result of periodic images along the relatively small y  and z  directions, 
there is a lateral “shadow” that extends laterally across the box and prevents the attainment of the 
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far-field uniform concentration at large y  or z . As the shear rate is increased, the influence of 
diffusion is reduced compared to longitudinal convective motion, and the upturn is postponed to 
larger aspect ratios. 
 
Fig. 2.8. Normalized concentration contours for the central xy  plane in a rectangular box with aspect ratio 
of 100, 0Pe = , without HI, and binning resolution=1 µm. 
 
Thus, while the longitudinal convective shadow is counteracted by lengthening the box in the x  
direction, this can eventually create a lateral diffusive shadow in y  and z  directions. So, the box 
length and width should be chosen to keep both shadows minimal. To wipe out the longitudinal 
shadow, the time for convection across the length of the box must be longer than the time 
required for lateral diffusion across the box. For long boxes, the time for convection across the 
box is dominated by the period of time that the particle is relatively close to the shadow region 
where the particle velocity is low; hence the convection time is of order Lx / (a !γ ) .  The time 
required for the sphere to diffuse across the box width is of order 2 /yL D , where D   is the sphere 
diffusivity. Thus, the condition for removing the longitudinal shadow is Ly
2 / D << Lx / (a !γ ) . In 
terms of Peclet number (Eq. (2.22)), this condition is expressed as:  
0.51( )y x
L L
a a Pe
<< ×  
(2.26) 
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On the other hand, to minimize the diffusive shadow in the lateral directions, y zL L=  should be 
chosen large enough that the particle cannot diffuse over the entire y  direction in the time it 
takes to convect along the box. If the particle can diffuse in this time, then the depletion zone 
around one sphere will be affected by the loss of particles due to collisions with a periodic image 
of the sphere separated by a distance yL  in the y  direction. This condition is just the opposite of 
the condition given by Eq. (2.26). So, minimizing both shadows simultaneously does not seem 
possible. However, since these equations are scaling laws, their prefactors could be quite 
different, making it possible to find an optimal range of box geometries that minimizes both 
shadows and allows extrapolation to an accurate solution. In fact, in the subsequent sections, it 
will be shown that for each Pe  value, it is possible to find a range of box aspect ratios for which 
the effects of both shadows are minimal.  In addition, it will be shown below that as the box 
width is increased, with box aspect ratio held within a specified range, the simulation results 
converge, and for fast and slow flows they converge to known asymptotic results.  
Figure 2.9 shows the normalized concentration profile of the second particle in the central yz  
plane. This contour map is for a rectangular box where 1000 , 10x y zL m L L mµ µ= = = . In order to 
increase the resolution, the bin size in the y  and z  directions have been reduced to 0.2 µm. On 
the other hand, for the sake of decreasing the binning noise, bin thickness has been kept 1 µm in 
the x  direction. This figure indicates that the diffusive shadow in the z  direction plays a more 
important role than its counterpart in the y  direction. Apparently the gradient of shear in the y  
direction makes the concentration profile more uniform in that direction compared to z . 
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Fig. 2.9. Normalized concentration contours in the central yz  plane, with 295Pe = , without HI, and 
binning dimension of 0.2 µm in y  and z  directions.   
 
2.3.2.2 Particle trajectories with HI 
When HI is considered, the motion of one particle affects the motion of the other. The accuracy 
of treatment of HI is tested by turning Brownian motion off, and comparing particle trajectories in 
Fig. 2.10 from our code with results published previously.23,24 In Fig. 2.10a, particles are initially 
placed such that the distance between the centers of spheres is 10 sphere radii in the longitudinal 
direction and 0.4 sphere radii in the lateral direction (Although in order to enhance clarity, a more 
restricted longitudinal range is shown in this figure). In Fig. 2.10b, the initial longitudinal 
distance is 6 sphere radii, while the lateral distance is varied from 0.8 to 2.4 sphere radii. Figure 
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2.10 indicates nearly perfect agreement between particle trajectories predicted by the present 
research with those previously determined using boundary element methods.23,24  
 
 
Fig. 2.10. Simulated particle trajectories. (a) Coordinates ( .x y ) of the second particle position in shear 
flow in a frame in which the origin moves with the test particle, compared with the trajectory from Zhu and 
Ingber.23 Test particle is shown with a closed circle, and second particle by an open circle. (b) The 
logarithmic variation of ε, gap normalized by the sphere radius a, vs. second particle longitudinal position 
compared with results of Pozrikidis.24 The particles are all placed in the xy  plane, with z  = 0. 
 
Table 2.1 compares relative velocities of particles scaled with !γa  (where !γ  is shear rate and a  is 
particle radius) from the present work with theoretical predictions reported from a high order 
expansion that includes both lubrication and far-field contributions, tabulated by Pozrikidis.24 It 
should be noted that in this case particles are placed at the same x  coordinate but separated in the 
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velocity gradient direction by a gap of h aε= . Table 2.1 shows that relative velocities of 
particles reported here are close to the higher order analytical solution.24 The reason for slight 
difference between the present work and those of Pozrikidis is that the high-order solution is 
derived from a 12th order far-field expansion and a higher-order lubrication solution than the 
solution drawn from Jeffrey and Onishi18 used in the current study. 
Table 2.1. Particles relative velocities scaled with !γa  as a function of non-dimensionalized gap (ε) 
compared with analytical values given by Pozrikidis.24 
 
 
 
 
 
 
 
 
2.3.2.3. Binding kinetics in the absence of hydrodynamic interactions 
Although there are many studies of shear-induced particle doublet formation in the absence of 
HI,11,12 the Pe  range covered has been limited. Here simulation results for doublet formation in 
the absence of HI are presented over the complete range of Pe  values, both to supply a 
comprehensive set of results and to validate our simulation results against previous studies. The 
predicted normalized collision times in the infinite dilution limit for a wide range of Pe  number 
are shown in Fig. 2.11. 
ε 0.05 0.001 0.0001 0.00001 
yˆV (Present work) 
0.9339 0.8639 0.8510 
0.8430 
yˆV (Analytical solution
24) 0.9237 0.8555 0.8424 0.8343 
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Fig. 2.11. Dependence of normalized collision time on Pe  in the absence of HI. (a) Comparison with 
Smoluchowski limit,12 with low-Pe  formula of van de Ven25 and with simulation results of Xu et al.11. (b) 
Fits for entire and partial ranges of Pe . 
 
Fig. 2.11-a shows that as Pe  becomes small, the simulation results approach the perturbation 
prediction of Van de Ven25 namely:  
0.5
1ˆ
1 0.5136 (2Pe)V P
t
α
=
+
 
(2.27) 
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In this equation, Pα  represents the perikinetic capture efficiency, which in the absence of HI is 
justαP =1. It should be noted that due to a difference in the definition of Pe , a factor of 2 
appears in Eq. (2.27) compared to the relation given by Van de Ven.25  
In addition, Fig. 2.11-a shows that for larger shear rates, the simulations results agree with those 
reported by Xu et al. obtained from the initial slope of the particle pair formation rate in 
simulations with thousands of particles.11 Moreover, this figure illustrates that for 60Pe > , the 
extrapolated values of the normalized binding time are practically indistinguishable from infinite-
shear-rate Smoluchowski limit (Eq. (2.2)). As a result, carrying out simulations of higher Pe  
values was not needed. Later, when the effects of HI with attractive inter-particle forces are 
considered, to attain the asymptotic limit for orthokinetic coagulation, it will be shown that it is 
essential to further increase Pe . 
Equation (2.2) shows that the collision time scales with 61/ ( )m Pe  when Pe  is very large, while 
Eq. (2.27) indicates that it scales with 
0.5
4 51/ ( )m m Pe+ , when Pe  is very small. Combining these 
two equations to get an expression for the whole curve results in 0.54 5 6ˆ 1/ ( )Vt m m Pe m Pe= + + . 
Taking the constants “ 4m ” and “ 6m ,” from the values for the zero-shear and infinite-shear-rate 
Smoluchowski predictions, and treating 5m  as a fitting parameter, yields 
0.5ˆ 1/ (1 0.362 0.425 )Vt Pe Pe= + + , which is given by the solid black line in Fig. 2.11-b. This 
expression provides an approximate formula for the whole range of Pe  in the absence of HI, and 
is especially accurate for very low and very high shear rates. A more accurate formula for low 
Pe  values ( 15Pe ≤ ) is 0.5ˆ 1/ (1 0.459 0.325 )Vt Pe Pe= + +  while for high Pe  values ( Pe ≥15 ), the 
expression ˆ 1/ (1.109 0.425 )Vt Pe= +  is accurate, as shown in Fig. 2.11-b. 
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2.3.2.4. Normalized collision time in the presence of HI 
Few studies have considered the effect of full HI on shear-induced coagulation of colloids,14 and 
those that have done so have been generally limited to a very restricted range of Pe  values. 
Figure 2.12 presents the normalized collision time computed from the simulations performed in 
this research as a function of Pe  with HI but no inter-particle interaction. Instead, an inner cut 
off distance for “collision” is set at 50 nm. Comparing Figs. 2.11 and 2.12, one can conclude that 
in shear flow, HI slows collision times and coagulation by a factor of around 2 at low shear rates 
and around 3 in the high-shear rate limit, using this cut off criterion for coagulation. Figure 2.12 
also shows agreement with the low-Pe  perturbation expansion for very low Pe  values (Eq. 
(2.28)).14 It should be noted that for this prediction W is calculated using Eq. (2.20), and is found 
to be 2.09, using the cut off distance of 50 nm.  
0.5
ˆ
1 0.257
V
Wt
Pe
W
=
+
 
(2.28) 
Similar to results in the absence of HI, an expression of the form  
0.5ˆ 1/ (0.488 0.165 0.115 )Vt Pe Pe= + +
 
shows good agreement with simulation results over a wide 
range of Pe  numbers.  
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Fig. 2.12. Dependence of normalized collision time on Pe  with HI. The line shows the low- Pe  
perturbation result from Russel et al.14 
 
2.3.2.5. Influence of inter-particle forces on coagulation kinetics 
2.3.2.5.1. Induced dipole attraction 
With inclusion of a Hamaker attractive potential, for the case of no flow, good agreement 
between simulation results and theoretical predictions was observed in Fig. 2.2. The asymptotic 
limit with a Hamaker potential for extremely high shear rates has been reported for fixed values 
of the “flow number” (called fl  hereafter), which is the ratio of flow strength to attractive 
potential, as defined in Eq. (2.29), given below.13 To maintain the fl  constant with increasing Pe, 
the Hamaker constant must also be increased proportionally. Figure 2.13 compares the 
dependence of extrapolated values of the collision time multiplied by Pe  for different box 
widths to an asymptotic solution reported by Feke and Schowalter13 for fl  of 1000.  
fl = 6πµa
3
A
!γ =
2kBT
A
Pe  
(2.29) 
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Fig. 2.13. Comparison of simulation results with those reported by Feke and Schowalter13 for fl  of 1000. 
For box width 20 µm and 40 µm, a fixed box length range (from 100 to 700 µm) was used, while for the 
other box widths, the box length range was varied to avoid the shear-induced shadow effects. Overlaps 
between simulation results, while box width is varied from 15 to 20 µm, and 20 to 40 µm is shown.  
 
It should be noted that since Pe  values are extremely high in this case, the aspect ratio of 
rectangular boxes must be made especially large, or the longitudinal shadow will corrupt the 
results; for example, for a Pe  value of 30,000 even a box aspect ratio of 1000 is not large 
enough. So, to avoid the adverse effect of the shadow for high Pe  values the box length should 
be set long enough that the particle has time to diffuse into the shadow and obviate it. However, if 
the box length is chosen too long, the lateral shadow produces an upturn in binding times vs. 1xL
− . 
So a range of box lengths spanning from approximately one third of the box length at which the 
upturn begins to the onset of the upturn is chosen to minimize the effects of both shadows at a 
typical high Pe  value. Also, with variation of shear rate or box width, the range of box lengths is 
varied according to the scaling given in Eq. (2.26). For a fl  of 1000, due to increased convection 
of fluid, it was necessary to decrease the inner cut off distance at which binding is deemed to 
occur from 15 to 1 nm to get converged results. 
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According to Fig. 2.13, as Pe  is increased, the deviation between the simulation results and 
those predicted by Feke and Schowalter13 decreases. Also, for extremely high Pe  values (> 104), 
the slope of the simulated values of the aggregation time multiplied by Pe  approaches the 
asymptotic horizontal line limit (zero slope) on a log-log plot.13 Furthermore, this figure shows 
for box widths of 5 to 15 µm, a wider box gives results more closely approaching the asymptotic 
predictions at very high shear rates. This provides confidence that as the box width is increased, 
the results approach the infinite dilution limit. This suggests that the effects of the convective and 
diffusive shadows can eventually be overcome by increasing box size while choosing box shape 
to minimize errors of both longitudinal and lateral shadows. 
For low and intermediate Pe  values, the longitudinal shadow for rectangular boxes is not as 
serious an issue as it is at the higher Pe. One can see this in Fig. 2.13 by noting that for Pe  in the 
range 100-200, the results for boxes of width 15 and 20 µm are almost identical. It should be 
noted that in this figure the results with box width of 20 µm were obtained using the previously 
specified fixed box length range from 100 to 700 µm, while for a box width of 15 µm, the box 
length was varied as described above. So for smaller Pe  values, it is possible to return to the 
previous method of using the fixed box length range from 100 to 700 µm. As shear rate is further 
reduced, the lateral shadow begins to play a significant role and an upturn in collision time tends 
to corrupt a larger portion of the simulation data. To solve this problem, as before, the box width 
is further increased to 40 µm in order to postpone the effect of the lateral shadow (See Fig. 2.13). 
Feke and Schowalter13 performed a perturbation expansion to solve for the asymptotic high-
shear-rate limit of coagulation with induced-dipole attraction, i.e., using the Hamaker potential 
given in Eq. (2.21). Their asymptotic solution yielded an expression for the aggregation time that 
included a zeroth and first order term in the aggregation rate, which can be written in terms of the 
aggregation time in the form 7 8/ ( )Vt Pe m m Pe= + , and thus is only valid at high shear rates. 
Here the constants 7m  and 8m  are both functions of the fl . The presented BD simulation method 
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is able to simulate shear flows at arbitrary Pe  numbers, and the results over the whole range are 
plotted in Fig. 2.14 with the Hamaker potential at two different fl  values. As described before, 
for high Pe , the box width is set to 15 µm, but as Pe  is decreased and the transverse shadow 
starts to become important, the box width is increased.  For example, to obtain Fig. 2.14, for 
fl =1, a box width of 20 µm was used for 15 138Pe< < , and a box width of 40 µm, 
for 15Pe < .  
 
Fig. 2.14. Simulation results over the entire range of Pe  with induced-dipole attraction at two different 
fl  values, along with asymptotic results from Feke and Schowalter.13  
 
According to Fig. 2.14, as Pe  is reduced, the relative deviation between normalized binding 
times for different fl  values decreases. As stated earlier, to keep the fl  constant, the Hamaker 
constant is varied in proportion to Pe. Thus, for very small Pe  values, the Hamaker constant is 
reduced so much that it has only a minor effect on the aggregation time. Also, the Feke and 
Schowalter results deviate from the numerical results as Pe  drops below 102, and the deviations 
are in opposite directions for fl  of 1 and 1000, because of the opposite signs of the 7m  term for 
1fl =  and 1000 in the Feke and Schowalter perturbation expression given above. Of course, the 
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diverging aggregation time for 1000fl = , resulting from the negative value of 7m  in the Feke 
and Schowalter results is invalid at Peclet numbers below around 200. The numerical results 
show little indication of a change in sign of the coefficient 7m  when fl  increases from 1 to 1000, 
indicating that the first order term with coefficient 7m  in the asymptotic expansion of Feke and 
Schowalter has a very limited range of applicability. To our knowledge, the results in Fig. 2.14 
represent the first determination of the range of applicability of the now-classic Feke and 
Schowalter analysis of particle coagulation in sheared dilute suspensions.  
 
2.3.2.5.2. Electrostatic repulsion and depletion attraction 
Next, a potential composed of an electrostatic repulsion (Eq. (2.30)) and a depletion attraction 
(Eq. (2.31a)) is implemented in the simulations. 
2 22 64 helectrostatic B
abU k Tn e
a b
κπ γ κ − −∞= +
 
(2.30) 
depletion p B overlapU n k TV= −  (2.31a) 
2 2 2 2
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⎩
 
 
(2.31b) 
, ,p pR a r r b r d a b h= + = + = + +  (2.31c) 
In the above, a  and b  are particle radii, Bk  is Boltzmann’s constant, T  is temperature, γ  is the 
reduced surface potential (=0.589), 1/κ  is the Debye length (=6.8 nm), and n∞  represents the 
number density of ions in the solution (= 23 312.04 10 #/m× ). Moreover, pr  is the depletant radius 
(=100 nm), pn  is the depletant number density (=
20 37.30 10 #/m× ), h  is the gap distance, and 
overlapV  is the gap-dependent volume of overlap of the two spheres.
6 The values of the above 
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parameters given in parentheses were chosen so that the total potential energy (Eq. (2.32)) has a 
minimum at the selected inner cut off distance that was used earlier in the absence of a potential 
(=50 nm). The potential depth at this minimum using these parameters is determined to 
be25.2 Bk T .  
total electrostatic depletionU U U= +  (2.32) 
Figure 2.15 shows the dependence of the normalized collision time on Pe  in the presence of this 
potential. Also shown is the normalized binding time in the absence of an explicit potential but 
with the cut off distance set to the location of the minimum in the potential, namely at 50 nm, and 
more limited results for a cut off set to 25 and 100 nm. 
 
 
 
 
Fig. 2.15. Dependence of normalized collision time on Pe  for an explicit potential given in Eqs. (30-32), 
and in the absence of a potential but with a cut off distance. 
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Figure 2.15 shows that the binding time obtained using a cut off set to the distance at the 
minimum of the potential is roughly a factor of two larger than what is obtained with the explicit 
potential, for this example. It also shows that one can bring the binding time down closer to what 
is predicted using an explicit potential by increasing the cut off distance by roughly a factor of 
two. This result hints at the errors incurred in setting an effective cut off distance in the absence 
of inter-particle forces, and suggests how more accurate results can be obtained. Since every 
change in parameters governing the potential would require a set of new simulations to give the 
binding time, the use of an effective cut off distance might be a simpler way of obtaining 
reasonable estimates, if a way could be found of estimating the best cut off distance.   
 
2.4. Binding kinetics for particles with surface anisotropy 
One of the advantages of the presented BD simulation method is its ability to study coagulation of 
particles with anisotropic interactions, such as Janus spheres having attractive as well as repulsive 
faces.4 As a simple illustration of the power of this method, simulations of Janus spheres are 
carried out in which particles are deemed to have collided when they not only have approached 
each other close enough but also present their attractive sides to each other; see Fig. 2.16a. Figure 
2.16-b depicts the variation of normalized binding times with Pe  for both isotropic and Janus 
particles. When the Janus particles approach each other closely enough to bind, but their 
attractive sides are not aligned appropriately, it is assumed that due to repulsive forces between 
the surfaces of particles their gap is no longer allowed to decrease, but is held to the cut off value, 
and the spheres are allowed to translate and rotate in the shear flow, until the particles either 
separate from each other or their attractive faces are aligned appropriately for them to bind. 
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Fig. 2.16. (a) Janus spheres relative orientations. Only state (i) leads to a binding event. (b) Binding time 
versus Pe  for uniform and Janus spheres with 50% of each sphere’s surface attractive, and an inner cut 
off for binding set to 50 nm. Simulation data are fit by the functional forms given in the legend. 
 
Figure 2.16-b illustrates that, as expected, coagulation of Janus particles is roughly four times 
slower than with isotropic particles. Similar to isotropic particles, an expression of the form 
0.5
4 5 6
ˆ 1/ ( )Vt m m Pe m Pe= + +
 
can be used to fit the normalized binding times for Janus particles 
where 4m , 5m , and 6m  are fitting parameters. The fitting expression is 
0.5ˆ 1/ (0.234 0.056 0.031 )Vt Pe Pe= + + , which captures the data in Fig. 2.16-b with reasonable 
accuracy.  The methods used to predict the results in Fig. 2.16-b could readily be used to consider 
realistic potentials, more complex particle anisotropic potentials, and unequal size spheres.   
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2.5. Conclusions 
A systematic study using BD method has been carried out to examine the binding kinetics of 
colloids under shear flow. The following are the main outcomes of this research: 
1) For the first time, a method was proposed to predict the coagulation rate of a particle pair 
with consideration of hydrodynamic interactions for across the entire range of Peclet 
numbers (Pe) including the perikinetic and orthokinetic limits. 
2) Rectangular simulation boxes were introduced to apply the boundary conditions 
appropriately, and avoid or minimize artificial concentration-depleted “shadow” effects. 
3) The effects of different types of inter-particle forces including induced-dipole attraction, 
a combination of depletion attraction and electrostatic repulsion, and simple abrupt 
binding at a cut off distance, were studied.  
4) The presented simulation results converged to the perturbation solutions of the 
convection-diffusion equation of Feke and Schowalter13 at high Pe  and determined that 
their validity is limited to Pe  > 100.   
5) Particles with surface anisotropy were simulated and binding times were determined. 
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Chapter 3 
Growth Kinetics in Layer-by-Layer Assemblies of Organic Nanoparticles and 
Polyelectrolytes 
 
The content of this chapter are published in: 
M Mohammadi, A Salehi, RJ Branch, LJ Cygan, C Besirli, RG Larson, Growth Kinetics in 
Layer-by-Layer Assemblies of Organic Nanoparticles and Polyelectrolytes, 2017, 
ChemPhysChem 18 (1), 128-141. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. 
Reproduced with permission. 
 
3.1. Introduction 
Functional thin films have attracted significant attention recently,1,2 due to their versatility and 
ease of fabrication. One of the most flexible methods of assembling these films is by layer-by-
layer (LbL) deposition, which is the alternating deposition of oppositely charged polyelectrolytes 
(PEs) or oppositely charged PEs and nanoparticles (NPs). LBL assembled thin films are easy to 
fabricate, inexpensive, and their properties can be finely tuned.3,4 Furthermore, the process of 
making these films does not need to be done under extreme conditions.5   
Even though the major driving force for the LbL assembly is usually electrostatic interactions, 
other interactions including hydrogen bonding, hydrophobic interactions, host-guest interactions, 
covalent bonding, etc., lead to the formation of such assemblies.4,6 In electrostatically driven 
PE/PE assembly, LbL growth occurs due to charge overcompensation, i.e. each film ingredient 
deposited on the surface reverses the surface charge, making it ready to adsorb the next LbL 
layer.4 LbL assembly of PEs and organic NPs has considerable applications in drug delivery, 
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coating, creation of three dimensional scaffolds, and sensors to name but a few.4,7-16 However, 
little is known about the mechanism of their growth, and its effective parameters. Thus, it is 
important to study PE/organic NP LbL films to better understand the effects of different 
parameters on their assembly and growth. 
A major parameter affecting the growth kinetics of LbL films is the molecular weight (MW) of 
the PE. MW affects the diffusion of the PE chains within the PE matrix and their mobility in the 
bulk solution. Moreover, MW influences the thermodynamic driving force for the diffusion and 
the overall integrity of the LbL film. For PE/PE films, several studies have shown the dramatic 
effect of MW on the thickness and morphology.17-20 Nestler et al. studied the effect of MW on the 
growth kinetics of poly(styrenesulfonate) (PSS hereafter)/ poly(diallyldimethylammonium 
chloride) (PDADMAC hereafter) multilayer films.17 Below a certain MW, they demonstrated that 
an increase in the MW of the polyanion (PSS) decreases both the film thickness and the layer 
number at which the growth rate changes to the linear regime. However, they reported a 
completely opposite trend in response to a variation of the MW of the polycation (PDADMAC). 
Shen et al. studied the effect of the polyanion (hyaluronan) MW on the growth kinetics of poly(L-
lysine)/hyaluronan LbL films.18 In contrast to Nestler et al.,17 they showed that increasing the 
polyanion MW increases the film thickness. This reveals the complex effect of MW of the PE on 
LbL growth and suggests that it depends on the specific system being studied.  
In contrast to PE/PE films, very few studies have addressed the effect of MW of the PE on the 
growth kinetics and surface morphology of PE/NP films, and even for these, the MW was not the 
main focus. Rahman and Taghavinia used poly(ethyleneimine) (PEI) with two different MWs 
(1.3 and 750 kg/mol) to grow PEI/TiO2 NP composites.3 They measured LbL growth with UV-
visible spectrophotometry and concluded that film growth is 25 % slower when PEI with the 
lower MW is employed. In another study by the same group, Rahman et al. showed greater 
deposition for PEI/TiO2 NP composites with lower MW PEI.21 They explained this opposite 
growth behavior by noting that the substrate and its geometry have important effects on the film 
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growth. In the later study, they grew composites on cellulose fibers as opposed to the planar 
quartz sheets that they employed for the earlier work. They claimed that PEI with lower MW 
could diffuse into the porous structure of cellulose faster. In addition, they showed that films with 
lower MW of PEI have a less porous structure. In contrast to findings of Rahman et al.3,21 which 
showed a large effect of MW of PE on growth and structure of TiO2 composites, Kniprath et al. 
illustrated that the surface characteristics of PSS/TiO2 NP or PDADMAC/TiO2 NP films are 
independent of the MW of the PE.5 They used MWs of 70 kg/mol and 1,000 kg/mol for PSS and 
< 100 kg/mol and 400 to 500 kg/mol for PDADMAC. In these studies, only a couple of MWs 
were considered, so it is hard to reach a conclusive picture of the effect of MW. Thus, there is 
need for further study of MW on the growth kinetics and surface morphology of PE/NP 
composite films.  
In addition to the MW of the PE, the pH and salinity of the deposition solutions are decisive 
factors affecting the buildup of the LbL films. The pH, for example, affects the charge density of 
weak PEs.22 Bieker and Schönhoff investigated the effect of the pH of the depositing solutions on 
the growth of poly(allyl amine hydrochloride) (PAH)/poly(acrylic acid) (PAA) LbL assemblies.23 
They discovered various growth regimes with different growth behavior (linear and exponential) 
and film quality (soft and rigid) with simple variation of pH. They rationalized their observations 
by noting that at different pH values, the degrees of ionization, electrostatic interactions, mobility 
and inter-diffusion of PE chains vary. Peng et al. studied the effect of pH and salinity of 
deposition solutions on the growth kinetics of PEI/SiO2 NP composites, showing that deposition 
of low pH SiO2 NPs and high pH PEI result in exponential film growth.24 They claimed that the 
pH difference between PEI and SiO2 solutions during the LbL assembly alters the charge of PEI 
chains and thereby enhances their diffusion, so that during a single nanoparticle deposition step, 
more nanoparticles are able to be deposited, leading to deposition of multiple layers of SiO2 NPs 
in a single deposition step. 
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Salt has two competing effects on the growth kinetics of LbL films. First, simple ions screen the 
electrostatic interactions and reduce the driving force for LbL assembly.22 Second, salt-induced 
weakening of electrostatic interactions increases the diffusivity of polymer chains and affects 
their conformation. Recently, Salehi et al. studied the effect of pH and salinity on the growth of 
PE/PE LbL films and how the growth rate correlates to the bulk complexation thermodynamics of 
the two PEs at the same pH and salinity.22 It was shown that even though there is no one-to-one 
correlation between different regimes of LbL growth (linear and exponential growth) and bulk 
complexation (precipitate and coacervate formation), salinity influences the growth kinetics in a 
more or less universal fashion. It was shown that growth rate increases with salinity at low salt 
concentration, while it decreases as the salt concentration approaches the critical concentration 
for dissolution of the bulk polymer-rich phase into a single-phase. It was demonstrated that 
depending on the PEs employed, variation of pH and salinity could dramatically alter the growth 
mode of LbL films from linear to exponential and vice versa.  
The effects of ionic strength of the deposition media on the growth rate of PE/NP composites 
have been studied as well.5,24-28 Ghannoum et al. studying the growth kinetics of LbL assembly of 
PDADMAC and platinum NPs capped with poly(acrylate), showed that film growth is very 
sensitive to the ionic strength of the suspension.25 They identified 50 mM as the optimum salt 
concentration beyond which film growth degrades. Some of the studies focused on the salinity of 
PE solutions, as the addition of salt to particulate suspensions could lead to aggregation as 
electrostatic repulsion is screened. Peng et al. demonstrated that addition of salt to a PEI solution 
degraded the growth of PEI/SiO2 NP films.24 In contrast, Ostendorf et al. reported that increasing 
the ionic strength of PAH solutions up to 1 M increases the thickness of PAH/gold NP films 
somewhat, although it did not seem to affect the amount of NPs deposited in the film.26 Kniprath 
et al., on the other hand, found that increasing the ionic strength of the PE solution from 0 to 1 M 
did not affect the surface morphology of the resulting PSS/TiO2 NP or PDADMAC/TiO2 NP 
films.5 All in all, it seems that the only clear conclusion that can be drawn is that the effect of 
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salinity on the growth and structure of LbL films strongly depends on the specific chemistry of 
the ingredients.  
Despite the importance of the observations made in previous studies, to the best of our 
knowledge, there is no systematic study of the effect of the MW of the PE on the growth kinetics 
of PE/organic NP LbL films. Therefore, the dependence of MW on growth kinetics with different 
NP size and salinity of the media (both PE and PS solutions) are elucidated. In addition, the 
surface morphology of the LbL films with different MWs using atomic force microscopy (AFM) 
and scanning electron microscopy (SEM) is investigated. As a model for organic NPs, 
polystyrene (PS) beads of different size and surface functionalization are chosen to study the 
growth kinetics of their LbL assembly with two different PEs, namely, PEI and PAA. Being 
weakly dissociating PEs, PEI and PAA are selected so that their charge density can be tuned with 
pH. Prior to studying the effect of MW, the effect of the NP concentration, the pH of the 
deposition solutions, and the deposition time are examined to find the optimal growth conditions 
for each parameter. This study is aimed at engineering the structure of LbL films composed of 
organic NPs and PEs and possibly use such films for drug delivery application.  
 
3.2. Experimental section 
3.2.1. Materials 
PEI and PAA with different MWs were employed as the polycation and polyanion, respectively. 
Branched PEI with MWs of 750 (Polydispersity index (PDI): 12.5) and 25 kg/mol (PDI: 2.5) 
were purchased from Sigma-Aldrich (St. Louis, MO). Branched PEI with a MW of 70 kg/mol 
(PDI: 13) and PAA with MWs of 2, 5 and 30 kg/mol (PDI for these polymers: 2.4) were 
purchased from Polysciences (Warrington, PA). PAA with a MW of 240 kg/mol was obtained 
from Acros Organics (Belgium). The PDIs were obtained from the manufacturers.29 Negatively 
charged PS (PS-) NPs bearing sulfate functional groups with particle sizes (diameters) of 26±3, 
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41±6, 100±8 nm as well as positively charged PS (PS+) NPs with amidine functionalization and 
particle sizes of 23±5, 44±6, 100±9 nm were purchased from Life Technologies (Eugene, OR). 
The sulfate-functionalized NPs (PS-) with sizes of 26, 41, and 100 nm had highly varying surface 
charge densities of 3.4, 0.6, and 0.2 µC/cm2, respectively. On the other hand, the NPs bearing 
amidine functionalization (PS+) with sizes of 23, 44, and 100 nm had nearly the same surface 
charge densities of 3.0, 3.4, and 3.2 µC/cm2, respectively. The surface charge densities and 
particle sizes were obtained from the manufacturer.29 KCl was obtained from Sigma Aldrich to 
study the effect of salinity on the LbL growth. All other materials were purchased from Sigma 
Aldrich. No additional purifications were performed on the materials.  
 
3.2.2. Quartz crystal microbalance measurements 
The growth of PE/NP multilayers deposited on quartz crystals was monitored in the dry condition 
with a quartz crystal microbalance (QCM-200, Stanford Research Systems Inc., Sunnyvale, CA). 
Chrome/gold coated quartz crystals were obtained from Stanford Research Systems and had a 
resonance frequency of around 5 MHz. Initially, crystals were treated using piranha solution (a 
mixture of sulfuric acid and 30 % hydrogen peroxide at 3 to 1 volumetric ratio) for 2.5 minutes. 
Note that piranha solution is very reactive and dangerous and considerable care should be taken 
when handling it. Piranha treatment not only cleans the substrate, but it also makes it negatively 
charged. Such a negatively charged substrate is needed for the subsequent PE deposition step. 
Next, the crystals were rinsed thoroughly with DI water and dried with airflow. HPLC water 
(Fisher Scientific, Waltham, MA) was used for preparing PE or PS solutions. PE solutions 
employed in this research all have the same monomer concentration of 0.23 M. Also, PS 
suspensions were used at a concentration of 0.1 wt% unless specified otherwise. PS suspensions 
were sonicated with a probe sonicator (Ultrasonic Processor, Cole-Parmer Inc., Vernon Hills, IL) 
for 33 seconds prior to use in order to avoid agglomeration of NPs. To adjust the pH value of the 
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PE/PS solutions, HCl and KOH were used and pH values were measured with an Orion 3Star 
Benchtop pH and conductivity meter (Thermo Scientific). In each plot in the results and 
discussion section, the pH for each solution used during multilayer growth is expressed in 
parentheses. The pH of deposition solutions was adjusted at the beginning of the LbL growth 
experiments. It was observed that for rinsing waters and NP suspensions, the pH drifts over time. 
For the case of rinsing water and NP suspension at a pH value of 7, pH drift was not significant 
and was typically below 0.5 units. However, for rinsing water with pH = 9.9, the variation in pH 
could be larger (even more than 1 pH unit). A similar pH variation during LbL growth has been 
reported by Peng et al.24 In the Appendix B (Fig. B.1), the effect of pH drift on LbL growth are 
compared. We believe that such a drift does not have a significant influence on the trend of the 
results as all of the experiments were performed in relatively similar condition and time duration. 
For the PE solution, pH drift was not found to be an issue, as the pH was stable over several days. 
To commence the LbL growth, the PE solution was poured onto the crystal surface and was left 
there for 15 minutes unless specified otherwise. Subsequently, using DI water with the pH of the 
deposition solution, the crystal was rinsed to remove excess PE chains that are not attached to the 
surface electrostatically. Next, the crystal was dried with a mild airflow. Afterwards, the variation 
in vibration frequency was recorded using the QCM. Subsequently, the above-mentioned 
procedure was repeated for the PS suspension to deposit a PS layer on top of the deposited PE 
layer. The deposition of PE/PS layers was continued until 8 bilayers were grown on the quartz 
substrate.  
As mentioned before, the resonance frequency shifts of the chrome/gold crystal oscillator were 
recorded after each deposition step in each experiment. According to the Sauerbrey equation for 
rigid films,24,30,31 the deposited mass per unit area (or thickness) is linearly related to the shift in 
resonance frequency as shown in Eq. (3.1). 
Δf = −C(Δm)  (3.1) 
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Where Δf is variation of vibration frequency of the QCM crystal, Δm represents the deposited 
mass per unit area, and C is crystal’s sensitivity factor which is 56.6 Hz.cm2/µg for the 
chrome/gold-coated quartz crystals as reported by the manufacturer.31   
Prior to the growth of a PAA/PS+ composite, a layer of PEI with a MW of 750 kg/mol and pH of 
7 was deposited onto the substrate as the precursor, or primer layer. However, PEI/PS- 
multilayers were directly grown on the crystal without needing a precursor layer. All the 
experiments were performed at room temperature of 22±3. It should be noted that in all the plots 
shown in the results and discussion section, odd-numbered and even-numbered steps represent PE 
and PS depositions, respectively.  
 
3.2.3. Growing thick multilayer films 
To grow films of several LBL assembled PE/PS double layers, an LbL robot (StratoSequence, 
nanoStrata Inc., Tallahassee, Fl) was used. The films were grown by dipping a microscope glass 
slide (Fisher Scientific, Waltham, MA) into PE/PS solutions for 10 minutes. For QCM 
experiments, a deposition time of 15 minutes was used. The effect of deposition time on LbL 
growth was studied using QCM and there was negligible variation in film growth between 10 and 
15 minutes deposition times (results shown in the Appendix B, Fig. B.2). Thus, a 10-minute 
deposition time was chosen for growing very thick films with the robot to reduce LBL buildup 
time while ensuring maximum film growth. After each deposition step, the glass slides were 
dipped successively into two beakers containing DI water with the pH set the same as in the 
preceding deposition solution. Subsequent to the rinsing steps, the film was blown dry with a 
flow of air for 3 minutes. The film buildup was continued until 59 double layers of PE/PS were 
deposited onto the surface. The glass slide was treated with piranha solution prior to the film 
growth. The amount of each dipping solution was constantly monitored to ensure that the solution 
volume remained at nearly 120 ml throughout the experiments. The PS suspension was sonicated 
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each time considerable agglomeration of NPs was seen due to dipping of the glass slide and 
possible complexation formation of free NPs with film ingredients. Fresh particle suspensions 
used for thick multilayer growth looked clear. When the PS suspension seemed too cloudy and 
contaminated by multiple dipping steps, the entire suspension was changed to a fresh one. For the 
PE solution, however, no noticeable change was observable in solution quality after the dipping 
steps. Nevertheless, as a precaution, the PE solution was changed after every 20-bilayer buildup, 
or so. Further, the rinsing waters were changed with fresh ones after every 4-double layer growth.  
 
3.2.4. Atomic force microscopy studies 
An atomic force microscope (Dimension Icon, Bruker Nano Inc., Santa Barbara, CA) was 
employed to study the surface morphology of the films during LbL growth. AFM tips (OTESPA, 
Bruker Nano Inc., Santa Barbara, CA) with a nominal resonant frequency of 300 kHz, spring 
constant of 26 N/m, and nominal tip radius of 7 nm were used. AFM measurements were carried 
out with a scan rate of 1 Hz and in tapping mode.  
In each LbL experiment, a fresh quartz crystal was employed. It should be noted that the surface 
of the LbL films was composed of some rough and smooth regions. As more layers were 
deposited onto the surface, the proportion of rougher areas increased. A sample photo taken by 
the optical microscope of AFM is shown in the Appendix B (Fig. B.3). The roughness of these 
areas could reach as high as a couple of microns for films with 8 PE/NP double layers, which was 
beyond the AFM measurable range. Thus, AFM analysis was done on relatively smooth areas 
only. For each sample, 8 different smooth areas were randomly selected for doing AFM and 
roughness values were averaged to increase measurement accuracy. We did not try to measure 
precisely the fraction of “smooth” surface present, but did notice that it decreased with increasing 
numbers of layers, from perhaps 60% “smooth” by the end of first double layer growth to around 
20% “smooth” after deposition of 8 double layers. 
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3.2.5. Scanning electron microscopy studies 
The surface of LbL films was imaged with a FEI XL30FEG scanning electron microscope, with 
an accelerating voltage of 10 kV, and magnifications of 400 and 80,000. A magnification of 
8,000 was chosen to obtain SEM cross section micrographs. As investigated LbL films were not 
conductive, prior to doing SEM, their surfaces were coated with a thin layer of gold.   
 
3.2.6. Error analysis 
The standard error for each parameter studied is calculated via Eq. (3.2). These parameters 
include frequency shift of QCM crystal (Δf), thickness (t) (determined using the Sauerbrey 
equation (Eq. 3.1) and converting the mass per unit area into thickness), and rms roughness 
values (R) obtained from AFM measurements.  
eX =
1
N (N −1)
(x − x
i=1
N
∑ )2  
(3.2) 
Where e is standard error, x is each parameter mentioned above, x  represents average value of x, 
and N is the number of replicate experiments done to assess the reproducibility of the results. For 
determining standard error in frequency shift or thickness, two or three replicate tests were 
performed for a few of the experiments. Due to time-consuming nature of LbL growth tests, it 
was practically impossible to repeat all the results reported in this research, and so the error bars 
given in some of the figures can be taken to be representative. To determine the roughness values, 
8 different areas of film were tested to ensure accuracy. The standard errors in LbL growth 
measurements based on variation of frequency shift were typically below ~15 %, as determined 
by replicate runs. The errors could be attributed mainly to small variations in properties of initial 
layers that are propagated and amplified in subsequently deposited layers. When salt was added 
to the solutions, the standard error could reach as high as 30 %. Increasing ionic strength is 
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known to reduce the stability of multilayer films27 and that might have caused the relatively 
higher error values in these cases.  
The standard errors in determining thickness and rms surface roughness of LbL films were 
generally less than 15 and 10%, respectively. Knowing the errors associated with thickness (t) 
and rms roughness (R), one can determine the error of the ratio of roughness to thickness using 
Eq. (3.3), which is a standard formula for propagation of errors. The calculated error was below 
18 % for the worst case studied.  
 
A number of LbL deposition experiments were carried out involving no polyelectrolytes, but only 
PS NPs, with opposite charges in alternating layers, the results of which were entirely 
irreproducible. Insufficient contact area between rigid spherical PS NPs is presumably to blame 
for the low inter-particle cohesion that compromises the integrity of the whole film. Whatever 
NPs managed to be deposited were likely washed off during the rinsing steps. Nonetheless, fairly 
reproducible growth kinetic data (with errors discussed above) were obtained upon replacing one 
of the two oppositely charged NP solutions with a like-charged PE solution. PEs seem to act as a 
glue between the PS NPs, stabilizing the resultant composites. 
 
3.3. Results and discussion 
3.3.1. PEI/PS- system 
Initially a multilayer system composed of positively charged PEI as the polyelectrolyte and 
negatively charged PS (PS- hereafter) NPs carrying strongly charged sulfate functional groups 
were chosen. The effects of deposition time, NP concentration, solution pH, and PEI MW on 
growth were studied. It will be shown that variation of these parameters enables one to tune the 
e(R
t
) = R
t
(e(t)
t
)2 + (e(R)
R
)2  
(3.3) 
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growth kinetics of PEI/PS- composites. Results for the effect of deposition time on film buildup 
are shown in the Appendix B (Fig. B.2) for brevity. 
 
3.3.1.1. Effect of nanoparticle concentration 
Figure 3.1 indicates the effect of NP concentration on the growth kinetics of a PEI/PS- composite.  
 
Fig. 3.1. The effect of NP concentration and size on the growth kinetics of a PEI/PS- thin film. PS- NPs are 
deposited during the even-numbered steps. PEI with a MW of 750 kg/mol is used. In the legend, the 
numbers in the parentheses indicate the pH value of the solutions. For each case, the diameter of the 
employed NPs is given in nm in the figure legend. “CP” stands for concentration of particles. In this and all 
figures, the polymer monomer concentration used in the solutions is 0.23 M. 
 
As shown in Fig. 3.1, for the same mass concentration of 0.1 wt%, smaller NPs (41 nm-sized 
ones) lead to larger frequency shifts and thus greater mass depositions in the PEI/PS- film, which 
may seem counter-intuitive. However, for the same mass concentration, larger NPs have a lower 
number density in the solution than do smaller ones. Due to their much slower diffusion, it is 
therefore less likely for the larger NPs to get adsorbed into the PEI/PS- composite.  
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To find the proper basis for assessing particle concentration, the growth of films with 100 nm-
sized particles was studied at the same particle number density as that for 41 nm-sized ones. A 
dense suspension of 100 nm-sized particles with a concentration of 1.5 wt% (which has the same 
number density as a 0.1 wt% suspension of 41-nm particles) was therefore used in combination 
with a PEI solution of the same concentration as before to grow PEI/PS- multilayers. For this 
case, the deposition rate of PS- NPs was so fast that the entire chrome/gold crystal was instantly 
coated by a visibly thick layer of NPs. At the same number density, the larger 100 nm particle 
suspension produces an LbL film with a frequency shift that is at least five times greater than that 
of the smaller 41 nm-sized particles. Thus, there does not seem to be an obvious choice for a 
concentration basis at which composite films of different NP sizes yield the same growth rate. 
Consequently, for simplicity, the rest of the experiments are carried out with PS NPs of 0.1 wt% 
concentration. It is also evident from Fig. 3.1 that for the same NP size of 100 nm, increasing the 
suspension concentration boosts the growth kinetics of PEI/PS- thin films.  
Finally, the data of Fig. 3.1 indicates that PEI/PS- thin films grow through a cooperation between 
PEI and PS- deposition steps. The more PEI that is deposited in an LbL step, the more PS- NPs 
are deposited in the subsequent step. Also, the “stepped” appearance of the growth or “odd-even” 
effect in this figure, with a relatively small mass added in the odd steps, shows that contribution 
of the PEs to the frequency shift was much less than that of the NPs. This trend was observable 
for all growth study experiments. This phenomenon has already been reported in the literature.28  
 
3.3.1.2. Effect of solution pH 
Figure 3.2 depicts the influence of pH on the buildup of PEI/PS- multilayers. PS- NPs are 
functionalized with sulfate groups, so their surface charge is independent of pH and they are 
stable over a wide range of pH. On the other hand, PEI is a weak PE (pKb~1024) whose charge 
density is dependent on pH. At pH = 9.9, PEI should be nearly 50 % charged, while decreasing 
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the pH to 7 renders PEI chains nearly fully charged. PS- NPs with a diameter of 41 nm were 
chosen, as their diameter was an intermediate value among the group of PS- NPs studied.    
 
Fig. 3.2. The effect of pH on LbL growth of a PEI/PS- composite. PEI with a MW of 70 kg/mol and 41 nm-
sized PS- particles are employed. The concentration of PS- NPs is 0.1 wt%.  
 
As shown in Fig. 3.2, the pH values of both the PEI solution and of the PS- suspension have 
considerable influence on the growth kinetics of the PEI/PS- composite. Furthermore, the growth 
rate of the PEI/PS- film is fastest when PEI and PS- solutions have pH values of 9.9 and 7, 
respectively. 
The degree of ionization has a dramatic influence on the growth rate of a PEI/PS- composite. 
When PEI and negatively charged PS solutions are deposited at the same pH (= 7.0), PEI chains 
are expected to be fully charged. When PEI chains are deposited at pH = 9.9, however, their 
charge is less than it is at pH = 7.0, and more chains need to deposit atop the underlying NPs to 
compensate the opposite charge on the film. Based on the pKb of PEI in the bulk, the charge 
density of PEI at pH 7 should be roughly twice as high as it is at pH 9.9. It should be noted, 
however, that weakly dissociating PEs of oppositely charged functional groups inside PE/PE 
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multilayer films have long been shown to be more highly charged than in solution via the charge 
regulation effect.32,33 The surface functional groups on PS- NPs can thus induce further charging 
in PEI chains at pH 9.9 once they are fully embedded in the film. However, since the growth is 
markedly faster for PEI chains depositing at pH 9.9 with PS- NPs at pH 7, as compared to the 
other two conditions studied in Fig. 3.2, the PEI chains depositing at pH 9.9 are likely far from 
being fully charged. Therefore, the PS- NPs need to absorb more PEI chains at pH 9.9 than they 
do at pH 7 to achieve charge compensation, leading to faster growth.  
The degrees of charge compensation for three different LbL growth experiments studied in this 
section are presented in the Appendix B (Fig. B.4). From the QCM data shown in Fig. 3.2, it is 
clear that the frequency shift ratio (or equivalently the mass per unit area ratio) of deposited NPs 
to that of PEs in each double layer is on the order of 10, while the charge compensation factor 
(defined as the ratio of charges associated with NPs to those of PEs) for each double layer for 
these experiments is on the order of only 0.01 (see Fig. B.4 in the Appendix B), indicating that 
the charges on the NP’s deposited in a layer fall far below that needed to compensate the charge 
on the PE layer deposited in the layer just beneath it. (The important caveat that the difference in 
total film mass between deposition of each layer is taken as a measure of the mass actually 
deposited from the solution should be noted. It is possible that mass of NP’s deposited is much 
greater than this, if an equivalent mass of PE is washed off the film as the NP’s are deposited.) 
The lack of strong charge regulation can thus be rationalized by fewer encounters between neutral 
PEI repeat units with particle surface functional groups in PE/NP films than would be expected in 
PE/PE films assembled under similar conditions. The NPs evidently serve as a sufficiently thick 
spacer between two alternating PEI layers that render a continuous film build-up feasible despite 
the very low charge compensation ratios observed. Such excess of charge on PE chains in 
conventional PE/PE LbL assembly is unsustainable owing to a huge electrostatic repulsion that 
would be created between narrowly spaced layers of PE present in excess. Evidently, in PE/NP 
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deposition, accumulation of PE charge from one bilayer to the next is possible. This is an unusual 
feature that to our knowledge is unique to PE/NP assemblies. 
Upon deposition of NPs at pH = 7 following PEI deposition at pH = 9.9, the neutral primary 
amine groups absorb a proton from the solution as a result of the sudden pH drop, thus creating a 
sudden jump in areal charge density of the chains decorating the surface. The higher charge 
density of the PEI-covered surface requires more sulfate-functionalized PS NPs to compensate, as 
compared to the cases without the abrupt pH change. Consistently, PEI and PS- NPs deposited at 
the same pH, either both at 7 or both at 9.9, yield thinner films than when the solutions are 
deposited at the two different pH values considered (Fig. 3.2). Such a sudden charging of PEI 
chains is lacking when the solutions are deposited at the same pH.  
Moreover, the film growth benefits from the high diffusivity of PEI chains into the film during 
the PEI deposition at pH = 9.9 due to lower charge density of PEI chains, which should lead to 
weaker binding to PS- particles, and hence faster diffusion.22 The higher diffusivity of PEI chains 
at pH = 9.9 is probably another reason for the faster growth kinetics of PEI/PS- composite at this 
pH compared to the case where both solutions are deposited at a pH of 7, despite the stronger 
electrostatic interactions in the latter case.  
As discussed in the experimental section, the pH of the rinsing water and of the PS NP suspension 
drift during the deposition. The result is that when the PS particles and PE polymer are deposited 
at different pH values, nominally pH = 7 for PS- and nominally pH = 9.9 for PEI, the actual pH 
values differ less from each other as more layers are deposited. As shown in the Appendix B (Fig. 
B.1), when the pH values of the rinsing water and of the PS- suspension were constantly 
monitored and maintained at their initial values, the film growth was improved. This observation 
further bolsters the argument that larger difference between pH values of deposition solutions and 
rinsing waters leads to faster LbL film buildup.  
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The effect of pH on the growth kinetics of PEI/PS- composites observed here is similar to that 
observed by Peng et al. for the multilayer buildup of SiO2 inorganic NPs and PEI.24 Here, it is 
shown that even though the interactions are not exactly the same, a similar trend holds.  
 
3.3.1.3. Effect of molecular weight 
Figures 3.3-3.5 indicate the role of PEI MW on the growth kinetics of PEI/PS- composites for 
different NP sizes. The NP concentration is set to 0.1 wt%.  
 
Fig. 3.3. The role of MW of PEI on growth of PEI/PS- LbL film, for PS- NP size of 26 nm. 
 
Conspicuous in Fig. 3.3 is the saw-tooth growth behavior of the films involving the 26 nm PS- 
particles. It seems that some of the deposited PS- NPs are washed off of the film during the 
deposition of the PEI (odd numbered steps). Some PEI must have been deposited during these 
steps to explain the continued growth of the film in the subsequent steps. Moreover, Fig. 3.3 
indicates that for 26-nm PS- particles, a higher MW of 750 kg/mol leads to a thicker PEI/PS- 
composite.  
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Fig. 3.4. The same as Fig. 3.3, except for a particle size of 41 nm. 
 
Figure 3.4 shows that for the 41 nm PS- particles, the PEI/PS- LbL buildup is maximum at an 
intermediate PEI MW of 70 kg/mol. Also, unlike the growth kinetics of the 26 nm-sized PS- 
particles, for 41 nm-sized PS- particles, out-diffusion of ingredients from the film is not observed. 
Moreover, all three data sets depicted in Fig. 3.4 show accelerating, or “exponential” growth for 
the particle deposition steps, with increasing numbers of layers. This is especially noticeable for 
the PEI with a MW of 70 kg/mol.  
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Fig. 3.5. The same as Fig. 3.3, for particle size of 100 nm.  
 
According to Fig. 3.5, for 100 nm-sized PS- particles, the PEI with the highest MW leads to the 
thickest film.  
 
3.3.2. PAA/PS+ system 
In the next set of experiments, another composite system composed of negatively charged PAA 
as the PE and positively charged PS (PS+ hereafter) NPs carrying amidine functional groups was 
selected. PAA is a weak PE (pKa of around 5-5.522). It is approximately 50 % charged at pH = 5, 
and therefore almost completely charged at a pH of 7. 
If the PE/NP LbL growth were entirely driven by electrostatic interactions, it would be plausible 
to expect that switching the sign of charges on both components should not alter the trends. The 
LbL experiments with PAA/PS+(amidine) system will thus establish whether the trends observed 
for the effect of MW on the growth of PEI/PS-(sulfate) multilayers discussed in the previous 
section are general, i.e. chemistry-independent. Similar to the PEI/PS- system, for the PAA/PS+ 
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composite, increasing the PS+ concentration boosts the growth rate, as shown in the Appendix B 
(Fig. B.5).  
 
3.3.2.1. Effect of molecular weight 
Figures 3.6-3.8 show the growth kinetics of PAA/PS+ LbL assemblies for different MWs of PAA 
and various NP sizes. Throughout this section, concentration of PS+ NPs was set to 0.1 wt%.   
 
Fig. 3.6. Effect of MW of PAA on PAA/PS+ LbL buildup with 23 nm-sized PS+ particles. For this and 
subsequent figures, the pH values for each deposition solution (PAA or PS+) is indicated in parenthesis in 
the figure legend. Note the small value of error bars for PAA with MW of 2 kg/mol.  
 
Unlike the PEI/PS- system with 26 nm-sized particles (Fig. 3.3), out-diffusion of the PS+ NPs of 
similar size, 23 nm, is not observed for the PAA/PS+ counterpart shown in Fig. 3.6.  
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Fig. 3.7.  The same as Fig. 3.6, for 44 nm-sized PS+ particles. Data for PAA with a MW of 30 kg/mol have 
error bars, but these are too small to be visible.  
 
According to Figs. 3.6 and 3.7, the MW has a non-monotonic effect on the LbL buildup of PS+ 
particle of sizes 23 and 44 nm. Decreasing the MW from 240 to 5 kg/mol boosts the LbL growth 
rate, but a further decrease in MW leads to a slower growth rate. Evidently a further decrease in 
the MW to 2 kg/mol lowers the capability of chains to immobilize the PS+ NPs in the composite 
film. Therefore, there is an optimum MW for the growth of PAA/PS+ multilayers, which is 5 
kg/mol for both 23 and 44 nm-sized PS+ particles.  
 
 
 76 
 
Fig. 3.8. The same as Fig. 3.6, for 100 nm-sized PS+ particles.  
 
Given the margin of error in Fig. 3.8, however, the growth of PAA and 100 nm-sized NP film is 
virtually insensitive to a further decrease of MW from 5 to 2 kg/mol. We speculate that, similar to 
behavior of the PS+ NPs of sizes 23 and 44 nm, for 100-nm particles there should be an 
intermediate MW that leads to the fastest growth of PAA/PS+ films, even though the optimal 
MW in the case of 100 nm-sized NPs is less than or equal to 2 kg/mol. Given that it is impossible 
to use AA acid monomers as building blocks in LbL assembly, one would intuitively expect there 
to be an optimum MW equal or less than 2 kg/mol for 100 nm-sized PS+ NPs. 
Table 3.1 summarizes the optimum growth behavior for the different NP sizes and PE MWs 
studied. For both PAA/PS+ composites with either 23 or 44 nm-sized particles (Figs. 3.6 and 3.7) 
and for PEI/PS- thin films with 41 nm-sized particles (Fig. 3.4), there is an intermediate MW that 
leads to the fastest LbL growth. However, the growth rate of PEI/PS- multilayers with 26-nm and 
100-nm sized particles does not show an optimal MW over the range of MWs considered (Figs. 
3.3 and 3.5). Consequently, one can conclude that the effect of MW on growth kinetics of PE/NP 
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thin films strongly depends on the specific chemistry of the ingredients as well as on the size of 
NPs employed. It should be noted that the surface charge density of the sulfate-functionalized 
particles (PS-) used in growth of PEI films varies greatly with particle size while the amidine-
charged particles (PS+) have nearly the same charge density for all three particle-sizes, and this 
may also play a role in the different behavior observed for the two systems. Further, as mentioned 
in the experimental section, PEIs had greater polydispersity indices compared to the PAAs. This 
could also contribute to the different growth kinetics seen for the two systems studied. Even 
though it is beyond the scope of the current study, the polydispersity of the polymer solutions 
employed could have a considerable effect on the growth behavior and is worth future 
investigation. 
Table 3.1. Optimum LbL buildup for different PE/NP composites studied as a function of NP size and MW 
of PE.  
 
Chain diffusion, particle and chain redissolution, specific chemistry involved in the complexation 
of opposite charges, surface overcompensation and interparticle bridging are some of the major 
factors whose relative influence controls the overall LbL growth rate. MW, in particular, affects 
each of the latter factors in different and even opposite ways. For instance, chain diffusion is 
enhanced while interparticle bridging is adversely impacted as MW decreases. The obtained 
PEI/PS- NPs multilayers PAA/PS+ NPs multilayers 
NP size Optimum MW NP size Optimum MW 
26 Large (750 kg/mol) 23 Intermediate (5 kg/mol) 
41 Intermediate (70 kg/mol) 44 Intermediate (5 kg/mol) 
100 Large (750 kg/mol) 100 Intermediate (2 and 5 kg/mol) 
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results demonstrate that flipping the sign of the charges borne by PEs and NPs leads to two 
distinct trends in dependence of LbL growth on MW. 
For neutral polymers, the self-diffusivity decreases as the MW increases.34 Decreasing the MW of 
the PE at otherwise identical conditions therefore increases the effective chain diffusivity, which 
tends to increase chain deposition into the film. On the other hand, we speculate that each 
deposited PE layer bridges the former and subsequent NP deposits. Longer chains can bridge the 
NPs more easily and the chain entanglement would strengthen such interparticle bridges, boosting 
the film mechanical integrity. A trade-off between the chain diffusivity and bridging could 
explain the intermediate optimum MW found for PEI/PS- composites with 41 nm-sized PS- 
particles, as well as PAA/PS+ LbL films. However, the reverse trend is observed for two of the 
particle sizes employed in PEI/PS- system (Table 3.1), where for 26 nm-sized particles, 
appreciable redissolution appears to control the deposition rate (Fig. 3.3). During chain 
deposition, the film surface charges arising from sulfate groups are compensated by the amine 
groups along PEI chains. The incoming chains generally overcompensate the surface charges, 
reversing the sign of the surface charge. Longer chains have been shown to lead to greater charge 
overcompensation.35 Even though a better charge overcompensation for the PEI with the highest 
MW can explain the deviation from the observed trend for PAA/PS+ NP system, further detailed 
experimental techniques are needed to definitively elucidate this observation and better 
understand the underlying physics. It might be possible, for example, to use confocal laser 
scanning microscopy or neutron reflectometry to track the diffusion of polymer in the LbL film 
which could shed light on the reason for different growth behaviors.36 Also, single-molecule force 
spectroscopy experiments could be done wherein a polymer chain is detached from the film and 
the detachment force profile is measured. This has been proven to be a useful method to 
determine polymer chain adhesion forces in films.37 
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For larger PS NPs, it is more difficult for PEs to create interparticle bridges and LbL films 
become unstable in this case. Interparticle bridging becomes even more difficult for shorter PE 
chains. This might be the reason for larger error bars seen in Fig. 3.8. 
 
3.3.2.2. Effect of salinity 
Salt screens the electrostatic interactions between charged functional groups and also impacts the 
PE diffusivity in the multilayer film. The effect of the salinity of the deposition solutions for 
PAA/PS+ films composed of 44 nm-sized PS+ particles and PAA with MWs of 5 and 240 kg/mol 
are shown in Figs. 3.9 and 3.10, respectively. PS+ NPs with diameter of 44 nm were chosen, as 
this size was an intermediate nanoparticle size among different PS+ nanoparticle sizes studied. 
According to Fig. 3.7, for this nanoparticle size, PAA with MWs of 5 and 240 kg/mol showed the 
fastest and slowest growth rates, respectively. Therefore these MWs were chosen to study the 
effect of salinity for both fast and slow growing films. For the PS+ suspension, even 100 mM salt 
content did not compromise the suspension stability as verified by dynamic light scattering. 
It should be noted that pH of PE and PS solutions were adjusted by the addition of KOH and 
HCl for different cases studied. This introduced additional K+ and Cl- ions to the solutions on top 
of those introduced by adding KCl. In this section, the term “salinity” refers to the K+ and/or Cl-
 added to the solutions via KCl salt, not including any ions contained in the pH buffer, KOH or 
HCl. To enhance clarity, the values of ionic strength of the deposition solutions (considering both 
ions introduced by addition of salt as well as pH buffers) are reported in figure captions. For the 
case of PS+ NPs, the concentration of ions added to the system for the pH adjustment was far 
lower than the amount of K+ and Cl- ions added to the system to study salinity, so their effect on 
ionic strength was negligible. For PAAs, however, that was not the case and the higher the salt 
concentration (KCl), the greater was the concentration of K- ions needed for pH adjustment. All 
in all, PAA solutions with higher salt contents needed more ions for pH adjustment too. 
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Fig. 3.9. The effect of KCl concentration on growth kinetics of PAA/PS+ multilayers, for PAA with a MW 
of 5 kg/mol, and 44 nm-sized PS+ particles. Concentration of NPs was 0.1 wt%. The concentrations of salt 
(CS) in the PAA and PS+ solutions are shown in the legend. The ionic strength was 37, 93, and 147 mM 
for PAA solutions with salt concentrations of 0, 50, and 100 mM, respectively. For PS+ suspensions 
however, pH adjustment did not change the ionic strength of the suspensions. Thus, the ionic strength 
values were the same as salt concentration reported.  
 
As shown in Fig. 3.9, the addition of KCl to solution of PAA with a MW of 5 kg/mol has a 
detrimental effect on the buildup of the PAA/PS+ composite film, with the growth rate decreasing 
when 50 mM salt is added to both PAA and PS+ solutions, and a further decrease when the salt 
concentration is increased to 100 mM. Also, introducing KCl to the PAA solution only leads to a 
weaker degradation than when it is added to both solutions. Finally, Fig. 3.9 also demonstrates 
that with the addition of KCl, composite films still grow linearly.  
The effect of salinity on the growth rate of multilayer films composed of PAA (MW= 240 kg/mol) 
and PS+ NPs (44 nm in size) is indicated in Fig. 3.10.  
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Fig. 3.10. The same as Fig. 3.9 except for PAA with a MW of 240 kg/mol. The concentration of PS+ NPs 
was set to 0.1 wt%. The ionic strength for PS+ suspensions with salt content of 0, 50, and 100 mM was 0, 
50, and 100 mM, respectively. Also, the ionic strength for PE solutions with salt concentrations of 0, 50, 
and 100 mM was 34, 92, 149 mM, respectively.  
 
Based on Fig. 3.10, for PAA with a MW of 240 kg/mol, the addition of KCl to both PAA and 
PS+ solutions or to PAA solution alone boosts the LbL growth kinetics. However, the LbL 
growth is slightly degraded when KCl is only introduced into the PS+ suspension. 
Figure 3.10 also illustrates that increasing the salt concentration from 50 mM to 100 mM 
decreases the growth rate of the PAA/PS+ composite film, for PAA with a MW of 240 kg/mol. 
Comparing Figs. 3.9 and 3.10, one can clearly observe that salinity of the medium has a stronger 
effect on frequency shifts of PAA/PS+ films for the smaller MW of 5 kg/mol than for MW of 240 
kg/mol. 240 kg/mol was the largest MW of PAA investigated in this study because for much 
higher MW values, the higher viscosity made it practically impossible to study their film growth 
kinetics.    
Although in the work presented here the PEs interact with surface functionalized NPs rather than 
with other polymers, as is the case for ordinary PE/PE deposition, the key interactions in both 
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cases are electrostatic, and can be screened by mobile salt ions. In both cases, increasing the ionic 
strength decreases the thermodynamic driving force for complexation of PE and NP functional 
groups, and enhances the diffusivity of PE chains inside the films, a competition that has been 
shown to affect PE/PE multilayer formation profoundly.22 Which of these two factors is dominant 
thus determines whether the film growth is enhanced or degraded by the addition of salt. The 
relative importance of these two factors in the present study is affected by the MW of the PE. The 
diffusivity of the PE with low MW is already so high that salt should have only a marginal effect 
on chain diffusivity. Consequently, for low MW PEs, the reduction of the driving force is the 
dominant factor, which progressively slows down the growth kinetics of low MW PAA/PS+ NP 
composites as the salt concentration increases (Fig. 3.9). Interestingly, adding salt only during 
PAA deposition (while using a salt free NP suspension) leads to an intermediate growth rate. 
For the PE with a higher MW, the boost in diffusivity due to the addition of salt apparently 
outweighs the reduced electrostatic attraction between the oppositely charged components, for 
salt concentrations up to 50 mM KCl, leading to a boost to LbL growth rate visible in Fig. 3.10. 
However, a further increase of salt concentration from 50 to 100 mM and the consequent 
reduction in the electrostatic driving force degrade the growth kinetics of PAA/PS+ composite. 
Unlike PEs, the deposition of NPs in Fig. 3.10 is weakly affected by KCl whereas changing the 
salt concentration in the PAA solution while holding that of the NP dispersion fixed appreciably 
alters the growth kinetics. In contrast with spherical NPs, PE chain conformation, 
thermodynamics and diffusivity are all drastically altered by the ionic strength of the media and 
LbL growth rate is thus more sensitive to salinity of the PAA solution than to that of the NP 
dispersion. 
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3.3.3. Film characterization 
3.3.3.1. Atomic force microscopy study 
To study the surface morphology, the PEI/PS- composites with 41 nm-sized PS- particles were 
selected. These composites are similar to most of the cases studied in that the intermediate value 
of MW led to the fastest growth rate (Fig. 3.4). Other than ions added to the solutions for pH 
adjustment, no extra salt ions were added to the either of the ingredients for the LbL buildup. 
Further, PEI and PS- solutions were deposited at pH values of 9.9 and 7, respectively. Figure 3.11 
depicts surface characteristics of composites with different PEI MWs. Instead of performing 
localized AFM on a very small area, which is a common practice in the literature, a larger area 
(30 µm×30 µm) was studied to obtain a more representative assessment of the surface 
morphology. As mentioned previously, 8 different areas of each sample were imaged, but a single 
image most typical in the range of roughness for each sample is shown in Fig. 3.11. The inset for 
each AFM image in Fig. 3.11 is in fact the same image as in the corresponding main figure, 
except with the color scale bar fixed to a range of 700 nm, while in the main figures the scale bars 
are adjusted to keep the contrast fixed. Thus, the insets allow one to compare the uniformity of 
roughness from sample to sample, with a uniform color and darkness indicating a film with 
relatively uniform roughness. The thin films, comprising a few layers, are uniformly dark in the 
insets because there can be little height variation on a scale of 700 nm when the films are much 
thinner than 700 nm. The main figures, with variable scale bars and fixed contrast, allow one to 
observe the surface topology, and the variation in height can be assessed for each figure from the 
corresponding color scale bar.  
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Fig. 3.11. AFM images of PEI/PS- composites with 41 nm-sized PS- particles and different MWs of PEI 
for different numbers of layers. All the images were obtained once PS- NPs are deposited for 1st, 3rd, 6th, 
and 8th bilayers. The pH values for the NP and PEI deposition steps were 7, and 9.9, respectively. No salt 
ions were added for the growth of these films except for the ions introduced to the system to adjust the pH. 
The scale bars for the main images are also shown. The insets show the corresponding images rendered 
using a fixed 700 nm scale bar to allow comparison of film height uniformity on an absolute scale.  
 
As can be seen in Fig. 3.11, surface roughness during the growth of LbL films increases 
dramatically. This trend is seen for all PEIs with different MWs. Some studies have mentioned 
that LbL growth under pH-amplified condition, i.e. deposition of film ingredients at different pH 
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values, could lead to rougher surfaces.18 The effect of pH-amplified deposition on the surface 
morphology of LbL films was studied by first depositing 8 bilayers of PEI and PS- at pH values 
of 9.9 and 7, respectively, and contrasting these results with those obtained by depositing the 
same number of layers of PEI and PS- solutions both at a pH of 7. Root-mean-squared (RMS) 
roughness values of film surface were determined by examining the results with Nanoscope 
Analysis software (Bruker Nano Inc.). AFM micrographs, in the Appendix B (Fig. B.6), show 
that in the latter case (equal pH), the rms surface roughness is around 32 % smaller than in the 
former (unequal pH). However, since the two cases produced differing total film thickness, and 
roughness generally increases with thickness (Fig. 3.11), rather than comparing the surface 
roughness for a fixed number of layers, the roughness-to-thickness ratio is a better basis for 
comparison, since normally one wants to achieve a layer of a given thickness. Due to much 
slower growth of PEI/PS- composite when both PEI and PS- solutions are deposited at a pH value 
of 7, in this case the ratio of roughness to thickness is around 30 % higher than in the pH 
amplified deposition condition. So, it seems that the amplification of LbL growth by using 
different pH values for different layers does not increase roughness, at least when roughness is 
normalized by film thickness. Another possible reason for the high surface roughness could be an 
uneven distribution of surface charge on the crystal surface, despite the fact that we were careful 
to be consistent when treating the substrates with piranha solution.  
Figure 3.12 depicts the variation of both absolute roughness (shown in the inset) and roughness 
normalized by the film thickness for PEI/PS- thin films with different PEI MWs. Average film 
thicknesses of PEI/PS- films composed of PEI with MWs of 25, 70, and 750 kg/mol were 
estimated to be 330, 825, and 270 nm, respectively. These estimations were obtained by 
converting the frequency shift (data in Fig. 3.4) of the QCM measurements to mass per unit area 
using the Sauerbrey equation (Eq. (1) shown in the experimental section). Knowing the mass per 
unit area and the density of film ingredients, one can estimate average film thickness. Because of 
the much greater mass deposition of NPs than of PE’s, the density of the PS (1.05 gm/cm3) is 
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used to convert the mass of film into thickness. This way, the effect of the small density 
difference between the PS and the PE’s is neglected. This makes calculations much easier, and 
generates minimal error (~0.3% in the worst case) in the final results.  
 
Fig. 3.12. Ratio of roughness to thickness, extracted from AFM images, for the PEI/PS- multilayers 
depicted in Fig. 3.11. The inset shows the variation of absolute roughness. For some data points, the error 
bar is too small to be visible.  
 
Figure 3.12 shows that regardless of the MW of the PEI, as more layers are deposited onto the 
films, the ratio of roughness to thickness decreases while the absolute roughness increases. 
Further, Fig. 3.12 shows that PEI with intermediate MW has the least roughness to thickness 
ratio, perhaps due to the fast growth of its thickness. As can be seen in the inset to Fig. 3.12, LbL 
films composed of PEI with MWs of 25 and 750 kg/mol have comparable roughness values. 
Interestingly, these films had a similar rate of multilayer buildup (Fig. 3.4).  
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3.3.3.2. Scanning electron microscopy study 
3.3.3.2.1. Effect of molecular weight 
Figure 3.13 shows SEM micrographs of the surfaces of LbL films with different molecular 
weights of PEI, grown with the same materials and under the same conditions as for the AFM 
images in Fig. 3.11. At least five different regions of the samples were randomly selected to 
obtain the micrographs with magnifications of 400. Those chosen for Fig. 3.13 represent the 
typical features observed in the images. For micrographs with a magnification of 80,000, 
however, only three different parts of the samples were imaged, since different micrographs 
looked very similar to each other at this magnification.  
  
(a) (b) 
 
(c) 
Fig. 3.13. Surface morphology of LbL films composed of 8 double layers of PEI and PS-, with the same 
materials and the same conditions as for Fig. 3.11, with PEI MWs of 25 kg/mol (a), 70 kg/mol (b), and 750 
kg/mol (c). The main figures have a magnification of 400 while the insets have a magnification of 80,000. 
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The scale bars represent a length of 100 µm in the main figures, while those of insets indicate a length of 
500 nm.  
 
Figure 3.13 shows that the PEI/PS- multilayer film composed of PEI with MW of 70 kg/mol has 
a more heterogeneous surface than do the films for the other two molecular weights studied, 
which is consistent with the AFM results.  
 
3.3.3.2.2. Thick film growth 
PEI with a MW of 70 kg/mol and 41 nm sized PS- particles led to the thickest LbL film among 
different PEI/PS- composites studied in the previous sections. Thus, for this multilayer film, the 
LbL growth was continued until 59 double layers of PEI/PS- NPs were deposited on the glass 
substrate. Then, the surface morphology and thickness of the film were studied. Figure 3.14 
depicts the characteristics of such composite obtained by SEM.  
 
  
(a) (b) 
Fig. 3.14. Characteristics of LbL film composed of 59 double layers of PEI and PS- NPs, with PEI MW of 
70 kg/mol. PEI and PS- solutions were deposited at pH values of 9.9 and 7, respectively. No salt was used 
in either of the film ingredients except for the addition of HCl or KOH for pH adjustment. (a) Surface of 
the film with a magnification of 400 in the main figure and 80,000 in the inset. The scale bars show a 
length of 100 µm for the main figure and 500 nm for the inset. (b) Cross sectional view of the film with a 
magnification of 8,000. The arrow indicates the interface between the substrate and the film.  
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As can be seen in the surface micrograph (Fig. 3.14 (a)), the glass slide is completely covered by 
the film ingredients. There were some cracks and uneven features noticeable on the surface of the 
film however. Comparing the insets of Fig. 3.13 and Fig. 3.14 (a), more dark regions are observed 
in the latter, possibly indicating that the films are more disorganized and particles are more 
aggregated for the thicker film shown in Fig. 3.14 (a). Moreover, Fig. 3.14 (b) shows that a 
relatively thick film with thickness of few microns is deposited on the substrate. Film thickness 
was not uniform throughout the cross section and could have drastic variations. To be able to do 
SEM on the film cross section, the substrate was broken. As can be seen in Fig. 3.14 (b), film 
cross section is slightly scratched as a result of breaking the glass slide.   
 
3.4. Conclusions 
The effect of molecular weight (MW) of polyelectrolytes (PEs), type and charge of PE, 
nanoparticle size, pH, and salinity on the growth kinetics of polyelectrolyte (PE)/organic 
nanoparticle (NP) multilayer films were studied. First, it was found out that oppositely charged 
NPs alternately on top of each other could not be deposited in a manner that could survive rinsing 
steps, unless there are intervening polyelectrolyte layers. This shows that the polyelectrolyte and 
its binding and bridging of NPs is an essential mechanism for LbL film growth involving NPs. 
For both cationic poly(ethyleneimine) (PEI) deposited alternately with anionic polystyrene (PS-) 
NPs and for anionic poly(acrylic acid) (PAA) deposited alternately with cationic PS (PS+) NPs, 
an intermediate value of MW can (with some exceptions) lead to the fastest film buildup. This 
behavior can be explained as a trade-off between faster diffusivity for smaller chains during the 
deposition step at the expense of weaker adhesion and wash-off of particles during the deposition 
or rinse step when the MW becomes too low. However, for films composed of PEI with 26 or 100 
nm sized particles, the PEI with the highest MW led to the thickest film.  
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The pH of PEI and PS- solutions had a dramatic influence on the LbL growth; in general, 
reducing the charge on the PEI by depositing it at higher pH caused greater deposition of PEI and 
of subsequent layers of PEI and NPs. Especially fast film growth was obtained by depositing PEI 
at pH = 9.9 and oppositely charged PS- NPs at 7.0. It was shown that salinity affects the growth 
kinetics of LbL films differently depending on MW of the PE. For low MW PEs, increasing the 
salt concentration decreased the film growth rate monotonically, while for larger PE MW, 
addition of salt first improved and then degraded the multilayer buildup.   
 
3.5. Changing direction for drug delivery application 
The overall goal of this PhD research was to develop a multidrug delivery implant. The initial 
plan was to synthesize such an implant with LbL assembly of drug loaded NPs and 
polyelectrolytes (Fig. 3.15-a). We hypothesized that once the implant is administered, the layers 
in the proximity of biological media degrade faster (Fig. 3.15-b), thus, by programming layers 
with different drug loaded NPs, drug release could be finely tuned (Fig. 3.15-c).  
         
 
 
Fig. 3.15. a) Preliminary design of a colloidal LBL drug carrier.  Letters of A, C, and P represent 
antibiotics, corticosteroid and IOP regulating agents, respectively that were planned to be loaded in the 
drug carrier.  b) Schematic depiction of layered release of drug content, c) Desired cumulative drug release 
profile for each layer of drug delivery implant over time required by clinicians. 
 
(a) (b) (c) 
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To achieve the goal of multidrug LbL implant, the plan was to perform layer growth optimization 
experiments with inexpensive polystyrene NPs, and to find the right parameters to achieve high 
film thickness. Then, the polystyrene particles would be replaced with valuable drug loaded NPs.  
Based on the results presented in this chapter, a comprehensive understanding of mechanism of 
growth of LbL films using polystyrene NPs was achieved. Results clearly showed that as NP size 
increase (around 100 nm), the growth of LbL films is considerably slowed down. It will be shown 
in the subsequent chapters that drug loaded particles should be large enough to have considerable 
loading and extended drug release duration. Jianshan Liao, a member of Larson Group took the 
lead on growing LbL films with biodegradable NPs, and she noticed that the growth of LbL films 
is much slower in this case.38  
In addition, AFM and SEM micrographs presented in this chapter clearly showed very high 
surface roughness and irregularities and made us realize that programming layers of LbL films to 
fine tune the drug release profile is not a viable strategy. In chapter 4, using thermoresponsive 
hydrogels to formulate multidrug delivery vehicle is explained.  
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Chapter 4 
Injectable Multi-drug Formulation for Postoperative Treatment Following Ocular Surgery 
 
4.1. Introduction 
More than 4 million ocular surgeries are performed every year in the US.1 Careful management 
with topical medications is crucial for preventing post-operative complications including vision 
loss after ocular surgery.2 Successful surgical outcome requires frequent applications of one or 
more ophthalmic drops over several days to several weeks and this process depends heavily on 
patient compliance. Similar to most other surgical procedures, incisional ophthalmic procedures 
carry a small risk of infection3,4 and a more common physiologic reaction of inflammation in the 
immediate post-operative period.5,6 Post-surgical inflammation as well as corticosteroid treatment 
may induce intraocular pressure (IOP) increase in many patients.2,7-9 Increase in IOP may require 
additional topical treatment with ocular hypotensives, adding to the overall burden of treatment 
and decreasing patient adherence. In the later stages of surgical recovery, secondary 
complications including rebound inflammation and elevated intraocular pressure may cause 
morbidity, suboptimal vision, and on rare occasions may lead to vision loss and further surgery. 
Strict medication adherence in the post-operative period is necessary for preventing 
complications from inflammation, infection, and IOP elevation.10-12 Numerous studies have 
shown that side effects of topically applied ocular agents and patient non-compliance are major 
contributing factors of therapeutic failure in ophthalmic diseases.13 
The vast majority of ophthalmic drugs are marketed as topical formulations. The delivery of 
topical drug formulations is greatly hindered by the ocular surface barrier and availability is 
limited by rapid clearance from the ocular surface by the tear flow.14,15 Despite these inherent 
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shortcomings, the most critical barrier for ophthalmic drug delivery continues to be poor patient 
adherence, limiting effective dosing and causing suboptimal therapy.13,16,17 Patient adherence is 
affected by numerous factors, including decreased cognitive and motor function of geriatric 
patients, ocular surface irritation and allergic reaction with pain and discomfort caused by topical 
ophthalmic agents.13,17-19  
Alternative ocular drug delivery mechanisms have been developed to replace topical drop 
administration, improving drug dosing and reducing side effects. These mechanisms employ 
distinct approaches to the drug delivery problem and include contact lenses, implants and 
hydrogels.14,17,20-23 Although most are still in the pre-clinical development phase, a handful of 
products have received FDA approval and are available for patient use.14,17  
Ocular drug implants can be categorized into different groups based on several characteristics 
including release duration, location of administration, and type of molecule delivered. The first 
FDA approved implant for ocular indications was Vitrasert® (Bausch & Lomb, Rochester, NY). 
It provided slow release of ganciclovir and was used to treat patients with cytomegalovirus 
retinitis.14 Being a non-biodegradable implant, Vitrasert® uses two polymeric layers composed of 
poly vinyl alcohol (PVA) and ethylene vinyl alcohol (EVA) to deliver ganciclovir at a constant 
rate with therapeutic effectiveness for five to eight months.14 This system had several 
disadvantages due to non-biodegradable design, including suboptimal biocompatibility and 
immunogenicity compared with a biodegradable system, and the need for vitreoretinal surgery for 
implantation and removal.24,25 The next implant that was approved by FDA was Retisert® 
(Bausch & Lomb, Rochester, NY). This implant is not biodegradable and is composed of silicon 
and PVA layers. Retisert delivers fluocinolone acetonide for up to 2.5 years and is used to treat 
chronic non-infectious uveitis.14 Similar to Vitrasert, Retisert® is inserted into the vitreous cavity 
via a transscleral route during vitreoretinal surgery. Some of the implant and surgical procedure-
related complications of Retisert® include elevated IOP, detachment of retina, and formation of 
cataract.14,26,27 
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Ozurdex® (Allergan, Irvine, CA) is an implant for delivering dexamethasone to treat non-
infectious posterior uveitis as well as macular edema secondary to diabetes and retinal vein 
occlusion.14 Being the first FDA-approved biodegradable implant for ocular indications, 
dexamethasone is encapsulated in a poly(lactide-co-glycolide) (PLGA) matrix, and the implant is 
administered via intravitreal injection. Steroid is released from the implant for up to six months.14 
The adverse effects of Ozurdex® is similar to other implants releasing corticosteroid agents and 
include cataract formation and elevated IOP.28,29 
Iluvien® (Alimera Sciences, Alpharetta, GA) is a next generation non-biodegradable intravitreal 
corticosteroid implant which was recently approved by FDA.  Unlike Retisert®, Iluvien® does 
not require surgical implantation and is delivered into the vitreous cavity via transscleral 
injection. The implant releases fluocinolone acetonide to treat diabetic macular edema up to 3 
years.14 Similar to other corticosteroids, Iluvien® causes cataract formation and leads to elevated 
IOP.30,31 Although this implant is not biodegradable, surgical removal is typically not required 
once the drug is depleted.  
Other biodegradable implants are currently under development, including Verisome® (Icon 
Bioscience, Sunnyvale, CA). This drug delivery technology encapsulates different drug 
molecules and can maintain drug release up to a year after intravitreal injection.14 A Dexycu® 
implant based on Verisome® technology releases dexamethasone and is currently being tested in 
a phase III clinical trial to treat post-operative inflammation after cataract surgery.32 
The above-mentioned drug delivery systems are limited to a single agent and there is a need to 
develop a multi-drug delivery system. Thermoresponsive hydrogels are attractive solutions for 
long-term release of one or more therapeutics to the eye. In their optimal formulation, they are 
liquid at room temperature to ensure injectability while they form a depot for drug molecules 
once they are warmed up to body temperature. A-B-A triblock copolymers are particularly 
desirable for ocular drug delivery due to their biocompatibility and biodegradability. In these 
triblock copolymers, block A is a hydrophobic polymer such as PLGA, Poly(lactic acid) (PLA), 
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Poly(lactide-co-caprolactone) (PLCL), or Poly(caprolactone) (PCL) while block B is a 
hydrophilic polymer such as poly(ethylene glycol) (PEG). These triblock copolymers form 
micelles in the solutions with hydrophobic polymer forming the core, while the hydrophilic block 
will form the outer layer of the micelle that is in contact with water. With elevation of 
temperature, the number of micelles, and the association between them is augmented, leading to 
formation of a hydrogel network.33  
Gervais reported the use of cyclosporine A-loaded PLGA-PEG-PLGA thermogels for the 
treatment of posterior capsule opacification, one of the sequelae of cataract surgery.34 By 
dissolving their hydrophobic drug in ethanol at 100 mg/ml concentration and adding a small 
volume of that solution to a triblock copolymer solution, the authors were able to load the drug 
into the hydrogel. To study the drug release, they incubated 250 µl of hydrogel and used 250 µl of 
Dulbecco’s modified Eagle medium as the release media. Their results showed a large burst 
release of drug one minute after initiation of the drug release experiment, with reduction in drug 
concentration over the next 24 hrs, albeit with drug level remaining detectable for up to a week 
after release. They noted that drug-releasing hydrogel should be modified to maintain drug 
concentration acceptable for longer duration and this will enable optimum therapeutic outcomes.  
Xie et al. loaded Avastin®, a large monoclonal antibody in PLGA-PEG-PLGA hydrogels for the 
treatment of vitreoretinal diseases.35 Fast drug release from the hydrogel appeared to occur 
despite large drug size. Even though Avastin® is orders of magnitude larger (molecular weight: 
149 kDa) than other small molecules discussed above, the majority of it was nevertheless released 
within 8 hours post incubation. In general, the initial burst release of drug molecule followed by 
rapid reduction in drug concentration is not favorable for the long-term treatment of ocular 
diseases. The takeaway message from these valuable studies is that when relying on A-B-A 
thermogels, one cannot achieve a controlled drug release profile for a sustained period (i.e., 
longer than a month) and as a result additional resistance against premature drug leakage is 
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needed. In addition, A-B-A thermogels alone cannot be used to release multiple drug molecules 
with different drug release rates and durations.  
Zhang et al. employed PLGA-PEG-PLGA hydrogels to prolong the release of dexamethasone.36 
Since the concentration of dexamethasone in the triblock copolymer solution was much higher 
than the drug solubility limit, it seems that dexamethasone “particles” were maintained within the 
polymer network. In addition, dexamethasone is very hydrophobic with low tendency to diffuse 
into aqueous media. These factors enabled enhancement of the release duration of dexamethasone 
for up to 18 days. They showed that by combining different triblock copolymer solutions, they 
were able to adjust the gelation temperature of the hydrogel and the dexamethasone release rate.  
However, still there is a therapeutic need to sustain the release of dexamethasone beyond even 
this period. 
Hirani et al. synthesized PEG-PLGA nanoparticles loaded with triamcinolone acetonide and 
added the resulting nanoparticles to a PLGA-PEG-PLGA hydrogel network for the treatment of 
age-related macular degeneration (AMD).37 Similar to previous studies, the majority of the 
reported release happened in the first 10 hours post incubation. However, since the drug molecule 
was encapsulated in the nanoparticles, Hirani et al. did not observe the huge burst release minutes 
after incubation reported by Gervais.34 Since drug release is governed by the diffusion of 
molecules from the particles, nanoparticles are generally too small to control the release of the 
drug beyond a few hours or days. In addition, nanoparticles can aggregate easily which could 
alter their drug-release kinetics, and they are in general harder to lyophilize and store for the long 
term compared to microparticles (MPs).   
Duvvuri et al. synthesized PLGA MPs encapsulating ganciclovir and loaded these into PLGA-
PEG-PLGA hydrogels.38 This enabled them to achieve sustained release of drug for more than a 
month. They programmed the drug release profile by blending the polymers used to make PLGA 
MPs as well as by mixing the particles made with different polymers.  Microparticles synthesized 
in this study were more than 200 µm in size.  
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Polymers that are more hydrophobic than PLGA, e.g. PLA, PLCL, or PCL, will generally 
degrade more slowly. Thus, using those more hydrophoblic polymers to make thermoresponsive 
hydrogels could potentially lead to slower and more linear drug release over time. There have 
been only limited studies focusing on the use of these types of polymers to make 
thermoresponsive hydrogels for ocular drug delivery.39,40 In addition, none of the current drug 
delivery technologies discussed above are designed to release multiple drug molecules while 
regulating release durations. A multi-drug delivery platform that temporally regulates drug 
release would be ideal for the treatment of many ophthalmic conditions, including post-operative 
management requiring multiple topical agents for inflammation, infection, and elevated IOP.  For 
other ocular diseases including age-related macular degeneration, previous studies have shown 
that combination therapy using multiple drug molecules, benefiting from their synergistic effects, 
is more effective than single-drug therapy in many patients.14,41 To address the shortcomings of 
existing technologies and fulfill an unmet need in ocular drug delivery, a novel drug delivery 
platform designed to release multiple drug molecules with precise temporal regulation is reported. 
This drug delivery system is administered via intraocular injection, and is composed of 
biocompatible and biodegradable materials for optimal ocular safety. 
As an initial therapeutic target, the drug delivery system designed here is intended to address the 
challenges of multi-drug delivery during postoperative management of cataract surgery. In 
routine care after cataract surgery, topical antibiotics are administered for 7 days to reduce the 
risk of infection, whereas topical corticosteroids are applied up to a month with decreasing 
frequency to reduce inflammation.10-12 Often an ocular hypotensive is added to the post-operative 
treatment regimen to reduce IOP increase secondary to inflammation and/or corticosteroid use.2,7-
9 Our drug delivery platform is designed to replace this topical treatment paradigm. In this 
formulation, a broad-spectrum antibiotic, 4th generation fluoroquinolone moxifloxacin, is 
designed to be delivered over a period of 7 days by adding it directly to the hydrogel network 
(Fig. 4.1-a). In addition, a potent corticosteroid, dexamethasone, is released from the drug 
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delivery system for more than a month to suppress inflammation. Because increased IOP is seen 
commonly with intraocular steroid implants, an ocular hypotensive agent, beta-blocker 
levobunolol,42,43 is delivered to control IOP. The anti-inflammatory and hypotensive drugs are 
encapsulated in PLGA MPs, which act as barriers by which drug release can be controlled and 
made significantly slower than release from the hydrogel alone. The particles are embedded into 
hydrogels to further regulate the control of drug release (Fig. 4.1-a). With our innovative design, 
drug release rate and time for each agent (regardless of their hydrophobicity) can be individually 
controlled for specific ocular indications. This can be done by changing the amount and loading 
of MPs and the composition of the triblock copolymers as well as polymer used to synthesize the 
particles. Since this drug delivery platform is in liquid phase at room temperature (Fig. 4.1-b) and 
forms a hydrogel network at body temperature (Fig. 4.1-c), implantation is accomplished through 
direct injection into the anterior chamber or vitreous cavity after a surgical procedure or in office 
(Fig. 4.1-d) 
 
         
 
 
Fig. 4.1. a) Our drug delivery platform enables delivery of at least three drug molecules. A broad-spectrum 
antibiotic (A) is added directly to the hydrogel network, while a potent corticosteroid (C) and ocular 
hypotensive agent (H) are encapsulated within the MPs and thereafter loaded into the hydrogel. b) The 
thermosensitive hydrogels are engineered to be liquids at room temperature, c) While they form a hydrogel 
network at body temperature. d) This eases the implantation via intraocular injections with a very small-
guage needle and thus provides minimal invasiveness.   
 
(b) (a) (c) (d) 
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4.2. Description of the experiment 
4.2.1. Materials 
To make the hydrogels of the optimum formulation (liquid at room temperature and a hydrogel at 
body temperature), the following triblock copolymers were purchased from PolySciTech (West 
Lafayette, IN) and are called throughout this chapter with the product number:  
AK12: PLGA-PEG-PLGA (with MWs of 1000:1000:1000 Da, ratio of lactic to glycolic acid 
(LA/GA): 1/1). 
Ak91: PLGA-PEG-PLGA (with MWs of 1500:1500:1500 Da, LA/GA: 6/1). 
AK100: PLA-PEG-PLA (with MWs of 1700:1500:1700 Da) 
AK108: PLCL-PEG-PLCL (with MWs of 1600:1500:1600 Da, caprolactone (CL)/LA: 3/1). 
AK109: PLCL-PEG-PLCL (with MWs of 1700:1500:1700 Da, CL/LA: 3/2). 
Different types of PLGA were used to make drug loaded MPs. For levobunolol loaded MPs, 
PLGA (with LA/GA of 60/40 (Product number: AP43), 75/25 (Product number: AP18), or 85/15 
(AP87), all with number averaged molecular weight of 45-55kDa) was purchased from 
PolySciTech. For dexamethasone-loaded MPs, PLGA (Resomer 503H with LA/GA ratio of 50/50 
and weight averaged molecular weight of 24-38 kDa) was purchased from Evonik Corporation 
(Essen, Germany). Dexamethasone (Product number: 46165) and moxifloxacin (Product number: 
PHR1542) were obtained from Sigma Aldrich (St. Louis, MO), while levobunolol hydrochloride 
(HCl) (Product number: 1359801) was purchased from United States Pharmacopeia (Rockville, 
MD). Poly(vinyl alcohol) (PVA, with molecular weight of 13-23 kDa, product number: 363170) 
was obtained from Sigma Aldrich. All other materials were obtained from Sigma Aldrich. Unless 
noted otherwise, the materials were used as received without further purification.   
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4.2.2. Synthesis of microparticles 
4.2.2.1. Deprotonation of levobunolol hydrochloride 
To remove the HCl salt from levobunolol HCl, 30 mg of the drug was dissolved in dimethyl 
sulfoxide (DMSO) at a concentration of 97 mg/ml. A one-to-one mole ratio of triethylamine 
(TEA) was added to that and the solution was constantly inverted at a speed of 11 rpm for 3 hrs to 
obtain deprotonated levobunolol. The resulting drug solution was kept at room temperature 
protected from light and was used to make the MPs the next day.  
 
4.2.2.2. Levobunolol loaded microparticles 
100 mg PLGA (60/40, 75/25 or 85/15) was dissolved in dichloromethane (DCM) at a 
concentration of 61 mg/ml. This solution was added to 10.7 mg levobunolol previously dissolved 
in DMSO and deprotonated in the presence of TEA (total DMSO plus TEA volume: 115 ul). The 
polymer-drug solutions were then mixed and sonicated with a bath sonicator for 45 seconds and 
split in half. Each half was transferred to a 40 ml aqueous solution of 0.75% PVA during 
homogenization at a speed of 15,000 rpm for 1 minute. The resulting MPs were transferred to a 
larger bath of PVA (80 ml at a concentration of 0.5%) while stirring at a speed of 990 rpm for 3.5 
hours. The MPs were pelleted by centrifugation at a speed of 3300 RCF for 5 mins, and washed 
three times with miliQ water. The MPs were then lyophilized and stored at -20 oC. To synthesize 
blank MPs, the same DMSO/TEA volume (115 ul) with no drug was mixed with PLGA solution 
in DCM.    
 
4.2.2.3. Levobunolol hydrochloride-loaded microparticles 
To make MPs loaded with levobunolol HCl, all the steps mentioned in the previous section were 
followed except that 10.7 mg of levobunolol HCl dissolved in DMSO at a concentration of 97 
mg/ml was used as the drug solution, in place of deprotonated levobunolol.  
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4.2.2.4. Dexamethasone-loaded microparticles 
Dexamethasone-loaded MPs were made following the same protocol as described for 
levobunolol, except that PLGA (50/50) was dissolved in DCM at a higher concentration of 68 
mg/ml. In addition, 20 mg of dexamethasone was dissolved in DMSO at a concentration of 250 
mg/ml and used as the drug solution.  
 
4.2.3. Preparation of the hydrogel  
To make the thermogels, the polymer solution is dissolved at a higher concentration than the 
intended concentration, so that liquid used to dilute the polymer solution to the right 
concentration, can also be used to add other components (e.g., addition of a drug molecule to 
polymer network or tonicity adjustment). Thus, even though the intended triblock copolymer 
concentration was 20 % wt/vol, the triblock copolymers were dissolved in milliQ water at a 
concentration of 28.6 % wt/vol by shaking while cold (2-8oC) for 3 days. The triblock copolymer 
solutions were then diluted to reach the intended polymer concentration by addition of excess 
water and 10X PBS. The volume of 10X PBS addition was chosen so that the final formulations 
were at 1X PBS concentration to minimize any osmotic pressure difference with the biological 
environment (isotonic concentration). 
Three different hydrogel types were developed, namely, PLGA-PEG-PLGA, PLA-PEG-PLA and 
PLCL-PEG-PLCL hydrogels by blending different triblock copolymers. The ideal triblock 
copolymer solution is one that is a liquid at room temperature to ensure injectability but forms a 
hydrogel network at body temperature. To achieve this, different polymer solutions need to be 
blended so that the gelation temperature is at around 37°C. The PLGA-PEG-PLGA was a 3/1 
blend of AK91 and AK12 triblock copolymer solutions. The PLA-PEG-PLA hydrogel was made 
with AK100 triblock copolymer solution only, as its gelation temperature was in the right range. 
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Furthermore, PLCL-PEG-PLCL hydrogels were a 6/1 blend of AK108/AK109 triblock 
copolymer solutions. By blending different amounts of triblock copolymers, the gelation 
temperature can be finely tuned.  
 
4.2.4. Hydrogel characterization  
To characterize the hydrogels, two different schemes were implemented, namely a qualitative vial 
inversion test to determine the gelation temperature for each triblock copolymer solution and 
quantitative rheological measurements to determine the mechanical strength of the hydrogel at 
different temperatures.  
To determine the phase diagram, copolymer solution at different concentrations of 10, 15, 20, and 
25 % wt/vol was incubated at each set temperature point for 15 minutes. Subsequently, the vial 
was placed upside-down for 30 seconds and the triblock copolymer solution was visually 
inspected. If the polymer solution was not able to flow during this time, it was considered a gel. 
Otherwise, it was a liquid or precipitate. The precipitate could be clearly identified by eye in that 
the polymer had crashed out of the solution and solution was transparent.  
Rheological experiments were performed using an ARES-G2 rheometer (TA Instruments, New 
Castle, DE) with a stainless steel rheometer plate with a diameter of 40 mm. This rheometer plate 
with a large diameter was chosen to maximize the torque signal generated by the triblock 
copolymer solution and enhance the accuracy of the data. Rheological experiments were 
performed with a temperature step of 3oC. At each specific temperature, a strain sweep 
experiment was done at a frequency of 0.1 Hz to determine the linear viscoelastic region of the 
material. Afterwards, a frequency sweep was performed in the linear viscoelastic region to 
determine the values of moduli at different frequencies. The elastic modulus (G’) is a measure of 
elasticity of the material (solid like behavior), while the viscose modulus (G”) is a measure of 
viscosity of the material (viscose liquid like behavior).  
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4.2.5. Drug release studies  
For the moxifloxacin, fast release of the drug in a week was desired, and as a result 500 µg of 
moxifloxacin was directly added to the hydrogel network. To do so, moxifloxacin solution at 12.5 
mg/ml was prepared and 40 ul was added to the triblock copolymer solution. A longer duration of 
release is desired for dexamethasone and levobunolol. In addition, for each of these two drug 
molecules a different release profile is required. For dexamethasone, the amount of drug release 
should be high initially and gradually decrease over time. However, levobunolol release should 
be low initially and increase later on to suppress any ocular pressure increase in the postoperative 
treatment period.44 To achieve this goal, these small drug molecules are encapsulated in MPs first 
and then the MPs are loaded in the hydrogel network. This provides two barriers against burst 
release and premature escape of the drug molecules. Unless noted otherwise, 7 mg of 
dexamethasone-loaded MPs and 17 mg of levobunolol-loaded MPs were loaded into the hydrogel 
network for drug release studies.  
Hydrogels were made with 200 µl triblock copolymer solution and were kept in a 1.5 ml 
centrifuge tube. After incubation of hydrogel at 37oC for half an hour, 1.2 ml of “pre-warmed” 
PBS was poured on it as the release media and the drug release was initiated. 1 ml of PBS was 
replaced with fresh PBS at certain intervals to make sure hydrogel was exposed to an effectively 
infinite-volume bath to release the drugs and to determine the released amount over time.  
To assess the effectiveness of hydrogels in sustaining the release of drugs, the drug release from 
the MP-loaded hydrogels was compared with that of MPs alone. To do so, drug release from MPs 
was studied by incubating the same amount of MPs (7 mg of dexamethasone-loaded MPs and 17 
mg of levobunolol-loaded MPs) in 1.2 ml 1X PBS. At certain timepoints, the tubes were 
centrifuged at 3000 RCF and 1 ml of PBS was replaced with fresh PBS. For the microparticle 
release samples, release media could evaporate over time (less than 7% in the worst case), even 
though the tubes were sealed with parafilm. The effect of evaporation of media on the release 
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results was taken into account. All drug-releasing hydrogels and MPs were shaken in a 37 oC 
incubator.  
In addition to drug-releasing hydrogels and MPs, three hydrogel samples representing PLGA-
PEG-PLGA, PLA-PEG-PLA, and PLCL-PEG-PLCL hydrogels loaded with blank MPs as well as 
a blank MP sample without hydrogel were made and incubated to serve as the negative controls 
and any signal from them (which was very small in most cases) was subtracted from that of drug-
releasing samples. 
 
4.2.6. Drug loading and release characterization 
To determine the loading of dexamethasone and levobunolol, PLGA encapsulating the drug 
molecules in MPs was degraded by incubation of particles in a basic environment (1M NaOH) for 
15 minutes at 37 oC. The resulting solutions were neutralized by addition of acid (1M HCl) and 
lyophilized. Next, the dried drug molecules were dissolved in DMSO, diluted by addition of 
excess methanol (DMSO/methanol: 1/10 volumetric ratio), centrifuged at a speed of 4,000 RCF 
for 5 mins and the supernatants were analyzed with high performance liquid chromatography 
(HPLC) in order to quantify the amount of drug loaded in the MPs. Loading was determined 
based on standard curves for each drug molecule with zero intercept. In this regard, 
dexamethasone was dissolved in water while levobunolol already in DMSO after deprotonation 
was diluted by addition of excess water. The drug solutions were turned into 1M basic 
environment by addition of same base volume at 2M concentration. Subsequently, the drug 
solutions were incubated at 37oC for 15 minutes (to simulate the steps taken to measure drug 
loading) and were subsequently neutralized by addition of acid (1M HCl). The samples were 
lyophilized, and reconstituted in DMSO/Methanol (1/10 volumetric ratio), and analyzed with 
HPLC to determine the standard curve for drug loading. 
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The release media taken from hydrogels or MP-containing samples were lyophilized and drug 
molecules were reconstituted in DMSO/methanol (at 1/10 volumetric ratio). The resulting 
solution was centrifuged at 21,000 RCF and supernatant was analyzed with HPLC to quantify the 
amount of released drug. To determine the standard curve for the analysis of release samples, 
moxifloxacin and dexamethasone were dissolved in PBS. However, a small volume of 
levobunolol in DMSO solution (because of deprotonation) was diluted with excess PBS. Next, 
the drug solutions in PBS at different concentrations were incubated at 37 oC for 24 hrs (to mimic 
exposure of released drugs to 37 oC environment during drug release experiments), lyophilized 
and reconstituted in DMSO/methanol (1/10 volumetric ratio) and analyzed with HPLC to 
determine standard curve for drug release with zero intercept. 
The mobile phase for HPLC was composed of mixture of acetonitrile (20%) and water (80%) for 
the first 9.5 minutes to elute levobunolol and moxifloxacin. Then a linear compositional ramp 
was induced and the proportion of acetonitrile was raised to 34% in 1 minute. The acetonitrile 
was then kept at 34% for 6.5 minutes to elute dexamethasone, which was a more hydrophobic 
compound than the other drugs studied. Levobunolol, moxifloxacin and dexamethasone signals 
were read at 221, 295 and 240 nm, respectively. The drug content was always checked with its 
UV absorption spectra to distinguish drug content from baseline oscillations.  The flow rate of 
solvent was set to 1 ml/min, and injection volume of the drug solution was 25 µl.  
 
4.2.7. Scanning electron microscopy 
To determine the relative size of MPs and their surface morphology, a LEO/Zeiss scanning 
electron microscope (SEM) was utilized. In this regard, MPs were deposited on a SEM mount, 
and were coated with a thin (<20 nm) layer of gold-palladium during 2 minutes deposition at a 
pressure of 200 mTorr. Operating voltage was set to 1kV to minimize sample damage during 
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microscopy. At least four SEM micrographs from different parts of the samples at a 
magnification of 1000X were taken and the results shown are chosen to be representatives.  
 
4.2.8. Error analysis 
The drug release experiments were performed in duplicate. Error bars represent the standard 
deviations between replicate measurements.  
 
4.3. Results 
4.3.1. Particle characterization  
Figure 4.2 illustrates the SEM micrographs taken from the MPs loaded with levobunolol or 
dexamethasone in this research. 
 
 
 
 
 
 
 
 
 
 110 
     
 
 
   
 
 
 
 
 
Fig. 4.2. SEM micrographs on a) levobunolol HCl-loaded MPs with 75/25 (lactic/glycolic acid ratio) 
PLGA, deprotonated levobunolol-loaded MPs with b) 60/40, c) 75/25 and d) 85/15 PLGA and e) 
dexamethasone-loaded MPs with 50/50 PLGA. All of the images were taken at a magnification of 1000, 
and scale bar shows a distance of 10 µm.   
  
(a) (b) 
(c) (d) 
(e) 
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Figure 4.2 confirms the presence of spherical particles after loading different drug molecules and 
using different polymer types. There are some minor irregularities in the particle shapes that are 
mainly due to high polymer concentration in DCM to achieve high loading. There is a trade-off 
between smooth isotropic spherical shape and drug loading and it was found out that the selected 
polymer concentrations (68 mg/ml for dexamethasone and 61 for levobunolol loaded MPs) are 
compromise values to achieve high enough drug loading while ensuring acceptable particle 
morphology.  
The loading of dexamethasone in MPs was found to be 3.2 µg/mg of MPs. In addition, the 
loadings of deprotonated levobunolol in MPs synthesized with 60/40, 75/25, and 85/15 PLGA 
were determined to be 6.9, 6.4, and 3.4 µg/mg of MPs, respectively. The loading of levobunolol 
HCl in MPs made with 75/25 PLGA was less than with the deprotonated version and was found 
to be 2.5 µg/mg of MPs. Levobunolol was a somewhat hydrophilic drug molecule (water 
solubility: 0.25 mg/ml45); thus, it is not naturally encapsulated in hydrophobic PLGA. Thus, the 
higher the hydrophobicity of the polymer, the less will be the loading of the levobunolol. In the 
subsequent sections, effect of deprotonating levobunolol on enhancing its hydrophobicity and 
increasing its loading in MPs is described. 
 
4.3.2. Hydrogel characterization 
Figure 4.3 illustrates the phase diagram for different triblock copolymers used in this study. All 
the formulations tested were at 1X PBS concentration.  
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                                      (a)                                                                     (b)  
 
        (c) 
Fig. 4.3. Phase diagram for different triblock copolymers used in this research, a) PLGA-PEG-PLGA, b) 
PLA-PEG-PLA, c) PLCL-PEG-PLCL.  
 
For PLGA-PEG-PLGA and PLCL-PEG-PLCL, two different triblock copolymers with different 
molecular weight and ratio of LA/GA, or CL/LA (as discussed in the Materials section) were 
blended to make sure that the resulting polymer solution was a liquid at room temperature and a 
gel at body temperature. PLA-PEG-PLA polymer solutions already possessed this property. 
Figure 4.3 confirms this and shows that at lower temperatures all of the polymer solutions are 
liquid. However, they will change into the gel form at around body temperature. Figure 4.3 also 
indicates that at very high temperatures, the polymers precipitate out of solution and can no 
longer form a gel network. According to Fig. 4.3, for each triblock copolymer concentration, 
there is a gelation temperature window. When the polymer concentration is increased, this 
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gelation window becomes wider. At very high polymer concentrations, there are enough micelles 
associated with each other that the triblock copolymer solution could form a hydrogel network 
even at room temperature. On the other hand, at lower polymer concentrations, the gelation 
window is too narrow to work with. As a result, in this research, the polymer concentration for all 
the hydrogels was set to 20% wt/vol. Interestingly, PLCL-PEG-PLCL polymer solutions have a 
much wider gelation window at each concentration, compared to PLGA-PEG-PLGA and PLA-
PEG-PLA polymer solutions.  
Figure 4.4 depicts the variation of storage and loss moduli for different triblock copolymers 
blended in this study. The polymer solution was formulated at 20% wt/vol in 1X PBS.  
  
 
 
Fig. 4.4. Rheological results for different triblock copolymers; a) Storage modulus, b) Loss modulus. 
Results were obtained at 1Hz oscillation frequency.  The PLGA-PEG-PLGA triblock copolymer was a 3/1 
blend of AK91 and AK12. The PLA-PEG-PLA was AK100 only. The PLCL-PEG-PLCL was a 6/1 blend 
of AK108 and AK109.  
 
Figure 4.4 shows that the resulting blend of triblock copolymers had a low value for both the 
storage and loss moduli at room temperature, indicating liquid-like behavior. However, with 
increasing temperatures, the mechanical properties of the gels shift as gelation occurs and the 
moduli are maximized near body temperature (37oC). As temperature is further increased, the 
polymer precipitates and the desirable mechanical properties decrease. Quantitative rheological 
observations support the qualitative observations depicted in phase diagrams. Figure 4.5 depicts 
(a) (b) 
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the variations of the moduli with frequency at different temperatures for the PLCL-PEG-PLCL 
triblock copolymer solution.  
 
 
 
Fig. 4.5. Variations of a) storage and b) loss moduli with oscillation frequency at different temperatures for 
PLCL-PEG-PLCL polymer solutions.  
 
According to Fig. 4.5, regardless of oscillation frequency, the moduli are maximum at body 
temperature.  
 
4.3.3. Effect of deprotonation on levobunolol loading and release  
For ocular hypotensives, daily release on the order of 1 µg is required to ensure effectiveness of 
the molecule in reducing the ocular pressure.46,47 Thus, a high loading of levobunolol in MPs was 
required to ensure the proper effect. To enhance the loading, levobunolol was deprotonated in the 
presence of TEA. A strong base like TEA attracts H+ ions, thus removing the HCl salt from the 
levobunolol and making it more hydrophobic due to removal of charged species. Deprotonation 
of levobunolol led to around 2.6-fold increase in its loading relative to the levobunolol HCl. To 
determine the effect of deprotonation on the drug release profile, two samples were made: one 
with 17 mg levobunolol-loaded MPs and the other with 17 mg of levobunolol HCl-loaded MPs 
both made with 75/25 PLGA. Both samples had 7 mg of dexamethasone-loaded MPs made with 
50/50 PLGA added to them to check whether the presence of levobunolol would impact the 
(a) (b) 
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release of dexamethasone. Release results from these samples are compared in Fig. 4.6. As can be 
seen, the daily release of deprotonated levobunolol and its cumulative release is roughly 2.5 fold 
higher than the sample with levobunolol HCl. Thus, deprotonation enabled enhancing the daily 
release of levobunolol from the MPs.  
 
 
 
(a) 
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Fig. 4.6. (a) Comparison of release of levobunolol with levobunolol HCl from MPs. (b) Release of 
dexamethasone from samples containing different levobunolol type. For these samples no hydrogel was 
present and drug release from MPs alone was compared. In this and all of the subsequent figures, error bars 
represent standard deviations between duplicate measurements and data points represent average values of 
duplicate measurements. 
 
Figure 4.6 also shows that daily release of dexamethasone from the two samples is the same, 
indicating that the presence of levobunolol MPs doesn’t impact the dexamethasone release. 
 
4.3.4. Effect of hydrogel on sustaining drug release  
Next, the effect of the hydrogel network on sustaining the drug release from MPs was determined 
by comparing results of MPs in hydrogel with those for MPs alone. To do so, two samples were 
made: one containing 17 mg of deprotonated levobunolol MPs with 75/25 PLGA and 7 mg of 
dexamethasone loaded MPs with 50/50 PLGA, and the other a PLCL-PEG-PLCL hydrogel 
containing the same amount and type of microparticles plus 500 µg of moxifloxacin added 
directly to the hydrogel network. Figure 4.7 compares the amount of levobunolol and 
dexamethasone released from each sample.  
(b) 
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Fig. 4.7. Comparison of drug released from MP-loaded in PLCL-PEG-PLCL hydrogels with that from MPs 
alone, a) levobunolol, b) dexamethasone.  
  
As can be seen in Fig. 4.7a, levobunolol release from MPs loaded in the hydrogel is nearly the 
same as that from MPs alone. Thus, the hydrogel does not seem to have much influence on the 
(a) 
(b) 
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release profile of levobunolol. On the other hand, release of dexamethasone from MPs in the 
hydrogel is considerably slowed down compared to release from MPs alone. Evident in Fig. 4.7b 
is the huge burst release of dexamethasone from MPs on day 1, which might be toxic for ocular 
cells. Also, for MPs, daily dexamethasone release is decreased abruptly over time and most of the 
drug is released within the first 5 days. However, for the MPs loaded in the hydrogel, burst drug 
release is eliminated and daily release of dexamethasone is constant for at least a week. Beyond 
the first week, daily drug release decreases gradually over time (which is greatly favorable for the 
clinical application). Dexamethasone release from MPs was detectable for up to 21 days, while 
for MPs in the hydrogel, the drug release was detectable for up to 51 days. As will be described in 
the subsequent section, if required, the drug release profile could be manipulated by varying the 
hydrophobicity of the polymer encapsulating the drug molecules. However, throughout the first 
month, daily release of dexamethasone was enough to have a therapeutically significant effect in 
accordance with literature. Notably, the amount of dexamethasone released to the vitreous cavity 
by implants should be between 0.2-1.2 ug daily initially, and the amount of drug should decrease 
gradually over time for postoperative management following cataract surgeries.44,48 
The mechanism behind sustaining the dexamethasone release by the hydrogel mainly stems from 
their chemical interaction. Dexamethasone has a fluorine and several hydroxyl and double 
bonded oxygen groups that could form hydrogen bonds with excess water content in the hydrogel 
or with its PEG block. However, levobunolol does not have as many groups capable of forming 
hydrogen bonds. In addition, dexamethasone is very hydrophobic compared to levobunolol, and 
the tendency of dexamethasone to diffuse out of the hydrogel network and go into release media 
is therefore low. A-B-A triblock copolymers form a hydrogel network with large pore sizes (~50-
100 µm),35 and therefore can’t physically avoid or slow down the release of small drug molecules 
studied in this research. As will be discussed in the subsequent section, the mechanical properties 
of the hydrogel network do not seem to effect the drug release kinetics, since drug release kinetics 
were found to be similar in hydrogels with significantly different moduli (Fig. 4.8-a).  
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Even though the PLCL-PEG-PLCL hydrogel did not have any effect on sustaining the release of 
levobunolol, still having the MPs in the hydrogel is more advantageous than administering MPs 
alone in the eye, since the hydrogel could hold the MPs in place, while the free MPs could 
potentially diffuse throughout the eye especially to the lens, interfere with vision and induce 
inflammation.  
 
4.3.5. Effect of hydrogel type on drug release profile 
Figure 4.8 depicts the effect of different hydrogel types on the release kinetics of moxifloxacin, 
dexamethasone and levobunolol, respectively.  
 
 
 
(a) 
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Fig. 4.8. Drug release kinetics for different types of hydrogels, a) Moxifloxacin, b) Levobunolol and c) 
Dexamethasone. Data points are the average between duplicate measurements and error bars represent 
standard deviation.  
 
Moxifloxacin is a hydrophilic drug molecule (water solubility: 24 mg/ml), and was added directly 
to the polymer solution, and upon hydrogel formation, it will be held “loosely” within the 
(c) 
(b) 
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hydrogel network. Its release profile as shown in Fig. 4.8-a contains a high burst release followed 
by gradual decrease in daily drug release amount with the majority of the drug being released 
within a week. To explain the release requiring a week despite the absence of microparticles, we 
suggest that there might be some chemical interactions between the drug and hydrogel network 
such as hydrogen bonding between fluorine, hydroxyl and double-bonded oxygen groups in 
Moxifloxacin with excess water content in hydrogel or its PEG part that has slowed down the 
release of this drug. This release profile was favorable for meeting clinical requirements to avoid 
infection.44,49 Figure 4.8-a also shows that there is not much difference in release kinetics of 
moxifloxacin between different hydrogel types. This is expected, as moxifloxacin was added 
directly to the hydrogel network and there was not a strong barrier against its release.  
On the other hand, for levobunolol and dexamethasone, drug release from PLGA-PEG-PLGA 
hydrogels is faster than from PLA-PEG-PLA for the first three weeks. Also, the drug release from 
PLA-PEG-PLA seems to be faster than from PLCL-PEG-PLCL hydrogels over this period of 
time. This trend is more noticeable for levobunolol. Compared with release from microparticles 
alone, it seems that the PLGA-PEG-PLGA hydrogels have accelerated the release of levobunolol 
(Fig. 4.8b). This seems counter-intuitive, since the hydrogels are a barrier and if anything they 
should slow down the drug release rate. However, this trend makes sense when one considers the 
fact that by hydrolysis and cleavage of ester bonds of PLGA in PLGA-PEG-PLGA hydrogels, the 
degradation products make the environment acidic, leading to faster degradation of microparticles 
that are embedded in the hydrogel network.50 The same phenomenon should happen by 
degradation of PLA-PEG-PLA and PLCL-PEG-PLCL hydrogels, but due to their higher 
hydrophobicity and slower degradation rate, it takes those hydrogels a longer time to make the 
environment acidic and thus their impact on acceleration of drug release is less pronounced.  
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4.3.6. Use of polymer type to fine-tune the drug release profile  
Depending on the specific disease model and its progression, ophthalmologists might be 
interested in having different release durations of a specific drug molecule. To do so, the drug 
delivery platform should have the ability to finely tune the drug release profile. One way to 
achieve this goal is to vary the type of polymer encapsulating the drug molecule. To demonstrate 
this, deprotonated levobunolol loaded MPs were made out of PLGA with differing 
hydrophobicity and degradation rate with LA/GA ratios of 60/40, 75/25, and 85/15. A higher 
ratio of lactic to glycolic acid leads to greater hydrophobicity and slower degradation rate. Three 
hydrogel release samples were prepared each containing 17 mg levobunolol-loaded MPs with 
different PLGA polymer types mentioned above, plus 7 mg dexamethasone-loaded MPs and 500 
µg moxifloxacin. PLCL-PEG-PLCL hydrogels were used for this experiment. Figure 4.9 depicts 
the levobunolol release profile from these hydrogels.  
 
Fig. 4.9. Effect of polymer encapsulating levobunolol on regulation of release duration from the drug 
delivery system.  
 
Evident in Figure 4.9 is the ability of the drug delivery platform to finely tune the drug release 
profile by simple variation of polymer used to encapsulate the drug molecule. PLGA with a 
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LA/GA ratio of 60/40 degrades faster and thus enables rapid and linear drug release kinetics. For 
this polymer, the majority of levobunolol release happens within 25 days. On the other hand, 
85/15 PLGA is the most hydrophobic polymer and releases the drug molecule more slowly and 
sustain the drug release for up to 60 days. Interestingly, for this polymer an increase in the drug 
release content was observable on the fourth week of drug release. It is probably because by 4-
week incubation at 37 oC, this highly hydrophobic PLGA has developed enough porous structure 
through degradation to allow the encapsulated drug molecules to escape the particles. Drug 
release from 75/25 PLGA is somewhere in between 60/40 and 85/15 PLGA with a slight increase 
in the drug release content in the second week. During the postoperative treatment period, 
elevation of ocular pressure as a side effect of steroids could happen during the second week for 
the patients.7,44,51 Therefore, it is highly desirable to have a boost in release of levobunolol in this 
window for the proper postoperative management of ocular surgeries. 
 
4.3.7. Varying the microparticle or moxifloxacin mass to tune the daily drug release 
In the previous section, the ability to finely tune the drug release profile by varying the type of 
polymer encapsulating levobunolol was highlighted. Another flexibility of the presented drug 
delivery system is the freedom to vary the mass of dexamethasone or levobunolol loaded MPs or 
moxifloxacin encapsulated in the same amount of hydrogel to change the daily drug release while 
keeping the overall release profile relatively constant. In this regard, two PLCL-PEG-PLCL 
hydrogels were synthesized. In the first hydrogel group, 17 mg deprotonated levobunolol loaded 
MPs made with 75/25 PLGA, 7 mg dexamethasone loaded MPs made with 50/50 PLGA and 500 
µg moxifloxacin were loaded. This group will be regarded as “full drug dosage.” While, in the 
second hydrogel category, half of the MPs and moxifloxacin mass were loaded in the hydrogel 
network and this hydrogel will be referred to as “half drug dosage.” Figure 4.10 compares the 
drug release from these two hydrogels.  
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Fig. 4.10. Comparison of a) moxifloxacin, b) levobunolol and c) dexamethasone release profile when the 
loaded drug content is decreased by a factor of 2. 
 
As can be seen in Fig. 4.10, by decreasing the amount of moxifloxacin dissolved in the triblock 
copolymer solution or by changing the mass of levobunolol or dexamethasone loaded MPs 
embedded in the hydrogel, one can vary the daily drug release content of each drug 
proportionally. However, the drug release profile remains relatively constant.  
 
4.3.8. Multi-drug delivery hydrogel 
Figure 4.11 depicts the variation in percent drug release over time for three different drug 
molecules loaded in the present multi-drug delivery platform. To determine the percent of drug 
release, drug release at each time point is divided by the maximum detected drug release from the 
hydrogel.  
(c) 
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Fig. 4.11. A multi-drug delivery hydrogel capable of releasing three different drug molecules at different 
release rates. 
 
Conspicuous in Figure 4.11 is the ability of the present drug delivery system to release different 
drug molecules regardless of their hydrophobicity over different durations chosen according to 
the application. Among the drug molecules chosen for this study, moxifloxacin was the most 
hydrophilic (water solubility: 24 mg/ml) and dexamethasone was the most hydrophobic drug 
(water solubility: <100 µg/ml52). Drug release duration could be adjusted on demand depending 
on the direct addition of drug to the polymer network (rapid drug release) or encapsulating the 
drug molecules in MPs and embedding the MPs in the hydrogel network (slow drug release). 
Even with the drug molecules loaded in the particles, the drug release profile could be modified 
depending on the polymer used to encapsulate the drug molecules. Using very hydrophobic 
polymer (85/15), one could achieve a slow drug release in the beginning followed by a rapid 
enhancement in drug release amount later on. However, with less hydrophobic polymers, more 
drugs could be released early on during the course of treatment.  
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4.4. Conclusions 
In this chapter, the first hydrogel-enabled multi-drug delivery platform for the postoperative 
management following cataract surgery is reported. The main conclusions are highlighted below:  
1) The drug delivery vehicle is a liquid at room temperature and forms a gel at body 
temperature. This allows delivery via simple intraocular injection, a common procedure 
during ocular surgery or in office patient visits. 
2) An antibiotic, a steroid and an ocular hypotensive were successfully loaded in the 
hydrogel and were released over different periods and dosages according to clinical 
requirements. The antibiotic was added directly to the hydrogel network to ensure its fast 
release, while the steroid and ocular hypotensive were loaded in microparticles which 
were embedded in the hydrogel network to prolong their release duration.  The complete 
system uses only biodegradable components. 
3) By deprotonating the levobunolol hydrochloride, its loading into MPs and its daily 
release was enhanced considerably.  
4) While there was not a significant difference between release of levobunolol from MPs 
compared to MPs loaded in PLCL-PEG-PLCL hydrogels, the hydrogel was able to 
eliminate the burst release of dexamethasone from MPs and prolong its release duration. 
5) PLGA-PEG-PLGA hydrogels produce faster release of drug molecules than do PLA-
PEG-PLA hydrogels. PLCL-PEG-PLCL hydrogels lead to the slowest and most linear 
drug release profile. 
6) Depending on the type of polymer encapsulating the ocular hypotensive, drug release can 
be designed to be slow in the beginning, but increase later on to help reduce the elevated 
ocular pressure due to inflammation or the use of steroids. The transition point in 
between these two release stages can be tuned by varying the type of polymer and its 
degradation rate.  
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7) To change the daily release of drug molecules but not altering the drug release profile, 
one can vary the mass of dexamethasone or levobunolol loaded microparticles or 
moxifloxacin loaded in the hydrogel network.   
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Chapter 5 
Blocking Expression of Hypoxia Inducible Factors with Sustained Release Strategies 
 
5.1. Introduction 
In order to produce ATP and enable several reactions in the human body, cells are in need of an 
oxygen supply. Therefore, hypoxia (lack of oxygen) adversely impacts cellular mechanisms in the 
body. The response of the cells to lack of oxygen is controlled by hypoxia inducible factors 
(HIF).1 HIF is a protein that has two different subunits of HIF-1α and HIF-1β. In vertebrates, HIF 
has two subunits of HIF-2α and HIF-1β.1 Due to their irregular vasculature growth and 
proliferation of cells, solid tumors often have highly hypoxic regions. HIF is shown to be a master 
regulator and have a profound influence on tumor growth, metastasis, angiogenesis, 
ineffectiveness of chemotherapy, and ultimately patient death.1,2 HIF has also been shown to 
significantly promote angiogenesis and formation of new blood vessels in the diseases of the back 
of the eye, including diabetic retinopathy leading to blindness.3,4 Thus, inhibition of the HIF could 
improve the treatment outcomes for patients with cancers or ocular diseases.  
Certain FDA-approved molecules have been identified as having HIF-1 inhibition activity, 
including acriflavine (Acr), and doxorubicin (Dox).1,2,5 Depending on the molecule type, their 
mechanism of action is different. Acr interferes with interaction of different subdomains of HIF 
protein, and consequently avoids transcription of genes related to HIF. On the other hand, through 
binding to DNA, Dox impacts binding of HIF to cells.1,5 Also, it has an impact on inhibition of 
growth factor expression related to angiogenesis.1 Recently, limited patients’ response to 
conventional anti-vascular endothelial growth factors (VEGF) therapies has brought about 
questions about their effectiveness. As a master regulator, if HIF is targeted rather than VEGF 
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(which is also regulated by HIF), improvement in treatment outcomes could occur. As a result, 
using HIF inhibitors alone or in combination with conventional anti-VEGF is a promising avenue 
in the treatment of patients with cancer or eye diseases.1 There are excellent reviews about HIF 
and its role on disease progression for the patients with cancer or ocular diseases.1,6-8  
The majority of HIF inhibitors are small molecules. They have a blood half-life on the order of 
few minutes and thus they are cleared by the body very fast. As a result, free small molecules 
have minimum duration of action. They require frequent drug administration and could increase 
the risk of patient noncompliance. In addition, since the drug molecules are cleared from body 
fast, higher drug dosages would need to be applied so that adequate drug reaches the target site 
and be effective for preventing HIF expression. However, high drug dosage could lead to serious 
side effects.9-11 To overcome these challenges, the small drug molecules could be encapsulated in 
sustained release vehicles (e.g. nanoparticles (NPs)) and administered to the body. For the case of 
cancer, NPs could be accumulated in the tumor following intravenous injection. This is due to the 
enhanced permeability and retention (EPR) effect. Tumor has leaky vasculatures, compared to 
normal body organs, and thus enables higher NP accumulation.12 As NPs biodegrade, they 
gradually release the drug molecules for several days. The aim of the work presented in this 
chapter was to synthesize NPs loaded with Acr and Dox. NPs should have a small size (<200 nm) 
and high drug loading (>10 µg/mg of NPs). NPs are engineered to have polyethylene glycol on 
their surface to reduce their interaction with blood constituents and enhance their half-life in the 
blood.16 The drug release profile from the NPs and their impact on inhibition of HIF expression 
was evaluated in vitro. Finally, the impact of NPs on inhibiting HIF and reducing angiogenesis 
was studied in vivo in two animal models.  
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5.2. Description of the experiment: 
5.2.1. Materials 
Dox and Acr were purchased from Sigma Aldrich (St. Louis, MO). poly(D,L-lactic-co-glycolic 
acid) (PLGA, Resomer 502H with lactic acid (LA)/glycolic acid (GA) ration of 50/50 and 
molecular weight of 7-17 kDa) was ordered from Evonik Corporation (Essen, Germany). 
PEGylated PLGA (with 50/50 ratio of LA/GA for PLGA, MWs of 5 and 20 kg/mol for PEG and 
PLGA, respectively) was obtained from Polyscitech (West Lafayette, IN). Cye7.5 was used as 
near infrared dye and was obtained from Lumiprobe (Cockeysville, MD). All other chemicals 
were ordered from Sigma Aldrich and the materials were used as received without further 
purification (unless noted otherwise).   
 
5.2.2. Doxorubicin loaded nanoparticles 
5.2.2.1. Deprotonation of doxorubicin hydrochloride 
The protocol to deprotonate Dox was adopted from James Shamul, a member of Green Lab.17 
Dox hydrochloride (Dox HCl in brief) was deprotonated at a concentration of 2.5 mg/ml in 
dimethylsulfoxide (DMSO) in the presence of three times excess moles of triethylamine (TEA). 
To do so, the mixture of Dox solution and TEA was stirred at 170 rpm for 3 hrs for the reaction to 
accomplish. Deprotonated Dox was refrigerated till it was used.  
 
5.2.2.2. Synthesis of doxorubicin loaded NPs 
The Dox loaded NPs were made with single emulsion method following previous literature13 with 
several modifications to enhance Dox loading and reduce the particle size. 50 mg of PEGylated 
PLGA was dissolved in dichloromethane (DCM) at a concentration of 10 mg/ml. 2 ml of 
deprotonated Doxsolution was mixed with PEG-PLGA solution in DCM. The mass ratio of drug 
to polymer was 10%. The resulting solution was sonicated at 60% amplitude for 45 seconds to 
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ensure proper mixing of the polymer and drug solution. Subsequently, the solution was added to 
10 ml of 2% polyvinyl alcohol (PVA) that was being sonicated at 60% amplitude for 3 minutes. 
Afterwards, the resulting Dox loaded NPs were added to 50 ml of 0.5% PVA that was being 
mixed at a speed of 500 rpm for 3 hrs. This ensures the evaporation of DCM and hardening of 
NPs. To reduce the NP size and polydispersity, the NPs were centrifuged at a speed of 8,000 RCF 
for 10 mins and the pellet was discarded. The NPs in the supernatant were washed three times 
with miliQ water. The washed NPs were resuspended in water and frozen at -80 OC. Before use, 
NPs were thawed, and concentrated (if required).  
For some experiments blank NPs were needed as control. To synthesize those NPs, all the steps 
mentioned above to synthesize Dox loaded NPs were followed, except instead of Dox solution, 
2ml DMSO was added to polymer solution 
    
5.2.2.3. Synthesis of dye loaded NPs 
To determine the biodistribution of the Dox loaded NPs, NPs were co-loaded with Dox and near 
infrared dye (Cye7.5, excitation wavelength: 800 nm, emission wavelength: 830 nm). To do so, 
the same steps were followed as described for the synthesis of Dox loaded NPs, except 0.5 mg 
dye dissolved in DMSO at a concentration of 10 mg/ml was mixed with Dox solution in DMSO. 
For the biodistribution study, there was an arm with dye loaded NPs only, to assess the impact of 
Dox loading on biodistribution. To synthesize these NPs, all the steps to synthesize dox+dye 
loaded NPs were followed, except instead of 2 ml of Dox solution in DMSO, 2 ml of DMSO was 
used.    
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5.2.3. Acr loaded NPs 
Unlike deprotonated Dox, Acr is extremely hydrophilic (water solubility: 330 mg/ml according to 
the manufacturer14), and it is challenging to load it in NPs with hydrophobic PLGA core. As a 
result, different techniques were tried to synthesize Acr loaded NPs. 
  
5.2.3.1. Nanoprecipitation 
PEGylated PLGA was dissolved in DMSO at a concentration of 10 mg/ml. To that Acr or Acr 
hydrochloride (Acr HCl in brief) was dissolved in the same solution to have a drug to polymer 
mass ratio of 0.1. The polymer-drug solution was added dropwise to a beaker containing 10 times 
higher volume of water that was being stirred at a speed of 500 rpm. NPs were washed after 
around 3 hrs, using amicon centrifuge tubes. For the case of Acr, instead of DMSO, 
dimethylformamide (DMF) was used as well to see its impact on NP size and loading.   
 
5.2.3.2. Double emulsion method 
20 mg of PEGylated PLGA was dissolved in DCM at a concentration of 10 mg/ml. 1 mg of Acr 
was dissolved in water at a concentration of 2.5 mg/ml. The two solutions were mixed and 
sonicated at an amplitude of 60% for 45 seconds to have small Acr in water droplets throughout 
the PLGA in DCM phase (water in oil emulsion). Subsequently, the mixture was poured in 4 ml 
of 3% PVA solution and was sonicated at an amplitude of 60% for 3 minutes to make nanoscale 
Acr-PLGA emulsions throughout the PVA phase (water in oil in water emulsion). The resulting 
NPs were transferred to a larger bath of PVA (50 ml) at a lower concentration (0.5%) and were 
stirred for 3 hrs so that the DCM evaporates and particles become hard. Afterwards, the NPs were 
washed three times with miliQ water. 
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5.2.3.3. Single emulsion method 
To synthesize the NPs with single emulsion method, all the steps were similar to double emulsion 
method except instead of dissolving the Acr in water, it was dissolved in DMSO. Even though the 
DMSO and DCM are miscible, the polymer-drug solutions were sonicated to make sure they are 
mixed homogenously.  
 
5.2.3.4. Single emulsion nanoprecipitation method 
The following protocol is from Dr. Corey Bishop a former lab member of the Green lab.15 Here, 
Dr. Bishop’s protocol was modified, since it was for synthesizing PLGA NPs without 
PEGylation. For systemic delivery of NPs to target site, having a hydrophilic PEG shield around 
NPs enhances their half-life and effectiveness.16 4.7 mg Acr was dissolved in 1 ml methanol. This 
solution was added to a solution of 50 mg 502H PLGA and 50 mg PEG-PLGA that was dissolved 
in 4 ml of acetone. The resulting solution was vortexed and quickly poured in 17.0 ml of 10 
mg/ml BSA solution that was being sonicated at an amplitude of 60% for 30 seconds. The 
resulting particles were stirred at 600 rpm in the cold condition (4OC) overnight. Particles were 
stirred on ice for another 24 hrs under the vacuum. This was to ensure evaporation of the organic 
solvents. Subsequently, NPs were washed three times with miliQ water and were used right after 
synthesis. The particle leftovers were stored at the temperature of -80oC at a low concentration of 
1 mg/ml. This way, particles could be stored for months and an aliquot could be thawed and 
concentrated (if required) for a subsequent use. Often during centrifugation, these NPs would 
aggregate, but the aggregates were separated by an additional centrifugation. The amount of 
particle loss by aggregate separation was taken into account by determining particle concentration 
afterwards.  
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5.2.4. Drug release characterization 
Drug release from the NPs was studied by incubating the NPs in a small centrifuge tube at 37oC 
in 1 ml PBS as the release media. At certain intervals, the NPs were centrifuged and certain 
amount of supernatant (900 ul for Dox NPs, and 800 ul for Acr NPs) was replaced with fresh 
PBS. The NP mass for drug release studies with Dox was 1.5 mg, while for Acr it was chosen to 
be 3.2 mg. Since Acr loading in NPs was less than that of Dox, more NPs were used for drug 
release studies to make sure signal from the release samples will be strong enough to have a 
reliable measurement. The release samples were lyophilized and reconstituted in DMSO and the 
fluorescence signal was read with a plate reader. All the release experiments were done in 
triplicate. The amount of drug detected was divided by the total detected drug release over the 
course of experiment to determine percent drug released.  
 
5.2.5. Blood half-life and biodistribution determination 
All of the animal preparations for biodistribution were done by Dr. Semenza’s group at the Johns 
Hopkins University School of Medicine. MDA-MB-231 breast cancer cells were injected 
orthotopically in 10 mice (Type: SCID) and once the tumor size reached ~200 mm3, the animals 
were treated with NPs. 5 mice were treated with Dox plus dye loaded NPs, while 5 mice received 
dye loaded NPs through tail vein injection. For both cases, the NP concentration was set to 50 
mg/ml, in 1X PBS media. Blood was collected from the mice from the saphenous vein at 5, 10, 
20, 40, 1 hr, 2hr and 24 hr timepoints and the fluorescence signal from the dye was analyzed by 
IVIS®. Each live animal was bled only 4 times during the course of the experiment. After 24 hrs, 
the animals were sacrificed, their organs were harvested and imaged with IVIS®. Images of the 
organs were used to determine NP biodistribution. 
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5.2.6. HIF assessment in cancer model in vivo 
All of the animal preparations for functional HIF assessment were conducted by Dr. Semenza’s 
group at the Johns Hopkins University School of Medicine. Hep3B-c1 cells were injected in the 
flank of 8 nude mice. Once tumor size reached approximately 100 mm3, the treatment was started 
with NPs loaded with Dox or Acri. For Dox treatment group, animals received a single injection 
of NPs, while for Acr group animals received two injections of NPs on day 1 and 14. All the NPs 
had a concentration of 50 mg/ml in 1X PBS. The efficacy of NPs in inhibiting HIF expression 
was evaluated by measuring the luminescence from the tumor via IVIS® at certain timepoints 
post NP injection. The tumor cells were programmed by Dr. Semenza’s group to have a HIF 
dependent reporter plasmid so that their luminescence was directly proportional to HIF activity. 
 
5.2.7. In vitro cell studies on ocular cells 
In vitro studies on ocular cells were performed by Dr. Sodhi’s group at Johns Hopkins University 
School of Medicine. In brief, MIOM1 cells were treated with free drugs (Dox or Acr) or NPs 
loaded with drugs in hypoxia (1% oxygen level) at 1-5 µM drug concentrations. At certain time 
points, proteins were extracted from the cells and HIF expression was measured by gel 
electrophoresis.  
 
5.2.8. In vivo studies for VEGF expression levels in the eye 
In vivo studies were done in collaboration with Dr. Sodhi’s group at Johns Hopkins University 
School of Medicine. 45 black mice (Type: C57bl/6) were treated through tail vein injection with 
free drug solutions, NP suspensions loaded with drugs. In addition, some of the animals received 
blank NPs or PBS as control. For Acr, two drug dosage was tested, 2.5 and 7.5 mg/Kg of body 
weight. While for Dox group, animals were treated with two drug dosages of 6 and 18 mg/Kg. 
For the case of NPs as well as high dosed free drugs, only one injection at day 0 occurred. 
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However, animals received free drugs at low dosages for 3 subsequent days. At certain timepoints 
(1, 3, and 7 days post treatment), the animals were sacrificed and Dr. Sodhi’s group collected the 
eyes, and extracted mRNA from the retina. Subsequently, they quantified VEGF expression 
levels by qPCR technique. 
 
5.2.9. Error analysis 
Error bars presented in each figure represent standard deviation between replicate measurements.  
 
5.3. Results 
5.3.1. Nanoparticle characterization  
5.3.1.1. Doxorubicin/dye loaded NPs 
The goal was to administer the drug molecules intravenously. To make sure NPs won’t lead to 
embolism in the small blood vessels of mice, NPs size should be small and stable.  Small size 
(<200 nm) also lead to higher accumulation of the NPs in the tumors due to enhanced 
permeability and retention effect.12 On the other hand, reduction in NP size could adversely 
impact the drug loading. Thus, the goal was to be able to synthesize drug loaded NPs with high 
drug loading and small particle size. Figure 5.1 shows the intensity-based particle size 
distribution for dox, Dox plus dye, and dye loaded NPs, synthesized in this research. In addition, 
intensity-based average NPs size (Z-average in brief), polydispersity index (PDI) and loading of 
NPs is illustrated in table 5.1. 
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Fig. 5.1. Dox/dye loaded NPs size distribution, a) Dox loaded NPs, b) dye plus Dox loaded NPs, c) dye 
loaded NPs. 
 
 
Table 5.1: Characteristics of dox, Dox plus dye and dye loaded NPs.  
Parameter 
NP type 
 
Z-average 
(nm) 
 
PDI 
 
Dox loading 
 (µg/mg NPs) 
Dox loaded NPs 111 0.074 38 
Dox plus dye loaded NPs 120 0.125 26 
Dye loaded NPs 127 0.108 - 
 
(c) (a) (b) 
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According to Fig. 5.1 and Table 5.1, all the NPs synthesized had narrow size distribution and 
small PDI. In addition, Z-average for all the NPs was below 200 nm which is acceptable for 
intravenous drug delivery. Table 5.1 also demonstrates that Dox loaded NPs had a drug loading 
of around 38 µg/mg of NPs which is acceptable (i.e. >10 µg/mg of NPs). An important 
contributor to enhancement of Dox loading was deprotonation of Dox in the presence of TEA17 
(This method of loading enhancement by removal of HCl salt was discussed in Chapter 4 as well 
to synthesize levobunolol loaded MPs). By removing the HCl salt from Dox in the presence of 
TEA, it becomes more hydrophobic, thereby its tendency to be encapsulated in hydrophobic 
PLGA increases. There was more than 4x enhancement in Dox loading by deprotonation. Finally, 
Table 1 indicates that Dox loading decreases by co-encapsulation of Dox and dye in NPs.  
 
5.3.1.2. Acriflavine loaded nanoparticles: 
As mentioned before, Acr is a hydrophilic drug molecule and thus had low encapsulation 
efficiency in hydrophobic PLGA NPs. As a result, several techniques were evaluated to see their 
impact on NPs’ characteristics. Figure 5.2 compares the size distribution of Acr loaded NPs 
synthesized with different methods obtained by dynamic light scattering (DLS) technique. 
Further, Table 5.2 highlights characteristics of these NPs.  
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Fig. 5.2. Z-average for Acr loaded NPs synthesized with a) nanoprecipitation (Acr.HCl), b) 
nanoprecipitation, c) double emulsion, d) single emulsion, e) single emulsion nanoprecipitation. Plots b-e 
are for NPs loaded with Acr.  
 
 
 
(a) (b) (c) 
(d) 
(e) 
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Table 5.2: Z-average, PDI and Acr loading for NPs synthesized with different schemes.  
Parameter 
NP type 
 
Z-average 
(nm) 
 
PDI 
 
Acr loading 
 (µg/mg polymer) 
Acr.HCl, nanoprecipitation 141 0.224 0.4 
Acr, nanoprecipitation 123 0.192 2.4 
Double emulsion 163 0.080 2.1 
Single emulsion 137 0.063 1.1 
Single emulsion 
nanoprecipitation 
131 0.205 15 
 
Different Acr loaded NPs had a relatively narrow size distribution shown in Fig. 5.2 and small 
PDI demonstrated in Table 5.2. NPs synthesized with single/double emulsion methods had 
particularly low PDI indices. The smaller peaks shown in Fig. 5.2a,b, and e for more than 1000 
nm size range is likely due to presence of dust in DLS cuvette. Table 5.3 also demonstrates that 
NPs had relatively small z-average, regardless of the method used to synthesize the NPs. 
However, the main challenge with Acr was to increase its loading in NPs. By switching from 
Acr.HCl to Acr without hydrochloride salt, the loading was enhanced significantly in 
nanoprecipitation method. However, the overall Acr loading was far below our target. For cancer 
and ocular diseases, a dosage of at least 100 µg Acr per injection in mice was required. Assuming 
that injection happens at a concentration of 50 mg/ml, and 200 µl NPs are injected, the loading of 
Acr in NPs should be at least 10 µg/mg of NPs. The effect of organic solvent used in 
nanprecipitation method was studied by switching from DMSO to DMF. Even though it increased 
Acr loading to 3.3 µg/mg of NPs, the loading was still below the target value.  
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For hydrophilic drug molecules, double emulsion method is particularly suitable, since the 
hydrophilic drug molecule is already in aqueous phase during NP synthesis, so its tendency to 
escape during NP formation would decrease. However, neither single nor double emulsion 
methods led to NPs with acceptable drug loading. The effect of polymer concentration in DCM, 
PVA volume and concentration were studied to probe their impact on Acr loading. However, it 
did not lead to a significant increase in Acr loading.  
Among the different methods tested, the single-emulsion nanoprecipitation method was the only 
method leading to NPs with adequate drug loading, yet small enough NP size and it was therefore 
chosen as the method of choice to test HIF expression inhibition in the subsequent experiments.  
 
5.3.2. Drug release characterization 
Dox loaded NPs were chosen to determine the blood half-life of NPs. In this regard, dye was co-
loaded with Dox to track the NPs in vivo. It is important to study the release kinetics of Dox plus 
dye from NPs and also compare it with Dox loaded NPs alone. In this regard, Fig. 5.3 compares 
the drug release kinetics from the two NP systems.   
 
Fig. 5.3. Percent released Dox from Dox loaded NPs compared with Dox plus dye loaded NPs.  
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As can be seen in Fig. 5.3, Dox loaded NPs had similar Dox release kinetics compared to Dox 
plus dye loaded NPs. Also, this figure shows that it takes around two weeks for the NPs to release 
dox, with 20% burst release on day 1. Figure 5.4 depicts percent released Acr from NPs 
synthesized with single emulsion nanoprecipitation technique.  
 
 
Fig. 5.4. Release kinetics of Acr from NPs, in vitro.  
 
Unlike dox, Acr is released from the NPs in about a week. Furthermore, around 60% of the Acr is 
released from the NPs in 24 hrs post incubation at 37 oC. Considering the higher hydrophilicity of 
Acr compared to Dox, the trend observed is understandable. Due to its hydrophilicity, Acr does 
not have the tendency to be loaded in hydrophobic core of PLGA NPs, so part of loaded Acr is 
presumably attached to NPs surface where hydrophilic PEG part is present. This together with 
high tendency of Acr to diffuse into aqueous media enabled a high burst release of Acr from NPs.  
 
5.3.3. HIF inhibition in the cancer model 
5.3.3.1. Nanoparticles half-life in the blood stream and biodistribution 
Figure 5.5 shows the logarithm of blood fluorescence signal normalized to blood signal at 5 
minutes timepoint vs. time post NP injection for the two treatment groups of Dox plus dye loaded 
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NPs and dye loaded NPs. The goal for comparing these two groups was to see if the Dox loading 
will have any impact on blood half-life and biodistribution. Dye plus Dox loaded NPs had max 
Dox loading, while dye loaded NPs had no Dox. By comparing these two groups, the two ends of 
the spectrum (zero to max Dox loading) are compared.  
 
 
Fig. 5.5. Blood half-life for the dye loaded NPs compared to the Dox plus dye loaded NPs in mice bearing 
breast tumor.  
 
The general trend observable in Fig. 5.3 (with an exception) is the decrease in the blood 
fluorescence intensity over time. NPs are gradually cleared from the blood stream and 
accumulated in different organs in the body. One should note the caveat that we are relying on the 
fluorescence intensity to determine blood half-life and biodistribution of NPs. This method relies 
on fluorescence intensity of the dye that is encapsulated in the NPs to track the NPs. Since the 
dye is very hydrophobic, it assumes that release of the dye from NPs is negligible. Before using 
the fluorescence dye, extensive experiments were performed extracting the Dox itself from 
organs and the blood. However, since Dox’s fluorescence is in the red channel, and the body has 
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plenty of auto-fluorescence in this channel, it proved to be impossible to get reliable data by 
relying on Dox’s intrinsic fluorescence.  
By fitting a linear line to the results presented in Fig. 5.3 and following Eq. (5.1), blood half-life 
for the NPs was determined.  
F (t) = F0 exp(−
t
τ
)   
(5.33) 
Where F(t) is the dye fluorescence intensity in the blood at a given time, F0 is the maximum dye 
fluorescence intensity after 5 mins of NP injection (to make sure NPs are circulated in the entire 
blood stream and there will be maximum blood fluorescence intensity), and τ is the NP half life in 
the blood stream. The half-life for the Dox+Dye treatment group turned out to be 62 minutes, 
while for the IR dye loaded particles only, it was 75 minutes. The difference between blood half-
life of the two NP treatment groups is small considering the deviation between data points in Fig. 
5.5 due to experimental error. Experimental errors in blood half-life could be difficulty in 
collecting enough blood from the animal and at required timepoint. Also, the accuracy of data 
could significantly increase by increasing the number of animals dedicated for the experiment.  
Figure 5.6 depicts the biodistribution of the NPs in different organs of the mice. In this figure, 
fluorescence signal is normalized by the total fluorescence of organs of interest in each animal. 
Afterwards, the signal from each organ is averaged between animals of the specific treatment 
plan. 
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Fig. 5.6. Biodistribution of the NPs in different organs.  
 
According to Fig. 5.6, the two treatment groups had similar biodistribution. The liver had the 
highest NP accumulation (~45%), which is expected considering its large size compared to other 
body organs. Tumor had around 15% NP accumulation. Accumulation of NPs in the tumor is 
very high which is favorable to enhance treatment efficacy. Small size of NPs and presence of a 
PEG shield around the NPs have enabled high NP accumulation in the tumor.  
 
5.3.3.2. HIF inhibition in vivo in a cancer model 
Figure 5.7 illustrates the variation of luminescence flux (HIF level) vs. days post NP injection.  
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Fig. 5.7. In vivo efficacy of NPs on inhibiting HIF in cancer model. Imaging of animals and analysis of the 
results were done by Dr. Debangshu Samanta and David Wilson.  
 
According to Fig. 5.7, for the case of Dox loaded NPs, HIF levels increases over time, and NPs 
were unable to inhibit HIF. On the other hand, Acr NPs were able to maintain the HIF levels for 
two weeks post NP injection. As a result, the Acr NP group was chosen as the treatment of choice 
to perform future studies.  
   
5.3.4. Ocular drug delivery 
The goal of this part of the project was to evaluate the effectiveness of Dox and Acr loaded NPs 
on treatment of diabetic retinopathy. This part of the project was performed in collaboration with 
Dr. Sodhi’s group at Johns Hopkins University School of Medicine. Diabetic retinopathy is a 
serious ocular disorder with excessive formation of blood vessels in the back of the eye which 
could obstruct the patients’ vision. Our collaborator had shown the effectiveness of the anti-HIF 
agents (e.g. Dox and Acr) on the inhibition of HIF and reduction of angiogenesis. However, free 
drug molecules had to be dosed daily and at a high concentration to ensure effectiveness, which 
were unfavorable for the translation of the idea into the clinic. NPs could release the drug 
molecules for at least a week, and could potentially prolong the effectiveness of treatment.  
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5.3.4.1. HIF inhibition in vitro 
Figure 5.8 compares the effectiveness of drug encapsulated NPs with free drugs in preventing 
HIF expression, in vitro.  
 
 
 
Fig. 5.8. HIF expression levels for free a) Acr and b) Dox compared with c) those drugs loaded in NPs, in 
vitro. At each condition, black band is indicative of HIF presence.  Experiments were performed by Dr. 
Sodhi’s group.  
 
Figure 5.8 illustrates that free drug molecules can only prevent HIF expression at high 
concentrations of 5 µM. In addition, free drugs are limited in duration of action. For Dox, HIF 
expression was inhibited for up to 48 hrs, while Acr was effective for only 24 hrs. On the other 
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hand, NPs have been effective in inhibiting HIF expression at even 1 µM drug concentration. In 
addition, they have extended drug duration of action to at least three days. Overall, NPs showed 
great promise in preventing HIF expression in vitro.  
 
5.3.4.2. Angiogenesis inhibition in vivo 
To assess the effectiveness of NPs in vivo, it is important to track mRNA levels of VEGF, as it is 
related to formation of abnormal formation of blood vessels in diabetic retinopathy. Figures 5.9-
5.11 show the variation of VEGF levels for after 1, 3, and 7 days post-treatment with NPs, 
respectively.  
 
Fig. 5.9. Effect of free drug compared with drug loaded NPs on VEGF levels after 1 day post-treatment, in 
vivo. Determination of VEGF level was done by Dr. Sodhi’s group. 
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Fig. 5.10. Effect of NPs on reduction of VEGF compared with free drug after 3 days post NP injection. a) 
Acr, b) Dox. In this and subsequent figure, control represents the animals that received PBS injection. 
BNPL and BNPH refer to animals that received blank NPs at a low and high concentrations, respectively. 
AFL and AFH represent animals that received free Acr at a dose of 2.5 and 7.5 mg/Kg, respectively, while 
DFL and DFH refer to animals that received free dox at dosages of 6 and 18 mg/Kg, respectively. ANPL, 
ANPH, DNPL and DNPH represent animals that received the same dosages of Acr or Dox mentioned 
before but in the NP form. VEGF level was determined by Dr. Sodhi’s group. 
 
(a) (b) 
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Fig. 5.11. VEGF levels in retina 7 days after treating the mice with free drug or drug loaded NPs. a) Acr, b) 
dox. VEGF level was assessed by Dr. Sodhi’s group. 
 
On day 1, both Acr and Dox (free or loaded in NPs) have been able to reduce the VEGF 
expression. On day 3, Acr NPs or free Acr are only effective at high dose (7.5 mg/Kg), while Dox 
(free or NP form) has been effective in reducing VEGF levels. It is remarkable how free Dox at 
high dose or NPs at either dosage have been able to completely block VEGF expression on day 3.  
On day 7, free Acr is no longer effective on reducing VEGF, while Acr loaded NPs are able to 
reduce VEGF at high dosage. In addition, free Dox is only able to reduce the VEGF at high 
(a) (b) 
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dosage, while Dox loaded NPs at either dosage have decreased VEGF expression. Overall, these 
results demonstrate that drug-loaded NPs are more effective than free drug in reducing VEGF 
expression. In addition, unlike cancer model, Dox seems to be more advantageous than Acr.   
Considering the fact that for 3 days and 7 days studies, low dose free drug was injected for three 
subsequent days, while animals received NPs only for day 0, it is clear that NPs have been 
effective in reducing treatment frequency.  
 
5.4. Conclusions 
This chapter highlighted preliminary results on using anti-HIF loaded NPs for the treatment of 
cancer and ocular diseases. The followings are the main conclusions of this ongoing study:  
1. PEGylated nanoparticles loaded with Acr or Dox were synthesized with small size 
(below 200 nm) and high drug loading (>10 µg/mg of NPs).  
2. Dox loaded NPs showed a half-life of around an hour and a high tumor accumulation of 
15% in the mouse with cancer model.  
3. Acr loaded NPs enabled inhibition of HIF expression for two weeks post NP injection in 
the cancer model, while Dox loaded NPs were not as effective in reducing HIF levels.  
4. In general, NPs showed longer lasting effectiveness on reducing VEGF expression 
compared to free drug. Also, in the ocular model, Dox loaded NPs were more effective 
compared to Acr loaded NPs.  
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Chapter 6 
Conclusions and Future Directions 
 
6.1. Binding kinetics of particles under flow 
In chapter 2 binding kinetics of spheres under shear flow in the dilute sphere limit was studied 
implementing BD simulations. The results presented were from the first theoretical model 
developed in Larson Group capable of determining the binding kinetics of two spheres for the 
whole Pe range and with hydrodynamic interactions. In addition, agreement with various limits 
obtained by literature was achieved. Furthermore, binding times were computed with either 
implementing an interparticle potential or by choosing a cut off distance. A major advantage of 
the technique presented was its ability to analyze particles with surface anisotropy.  
The successful implementation of a BD simulation method to particles under flow opens the door 
to many further opportunities. A handful of them are as follows: 
1) The method introduced here is not limited to shear flows and could hopefully be applied 
to other types of flows as well, such as extensional flow, mixed shear, and extensional 
flows, etc. To this end, proper development and application of boundary conditions, and 
periodic box dimensions that allow imposition of these boundary conditions are 
essential.1 
2) Investigation of binding kinetics of more complex patterned colloids, such as patchy 
particles2 with multiple patches under shear flow is another area of interest. Lock and key 
colloids,3 could also be studied if the deviations from spherical shape could be accounted 
for, perhaps in some approximate way. Other shapes could be considered using 
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hydrodynamic functions developed by Kim and Karrila4 for particles without spherical 
symmetry.  
3) The binding kinetics of non-dilute denser suspensions under shear flow could be 
implemented using the methods of Stokesian dynamics5 to handle multi-particle 
interactions. 
 
6.2. Layer-by-layer assembly of polyelectrolytes and nanopartilces 
In chapter 3, different parameters impacting layer-by-layer growth of polyelectrolytes (PEs) and 
nanoparticles (NPs) including polyelectrolyte molecular weight (MW), NP size and charge, as 
well as pH and salinity of the deposition media were examined. Obtained results indicated the 
importance of polyelectrolyte layer in between NP deposition steps to enhance the integrity of 
LbL films. In general, intermediate values of PE MW led to rapid LbL film growth in most of the 
cases. It was due to a competition between high layer integrity and bridging between two 
subsequent NP deposition steps for larger chain PEs and high diffusivity for smaller PE chains.  
When the polyethylenimine (PEI) was deposited at a higher pH of 9.9 (lower charge) followed by 
NP deposition at a lower pH of 7, highest film growth occurred. It was due to sudden 
enhancement in PEI charge during deposition of NPs and its desire to absorb more NPs to 
compensate for charge increase. In addition, a relation between salinity and MW of PEs on LbL 
film growth was demonstrated.  
Some of these trends, especially the effects of pH and PE molecular weight, and to some extent 
the effect of salinity, can be understood qualitatively.  But even the general trends observed were 
defied for some particle sizes, depending on the particular PE. Even when the expected trend was 
followed, for example the non-monotonic dependence of growth rate on PE molecular weight, the 
value of the optimal molecular weight varied greatly (more than an order of magnitude) from PEI 
to poly(acrylic acid) (PAA), for no reason we could determine. Hence, while some qualitative 
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trends are now evident and explicable, even semi-quantitative predictions are not yet in sight, and 
there are polymer-specific exceptions to even the qualitative trends.  
Clearly, much progress is still needed to develop an improved qualitative and quantitative 
understanding of LbL deposition of PEs and NPs. In addition to further systematic LbL growth 
experiments such as those performed here, more detailed microscope experiments could be very 
helpful, such as atomic force microscopy (AFM) studies of binding and adhesion forces between 
individual NPs and PEs, direct measurements of PE and NP diffusion in the film, fluorescence 
resonance energy transfer (FRET) measurements of binding and unbinding events, and other 
direct measurements of molecular structures and transitions. Finally, using fluorescently labeled 
PEs and monitoring their diffusion within the film network could provide significant insights on 
the physics behind different phenomena observed.  
 
6.3. Multidrug carrier for the postoperative management of ocular surgery 
In chapter 4, a multidrug delivery system was developed for the postoperative treatment of ocular 
surgery (cataract surgery in particular). The formulation was made up of temperature sensitive A-
B-A triblock copolymer solutions, where A block could be poly(D,L-lactide-co-glycolide) 
(PLGA),  Poly(lactic acid) (PLA) or Poly(lactide-co-caprolactone) (PLCL), while the B block 
was poly(ethylene glycol) (PEG). In the optimal formulation, these polymer solutions were liquid 
at room temperature and formed a hydrogel depot at body temperatures. An antibiotic 
(moxifloxacin) was directly added to the co-polymer solution and was “loosely” entrapped in the 
hydrogel network once the temperature was raised to the body temperature. This enabled rapid 
release of moxifloxacin for about a week. However, a steroid (dexamethasone) and an ocular 
hypotensive drug molecule (levobunolol) were encapsulated in the microparticles (MPs) first and 
then loaded in the hydrogel network. Encapsulating the drug molecules in MPs considerably 
enhanced the duration of release of drug molecules to several weeks. Deprotonation of 
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levobunolol hydrochloride dramatically enhanced its loading in MPs. Due to their rapid 
degradation and creation of a local acidic environment, PLGA-PEG-PLGA accelerated the 
release of drug molecules entrapped in MPs. On the other hand, PLCL-PEG-PLCL hydrogels 
illustrated slow drug release. Finally, it was demonstrated that by changing the hydrophobicity of 
the polymer encapsulating the levobunolol, its drug release profile could be fine-tuned.  
The results presented in this chapter were preliminary demonstration of the suitability of 
thermoresponsive hydrogels as ocular drug carriers. However, the following points should be 
addressed in the future:  
1) Illustration of proper gelation of formulation, in vivo. The resulting hydrogel should not 
block the visual axis or interfere with the vision. 
2) Demonstration of the ability of the formulation to prevent infection, inflammation and 
management of intraocular pressure, in vivo. 
Even though the multidrug delivery formulation developed in this chapter was designed as a drug 
carrier to manage postoperative treatment following ocular surgery, it could be applied to co-
deliver different types of drug molecules for other ocular indications as well. A direct application 
could be reformulating the hydrogel to release anti-hypoxia inducible factors (anti-HIF) for 
several weeks to be used for the treatment of diabetic retinopathy that was described in chapter 5.  
 
6.4. Inhibiting HIF expression for drug delivery for cancer or ocular diseases 
In chapter 5 preliminary results on using NPs to sustain the inhibition of HIF expression was 
discussed for cancer and ocular drug delivery. By deprotonation of doxorubicin (Dox), its loading 
in NPs was enhanced significantly. Several NP synthesis protocols were examined to synthesize 
acriflavine (Acr) loaded NPs with small size (<200 nm) and adequate drug loading (>10 µg/mg of 
NPs). It turned out that single emulsion nanoprecipitation method is the best method for synthesis 
of Acr loaded NPs.  
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The blood half-life and biodistribution in the cancer model was studied with Dox loaded NPs. 
NPs had a half-life of about an hour and demonstrated 15% tumor accumulation. In the cancer 
model, even though Dox loaded NPs were not effective in inhibition of HIF expression, Acr 
loaded NPs maintained HIF levels low for two weeks. Finally, unlike free drug, NPs had a much 
longer effect on reducing the angiogenesis in the eye. Also, Dox was superior than Acr for the 
eye model.  
It should be noted that the preliminary studies for eye models were performed on healthy animals. 
Evaluation of NPs impact on reduction of angiogenesis in animals with diabetic retinopathy is the 
next step in this study. Given NPs were very effective in reducing the VEGF levels in healthy 
animals (which were already low), it would be interesting to see the impact of NPs on reducing 
angiogenesis and VEGF levels on mice with diabetic retinopathy.  
In addition, systemic delivery of NPs for the treatment of ocular diseases may not be the best 
approach. Since eyes have a much smaller volume compared to other body organs, the portion of 
NPs that will end up to the eye is low. It may be best to deliver NPs directly to the eye through 
intravitreal injection. However, NPs could scatter throughout the eye surface and potentially 
cause “snow-globe” effect. Furthermore, as mentioned in chapter 4, due to their small size NPs 
are not effective in releasing the drug molecules for the long term (at least a month). Utilizing the 
technology developed in this thesis (Chapter 4) would be the best solution to sustain the release of 
anti-HIF molecules for the long term as well as finely tune their daily dosage.  
On the other hand, for the case of cancer treatment, using NPs is a more suitable strategy. Since 
the best approach to deliver anti-HIF agents to leaky tumor vasculatures is through their systemic 
delivery. Our preliminary results indicated significant HIF inhibition for the case of Acr loaded 
NPs. For cancer and eye diseases, combination of anti-HIF agents might be much more effective, 
since they could have some synergistic effects and could reduce the overall drug dosage and 
inherent side effects.  
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Appendices 
Appendix A: Supplementary Information for Chapter 2 
A.1. Brownian Dynamics method 
When the suspension is dilute enough, two-body interactions dominate. Periodic boundary 
conditions are implemented with box dimensions chosen to approach the dilute limit and 
minimize artificial effects of the box geometry on binding kinetics. 
The Langevin equation governing the particles’ motion under shear flow is given by 
1( ) ( ) ( (t)) ( )[ (t) (t)] ( : ) ( )C B SBr t t r t k T M t M t F F t N E t v t tδ δ µ δ δ δ
−+ = + ∇⋅ + + + +  (A1) 
where r  can represent the positions as well as angles of both particles (12 degrees of freedom), 
Bk  is the Boltzmann constant, T  is temperature, M  is the mobility matrix (inverse of resistance 
matrix described previously1), tδ  is the timestep for numerical integration, 
CF  denotes the 
conservative force, BF  is Brownian force, and Sv  represents imposed shear velocity. Also, 
elements of N  are obtained from g  and h  third-rank tensors reported by Jefferey2 and E  is rate 
of strain tensor for shear flow.  
To prevent doing the expensive calculations to obtain the divergence of the mobility matrix, a 
midpoint algorithm for the absence of shear flow has been suggested which implicitly applies the 
effect of this term.3,4 This algorithm has been modified as shown in Eq. (B2-a) to account for the 
effect of shear flow:  
* 1( ) ( ) (t)[ (t) (t)]
2
C B tr t r t M F F δµ−= + +  
(A2-a) 
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1 *( ) (t) (t )[ (t) (t)] ( : ) ( )C B sr t t r M F F t N E t v t tδ µ δ δ δ−+ = + + + +  (A2-b) 
Here *t  is the mid-point of a timestep that spans the interval [ t , t tδ+ ]. (Inclusion of the shear 
flow terms in Eq. (A2-a) was also tested, and the effect on the average binding times was around 
1.3 %, within statistical error.)  
Equation (A3), which represents a Cholesky decomposition of the resistance matrix R  (inverse 
of mobility matrix), is used to determine the Brownian force/torque:
   
 
6 ,B B TB r
k TRF orT N R L L
tδ
= = ×  
(A3) 
where rN  represents 12 different random numbers in the range of (-1, +1) for the three elements 
of Brownian force and three elements of Brownian torque for both particles.  The resistance 
matrix is written as the product of a lower triangular matrix with its transpose.1 
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Appendix B: Supplementary Information for Chapter 3 
B.1. Effect of pH drift 
Figure B.1 shows the effect of pH drift on LBL growth of a PEI/PS- composite. PEI with a MW 
of 750 kg/mol and 41 nm-sized PS- particles were used for this experiment. For one case the pH 
of PS- suspension and rinsing waters was monitored prior to each respective deposition, while for 
the case without pH monitoring, the pH value of the solutions and rinsing waters was set at the 
beginning of the experiment.  
 
 
Fig. B.1. Influence of pH drift on the PEI/PS- film buildup, PEI (odd numbered steps) and PS- (even 
numbered steps) are deposited at pH values of 9.9 and 7, respectively. No salt was added to either of the 
ingredient of the LbL film except for the ions introduced to the solutions by pH adjustment.  
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As shown in Fig. B.1, by constantly monitoring and adjusting the pH, a boost in LbL growth is 
achieved. As mentioned in the Chapter 3, when the pH difference between PEI and PS- 
deposition steps is increased, faster LbL growth occurs. Adjusting the pH value of deposition 
solutions during LbL assembly enables one to better maintain such a pH difference.  
B.2. Effect of deposition time 
Figure B.2 depicts the effect of deposition time on the growth kinetics of a poly(ethyleneimine) 
(PEI)/polystyrene (PS) layer-by-layer (LbL) assembled film. PEI with a molecular weight (MW) 
of 70 kg/mol and 41 nm-sized negatively charged PS (PS- hereafter) nanoparticles were chosen 
for this experiment.  
 
 
Fig. B.2. The effect of deposition time on LbL growth of PEI/PS- composite.  
 
As shown in Fig. B.2, increasing the deposition time boosts the growth of PEI/PS- composites up 
to around 10 minutes deposition time. Upon increasing the deposition time up to this limit, 
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polyelectrolytes (PEs) and nanoparticles (NPs) are evidently more diffused to the film. However, 
it seems that the growth of the film becomes saturated and does not vary much beyond a 
deposition time of 10 minutes. This trend was observed in other LbL film buildup studies as 
well.1 Based on these observations, 15 minutes was allowed for deposition during each step of 
LbL growth with QCM (8 double layers) in our experiments. However, for growing thick LbL 
films (59 double layers), a deposition time of 10 minutes was considered to save time while 
maintaining considerable film growth. 
 
 
 
B.3. Film surface 
Figure B.3 shows surface features of a sample LbL film obtained by optical microscope of the 
AFM.  
 
Fig. B.3. An optical micrograph of the surface features of the LbL films. PEI with a MW of 70 kg/mol and 
PS- particle size of 41 nm were used, with six double layers deposited. 
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B.4. Charge compensation factor 
For the data shown in Fig. 3.2 in Chapter 3 of this dissertation, charge compensation factor 
defined by following equations is calculated and shown in Fig. B.4 below. 
 
(B.1) 
 
(B.1.1) 
 
(B.1.2) 
In Eq. (B.1), Γi is the charge compensation factor calculated for each PE/NP double layer i, Δmi is 
the deposited mass for each NP or PE layer, σ is the surface charge per unit weight, and fPE is 
linear charge density of PE bounded within [0,1] such that a fully charged PE corresponds to fPE = 
1. The MW of a PEI monomer is 43.07 g/mol. The number of charged functional groups on the 
NP surface is determined using the surface charge density reported by the manufacturer.  Note 
that the PE layer goes down first followed by the PS layer. Hence, overcompensation of PE 
charge by the deposited PS layer would require that Γi > 1.  If Γi < 1, the PE charge is 
undercompensated. 
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Fig. B.4. Charge compensation factor for PEI/PS- composites grown with different pH values (pH of each 
deposition solution is shown in the parentheses in the legend). PEI with a MW of 70 kg/mol and 41 nm-
sized PS- particles are used for this experiment.  
 
Conspicuous in Fig. B.4 is the very low charge compensation factor (on the order of 0.01) for 
PEI/PS- composites. We believe that NPs act as spacers and promote LbL growth despite not 
having a 1-to-1 charge compensation in the film.  
In Fig. B.4, the data for the first double layer is not shown, since the value for Δmi of PE for the 
first double layer was very low and the resulting value of compensation factor became very large, 
placing it significantly outside the range of the charge compensation factors for the rest of data 
points. 
B.5. Effect of nanoparticle concentration on the growth of PAA/PS+ composite 
Figure B.5 shows the role of concentration of positively charged PS (PS+ hereafter) NPs on the 
growth kinetics of poly(acrylic acid) (PAA hereafter)/PS+ multilayers.  
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Fig. B.5. The effect of PS+ concentration on LbL film buildup of PAA/PS+ composite. PAA with MW of 
240 kg/mol and 100 nm-sized PS+ particles were employed. CP refers to the concentration of particles.  
 
According to Fig. B.5, increasing the PS+ concentration increases the film growth rate. The 
enhancement in the growth kinetics is more pronounced when the concentration is incremented 
from 0.1wt% to 0.2wt%. The rise in the number of NPs in the media presumably increases their 
availability near the solution-film interface and results in more adsorption into the film.  
B.6. Effect of deposition pH on surface morphology of the LbL films 
Figure B.6 contrasts the surface morphology of two LbL films deposited at different pH 
conditions. For both cases PEI with a MW of 70 kg/mol and PS- particles with 41 nm size were 
used. Other than ions introduced to the solutions for pH adjustment, no salt ions were added to 
the deposition solutions.  
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(a) (b) 
Fig. B.6. Surface characteristics of LbL films composed of 8 bilayers of PEI with MW of 70 kg/mol and 41 
nm sized PS- particles deposited at different pH values. No salt was added for the deposition of either of 
film ingredients. a) Film growth at pH amplified condition. PEI and PS- are deposited at pH values of 9.9 
and 7, respectively. b) PEI and PS- are both deposited at pH value of 7. For the plots in the inset, maximum 
value of color bar is fixed to 700 nm.  
 
As seen in Fig. B.6, films deposited at pH-amplified condition have a larger absolute roughness. 
However, as mentioned in the dissertation, this film has a much faster growth rate. Comparing the 
two plots in Fig. B.6 considering roughness to thickness ratio, one can understand that for a given 
film thickness, the film deposited in pH amplified condition has around 30 % less roughness 
value.   
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